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Abstract 
 
Artemisinin susceptibility in Plasmodium falciparum is modulated by mutations in the 
gene pfk13, which encodes a kelch propeller domain protein of unknown function. Reduced 
susceptibility is demonstrated in vitro by elevated parasite survival after short exposures to 
physiologic concentrations of drug in the early ring stage. Using CRISPR-Cas9 genome 
editing, we provide the first evidence of a similar but K13-independent in vitro artemisinin 
resistance caused by single base changes in the genes encoding the AP-2 adaptor complex µ-
subunit (pfap2mu) and the deubiquitinase Ubp1. Through extensive fluorescence and electron 
microscopy and proteomics, functional characterisation of PfAP2µ shows that gene as 
encoding a non-canonical AP-2 trafficking factor that may interact with K13 and other 
important factors in the cytosol and near the ER and is essential for asexual parasite survival. 
This thesis provides evidence that disruption of trafficking in early rings initiates an ER-based 
stress response that underlies artemisinin resistance and induced dormancy. A model depicting 
a role for ER trafficking components in ring-stage artemisinin action is proposed. Brief 
characterisations of Ubp1 and clathrin heavy chain are also provided, showing for the first 
time that clathrin may support multiple key secretory organelles and that malarial 
deubiquitinases are attractive drug targets. 
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Summary 
 
Despite considerable reductions in malaria mortality achieved by collective parasite 
and vector control efforts over the last 20 years, malaria still remains one of the top causes 
of death among children under the age of 5 globally1. Further, important gains against 
Plasmodium falciparum, the species responsible for the majority of malaria deaths, are 
currently threatened by growing parasite resistance to frontline chemotherapies1. Genomic 
investigations into the roots of resistance in our lab and many others have correlated parasite 
drug responses with a complicated web of polymorphisms in many genes including pfk13, 
pfcrt, pfmdr1, pfdhfr, pfdhps, pfap2µ, and pfubp1. Though statistically significant, these 
correlations cannot prove causation. Therefore, studies that blend in vitro biochemical 
assays with manipulation of the parasite genome could shed important light on the biological 
roles of individual or combinations of mutations in modulating drug sensitivity in vivo.  
This thesis will characterize the phenotypic impacts of mutations in the pfap2µ and 
pfubp1 genes that have been tracked over the past several years in our laboratory through 
high-throughput PCR-seq studies of parasite DNA samples from sub-Saharan Africa and in 
vitro transgenesis. Specifically, I will perform a retrospective genetic analysis on blood 
samples from patients who have undergone ACT treatment to evaluate the prevalence, 
distribution, and dynamics of SNPs in these alleles in East Africa. Informed by these studies, 
I will use the CRISPR-Cas9 genome manipulation system recently established in P. 
falciparum to perform reverse genetics experiments by engineering mutations that have been 
correlated with resistant phenotypes in vitro and in vivo into parasites and fully characterise 
their sensitivity profiles to chloroquine, artemisinin, and ACT partner drugs such as 
lumefantrine and mefloquine. I will then characterise the biological role of these proteins 
and seek to provide mechanistic insight into how artemisinin resistance occurs. This thesis 
will contribute to our understanding of the molecular and genetic determinants of drug 
resistance and provide critical information to healthcare practitioners and regional health 
experts about the roles of particular mutations in their surveillance networks.   
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Chapter 1 
Introduction 
 
 
1.1 Malaria as a global problem 
 
 Malaria is the clinical term for the human and animal infectious disease 
caused by infection with one of several parasites of the genus Plasmodium. Although 
malaria symptoms were first recorded nearly five thousand years ago in ancient 
Chinese medical texts, Plasmodium parasites are believed to have existed on Earth 
for more than thirty million years1,2. In 2015, the World Health Organization 
estimated 214 million clinical cases and 438,000 deaths occurred worldwide while 
nearly 3.2 billion people were at risk of developing malaria3. Of these cases and 
deaths, the vast majority occur in young children. Though these data represent a 48 
per cent decline in mortality since 2000, malaria remains a major oppressive force in 
tropical developing nations.  
 
 
1.2 Several Plasmodium species cause clinical malaria 
 
While there are more than 250 members of the Plasmodium genus, only six 
species are known to cause naturally-occurring malaria in humans: P. falciparum, P. 
vivax, P. malariae, P. knowlesi, P. ovale curtisi, and P. ovale wallikeri. Recent 
evidence suggests that other species including Plasmodium cynomolgi, Plasmodium 
simium, Plasmodium inui, and Plasmodium brasilianum, which were previously  
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Figure 1 Global Incidence of P. falciparum 
Global distribution map of Plasmodium falciparum based on data from the 2017 World Malaria 
Report3.   
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thought to exclusively infect non-human primates, may also be able to infect human 
hosts, though further investigation is needed 4–7. Although the distribution of species 
varies geographically, P. falciparum is responsible for the vast majority of cases 
worldwide. P. vivax is the next most prevalent parasite at roughly 1 in 5 cases, and 
the other Plasmodium spp. contribute the remaining incidence. Polyclonal and multi-
species infections also contribute to this incidence.   
Recent evidence suggests that these data may not reflect the true distribution 
of cases for several reasons. For example, P. ovale spp. are sympatric and can only 
be differentiated by PCR8. Morphologically, they resemble P. vivax. Likewise, the 
morphology of P. knowlesi is nearly identical to P. malariae. Interestingly, though P. 
malariae is thought to be responsible for a small portion of the overall malaria 
disease burden, it has been found as a co-infecting species in as many as 50% of 
RDT-confirmed falciparum infections in Southern Uganda and 4-8% of infections in 
other parts of equatorial Africa 9–12. These underlying P. malariae infections are less 
likely to be cleared during standard ACT treatment and presumably account for an 
unknown number of asymptomatic infections13. Therefore, while P. ovale, P. 
knowlesi, and P. malariae may be less prevalent than falciparum infections overall, 
these species are likely underreported and remain important contributors to human 
malaria infection12. 
 
 
1.2.1 The Plasmodium lifecycle 
 
Though there are divergences in morphology and geographic localization, the 
life cycles of all six Plasmodium species can be understood as slight variations on 
the P. falciparum stages (Fig 2). In the blood, merozoites, the short-lived, 
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exoerythrocytic parasite stage, quickly adhere to and invade an uninfected red blood 
cell.  Once inside a red blood cell, the parasites have a roughly 48 hour life cycle 
during which the parasite undergoes considerable morphologic, metabolic, and gene 
regulatory changes as it progresses from the early ring stage to the later trophozoite 
and schizont stages 14,15. In P. knowlesi and P. malariae, the asexual cycle progresses 
over 24 and 72 hours, respectively. Near the end of this asexual cycle, the parasite 
undergoes several rounds of asexual, nuclear replication and division followed by a 
specialised cytokinesis in a process called schizogony, producing up to, in P. 
falciparum, 16-24 daughter merozoites primed for release. Shortly thereafter, the 
blood cell ruptures, and the merozoites egress. 
Thus, a patient’s total parasitaemia (percentage of infected red cells) can 
increase quite rapidly over the course of a few days in an untreated or drug resistant 
infection and in some cases lead to cerebral malaria, severe anaemia, and/or death. 
Because this blood stage is responsible for the clinical symptoms and mortality of 
malaria, most pharmacologic interventions aim to rapidly reduce the parasite burden 
in the periphery.  
During the course of an infection, some of these asexual parasites will 
differentiate into male and female gametocytes. In P. falciparum, cyclic nucleotide 
signalling cascades initiated by cGMP-dependent protein kinase in schizonts control 
this process, which ultimately concludes in the development of elongated Stage V 
gametocytes. In other species, gametocytes are present throughout the infection, and 
the mechanisms underpinning their development are less clear. Gametocytogenesis 
is the subject of intense investigation from perspectives of basic biology, drug 
design, and vaccine development. By targeting the gametocyte stages, drugs or 
vaccines could block transmission. Recent analysis of these so-called transmission-
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blocking drugs and vaccines by Andrew Blagborough suggests, unlike drugs or 
vaccines that target the blood-stage, the efficacy of transmission-blocking agents can 
be low and still have a remarkable impact on transmission16.  
Once gametocytes taken up during a bloodmeal by a female Anopheline 
mosquito reach the gut, 8-12 male gametes undergo egress and exflagellation into 
male microgametes. Each microgamete is capable of fertilising the female 
macrogamete and producing a zygote, which matures into an ookinete. Mature 
ookinetes exit the insect midgut through the basement membrane of the gut 
epithelium via the action of secreted prochitinases (activated by trypsin in the gut) 
and traverse the gut wall, forming oocysts. Oocysts divide into multiple sporozoites 
via a division process resembling schizogony called sporogony, and these 
sporozoites migrate to the mosquito salivary glands. This entire process can take up 
to two weeks.  
The number of sporozoites that an infective mosquito injects into a host 
during a bloodmeal varies from less than ten to potentially more than one hundred 17. 
Sporozoites in the host bloodstream or lymphatics will infect hepatocytes in the liver 
and undergo multiple rounds of asexual replication during the pre-erythrocytic liver 
stage of the infection. After several divisions, merozoites will enter peripheral 
circulation and infect erythrocytes, beginning a new bloodstage infection.  
Interestingly, by an unknown mechanism, P. vivax and P. ovale spp. are able 
to differentiate some liver stage parasites into dormant hypnozoite parasites that 
awaken periodically to release new infectious merozoites, which trigger a new blood 
stage infection even after a previous blood stage infection has been successfully 
cured or cleared or supressed by immunity.   
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Figure 2 Full lifecycle of Plasmodium species 
The lifecycle of the human-infecting Plasmodium species exists between two hosts. Mosquitos 
inject mature sporozoites via a bite. These sporozoites infect the liver and ultimately differentiate 
into asexual merozoites, which infect red blood cells in circulation. During the course of the 
bloodstage infection, some of these parasites differentiate into sexual gametocytes, which are 
taken up by a mosquito bite.   
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1.3 Current anti-malaria efforts and challenges 
 
 On the most fundamental level, malaria infections involve people, parasites, 
and mosquitoes. These basic groups represent the major focal points for 
interventions to treat, prevent, and eradicate malaria. Parasites can be eliminated 
with drugs; new infections can be prevented with vaccine-induced host immunity; 
transmission can be blocked with insecticides, bed nets, and transmission-blocking 
drugs and vaccines (Fig 3). Each avenue is currently subject to intense scientific 
investigation, and while great advances have been made in each category, some 
considerable challenges still frustrate global malaria eradication efforts.  
 
 
1.3.1 Drugs and drug resistance  
 
 Malaria chemotherapy has a long and storied history. For centuries, medical 
practitioners successfully treated malaria fevers and symptoms using herbal remedies 
derived from cinchona bark and the qinghao plant, which we now know to contain 
quinine and artemisinin (qinghaosu), respectively. These drugs were eventually 
isolated from their natural sources, and quinine dominated malaria therapy into the 
20th century. In support of the soldiers and efforts of many countries involved in the 
World Wars, analogues of quinine and novel anti-malarials were developed and 
deployed to great success 18. Widespread use during the first half of the century led 
to evidence of drug resistance by the late 1950s. By implementing state-level malaria 
drug schedules and distributing novel “artemisinin-combination therapies” (ACT) 
where an artemisinin is co-administered with a partner drug, we have temporarily 
regained the upper hand over the Plasmodium parasites and dramatically reduced 
infection rates and mortality, especially in children. Further, by administering 
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antimalarials as prophylaxis to pregnant mothers and infants through intermittent 
preventative treatment regimens (IPTp and IPTi), millions of cases of placental 
malaria and severe anaemia have been avoided across Sub-Saharan Africa 19–23. 
However, recent evidence suggests that even the effectiveness of frontline ACTs are 
decreasing. A better understanding of parasite evolution dynamics and drug 
resistance pathways are needed to inform national malaria elimination programs, 
improve the regimens of our existing drugs, and design novel antimalarials to 
overcome the parasites' adaptive and persistent nature. Specific details about 
frontline chemotherapies and resistance are discussed in Sections 1.4 and 1.5, 
respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 Common antimalarial interventions 
Many interventions have been deployed in the fight to eradicate malaria. These involve targeting 
the parasite in both the human host and mosquito vector but also encompass environmental 
interventions.  
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1.3.2 A malaria vaccine 
  
As with smallpox, the best hope for eradication of malaria worldwide is a 
vaccine. However, the malaria parasite presents several layers of greater complexity 
over the smallpox virus. There are several Plasmodium parasites that cause malaria, 
and exposed antigens are highly polymorphic even within a single life cycle stage. 
The parasite undergoes dramatic changes throughout its infectious cycle, and many 
of the presented antigens are not sufficiently immunogenic to stimulate a strong 
immune response that provides long-lasting memory. Although the first vaccine was 
proposed back in the 1960s, these issues continue to complicate vaccine 
development 24. Today, the RTS,S vaccine (Mosquirix) pioneered by 
GlaxoSmithKline and the US Army is the best candidate and uses a unique 
recombinant fusion between a P. falciparum surface protein and the highly 
immunogenic HepB surface antigen along with adjuvant to stimulate an immune 
response. However, data from the latest clinical trials show RTS,S is only 25-50% 
effective in preventing liver infections in very young children and is not effective in 
adults 25–27. These recombinant technologies and lessons learned from the current 
iteration of the RTS,S vaccine may give way to a more broadly effective next-
generation vaccine.  
Additionally, other approaches to vaccine development include the use of 
attenuated whole sporozoites and exposure under drug cover. The pharmaceutical 
giant Sanaria is currently pioneering PfSPZ-CVac, a vaccine based on irradiated P. 
falciparum sporozoites. Initial results suggested this type of vaccine could provide 
protective immunity, and larger trials with heterologous P. falciparum challenges are 
underway 28. These data suggest PfSPZ-CVac may induce greater protection than 
RTS,S. A 2013 study described the second approach in rodents using a live 
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sporozoite challenge from an infected mosquito 29. After infection, the animals were 
administered chloroquine to prevent a bloodstage infection. Interestingly, these 
rodents developed immunity against subsequent challenges suggesting that an 
adaptive immune response with memory can result from a liver-stage infection and 
the presence of a bloodstage infection may normally suppress this immune response. 
Further work will be needed to evaluate this approach in higher order mammals and 
humans.  
 
 
1.3.3 Insecticide spraying, bed nets, and genetic manipulation of 
mosquitos  
  
As previously discussed, the female members of about 40 species of 
anopheline mosquitoes are responsible for the transmission of Plasmodium parasites 
to humans. Of all the interventions that have been deployed against malaria over the 
past century, vector control had the most dramatic effects in reducing the global 
malaria burden. In the United States, a highly organised and well-funded effort 
combining insecticide dumping, swamp drainage, mosquito screen installation, 
indoor residual spraying (spraying of insecticides on indoor surfaces where 
mosquitos rest at night typically after blood meals), and personal protection 
measures culminated in the eradication of malaria over the course of four years from 
1947-1951 18. Indeed, bed net usage, environmental management to reduce vector 
populations, and indoor residual spraying were all key to the reductions in malaria 
incidence achieved over the last decade. However, despite it being nearly universally 
recommended under national malaria programmes, the 2017 World Malaria Report 
indicates that the number of households using indoor spraying has dropped by nearly 
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50% around the world since 2010. This drop is concerning and should be further 
investigated to improve compliance because IRS remains an indispensable tool in the 
fight to reduce vector populations.  
Broadly, malaria occurs on an entirely different scale in Sub-Saharan Africa 
than the American South, and political willpower, commitment, and organisation 
have long been stumbling blocks for managing sustainable and effective 
environmental vector control programs 30. Further, continuous use of some 
insecticides for public health programs and agricultural practises has contributed to 
the rise of insecticide-resistant mosquito populations 30. Insecticide-resistant vectors 
do not necessarily predict the return of malaria to areas that previously were malaria-
free – some studies question the vectorial capacity of resistant mosquitoes 31,32. 
However, they certainly pose a challenge to communities struggling to reach malaria 
elimination targets. 
 Most recently, groups of scientists have developed and adapted various 
approaches to genetically modify anopheline mosquitos so that they are incapable of 
transmitting malaria 33–36. Although promising, these studies are still in their infancy 
and may not be robust enough to be used as a global solution. Instead, long lasting 
insecticide-treated nets (LLINs) will remain one of the best transmission-blocking 
interventions. These nets protect both the user underneath them by providing a 
barrier that the mosquito cannot penetrate and the community at large by reducing 
access of mosquitos to infected people. Insecticide-resistant mosquitos and improper 
use of LLINs such as for fishing are two significant challenges to their effectiveness 
37–40.  
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1.4 Antimalarial drugs 
 
Though they are all structurally very different, frontline antimalarial compounds can 
be broadly classified based on core chemical scaffolds and shared molecular targets 
as aryl-amino alcohols, quinoline derivatives, antifolates, antimicrobials, or 
endoperoxides. Within these major groups, all of the antimalarial drugs can be sub-
classified based on their unique chemical structures and properties. This section will 
only provide background on antimalarials discussed in this thesis. There are 
hundreds of compounds with antimalarial properties at various stages of 
investigation and implementation, and the molecules not reviewed below are well 
reviewed elsewhere.   
 
 
1.4.1 Aryl-Amino Alcohols: quinine, mefloquine, and lumefantrine 
 
 When discussing the history of modern antimalarial treatment, it is 
appropriate to begin with the aryl-amino alcohols, namely quinine. Quinine was the 
first chemical compound isolated and used to successfully treat clinical malaria 41. 
Structurally, the quinine molecule is comprised of a bicyclic quinuclide group 
conjugated to a quinoline ring group by an alcoholic carbon. Together, this chiral 
alcoholic carbon centre forms the core amino alcohol with the nitrogen atom of the 
bicyclo-ring 42. 
Quinine was isolated as the active chemical in the bark of the Cinchona tree 
in 1820 by Pierre Joseph Pelletier and Joseph Bienaimé Caventou, though extracts of 
this bark had been used to treat malaria since the mid-17th century 41. Extracts of 
Cinchona bark had previously been used as a muscle relaxant and anti-diarrhoeal by 
indigenous populations in South America and eventually the Spanish in the 1500s. 
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Figure 4 Structures of common antimalarials 
The structures of several representative molecules of frontline chemotherapy classes are presented. 
These antimalarials cover compounds used as monotherapy, combination therapy, and rescue therapy 
as well as compounds which are currently under research and development.   
 29 
Jesuit missionaries realised the antimalarial properties of the bark and sent 
samples to Rome where these properties were confirmed. Over the course of the next 
one hundred years, quinine in these extracts saved the lives of countless Europeans, 
including King Charles II. By 1850, some had begun to use quinine as a 
prophylactic.  
 Despite repeated attempts over the years, nobody has been able to 
successfully synthesise quinine at mass-production scale more cheaply than 
extracting the molecule from the bark of the trees. Consequently, South American 
countries held a monopoly over the supply of the raw product to the rest of the world 
18. Eventually other countries throughout the tropics were able to grow the trees and 
compete for market share. Throughout the war years, hostilities in the Pacific 
Theatre restricted production of quinine, and the Dutch were able to corner the 
market by establishing Cinchona seedlings in Indonesia. The Americans attempted 
to begin production out of Costa Rica, but these supplies ultimately arrived too late 
18. Despite its success, early reports of resistance surfaced in the early 1900s 43. The 
discovery of synthetic drugs like chloroquine and ultimately artemisinins led to 
reduced reliance on quinine worldwide; however, quinine remains an indispensable 
rescue treatment for severe or drug-resistant malaria.  
 The mechanism of action of quinine remains poorly understood despite its 
storied history. At present, quinine is thought to exert its cytotoxic effect by 
somehow interfering with haemoglobin metabolism, like many other antimalarial 
drugs. Chloroquine accumulates and blocks haem detoxification in the digestive 
vacuole, and quinine seems to similarly accumulate in this organelle 42.  
 As chloroquine-resistant parasites began to emerge and spread, the United 
States, while deeply embattled in the Vietnam War, began searching for alternatives 
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18. During the 1960s, the Walter Reed Army Institute of Research in Maryland 
screened nearly a quarter of a million compounds in search of molecules that 
displayed high potency against malaria parasites 44. The researchers found 
mefloquine and halofantrine, both amino alcohols like quinine. Due to the urgency 
of the situation, the Army partnered with F. Hoffman-La Roche and Smith Kline 
Beecham to push the drugs forward. Safety and tolerability trials were skipped, and 
mefloquine was swiftly approved for prophylaxis by the FDA in the late 1980s, 
unfortunately too late for the war effort 44. Initial data suggested mefloquine could be 
a single-dose radical cure because of its very long half-life in the body of about 3 
weeks 45,46. However, reports quickly surfaced of substantial neurological and 
psychological side effects. Work at the end of the century suggested combining 
mefloquine with artemisinin derivatives to potentially lower the required dose of 
mefloquine and improve safety 47.  
 As we now know, mefloquine is neurotoxic and is associated with potentially 
severe neuropsychiatric side effects 44,48. Recent concerns about neurotoxicity and 
side effects led the British Government to ban the use of mefloquine for prophylaxis 
in soldiers in 2016, citing potential increased risk of suicide 49. However, to this day, 
mefloquine remains a key part of artemisinin combination therapies for treating 
clinical cases, when paired with artesunate, around the developing world. Like most 
antimalarials, the mechanism of action is still unknown, though believed to involve 
haemoglobin detoxification. 
 On the other side of the Pacific, the People’s Republic of China was also 
busy generating and studying new antimalarial compounds also in support of the 
Vietnam War effort, though for the North Vietnamese. “Project 523” was highly 
productive and led to the discovery and isolation of artemisinin, artemether, 
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artesunate, pyronaridine, napthoquine, and lumefantrine. Lumefantrine in particular, 
discovered in 1976, belongs to the same aryl amino alcohol family as quinine, 
though its substituent groups are quite different. In vivo, lumefantrine has a half-life 
of approximately 3-6 days, but must be taken with food to increase 
bioabsorportion50. Given its shorter half-life and poor uptake, lumefantrine was 
never used as monotherapy, unlike mefloquine. At the turn of the century, 
lumefantrine was paired with artemether in the artemether/lumefantrine ACT and 
commercialised and since then has been widely used around the world 51–53. 
Aryl amino alcohols do not have activity against liver stage parasites, and 
while they do kill other Plasmodium species including vivax in the blood stages, they 
must be combined with primaquine to cure a relapsing infection.  
 
 
1.4.2 4-Aminoquinolines: chloroquine, piperaquine, and amodiaquine 
 
 After quinine, the next most successful antimalarial drug of the 20th century 
was chloroquine. Chloroquine was discovered between the Wars in 1934 by Hans 
Andersag in Germany at Bayer Labs as part of an effort to discover and evaluate new 
molecules to replace quinine. At the time, Bayer produced resochin and sontochin, 
but shelved both compounds because they were believed to be toxic. The detailed 
history of chloroquine is intimately tied with pre-World War II political alignments 
between Allied and Axis powers. This history is well reviewed by Karen Masterson 
18. But in short, American drug manufacturers Merck & Co and Winthrop Chemical 
Co. had a working relationship with the German firms IG Farben and Bayer before 
hostilities broke out in Europe. Afterwards, the American chemists were left totally 
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cut off from their more skilled German colleagues once anti-Nazi financial 
regulations were levied by the US Treasury.  
German scientists had been testing sontochin in North Africa when the Allies 
invaded in 1943. During the invasion, a German scientist, Professor Schneider, 
surrendered his data and compounds to the Americans, who shortly thereafter 
synthesised chloroquine and realised its gamechanging potential 18,54. Successful 
efficacy and safety trials after the war led to global adoption. Chloroquine currently 
costs only $0.04 per dose in the developing world, and chloroquine monotherapy 
dominated clinical treatment recommendations. However, reports of resistance in 
1960 inspired the search for alternative drugs. Investigation into resistance 
mechanisms uncovered key aspects of chloroquine’s mechanism of action, which 
involves accumulation in the digestive vacuole. In the digestive vacuole, chloroquine 
blocks haem polymerisation into crystalline haemazoin, which leads to accumulation 
of toxic haem molecules and ultimately cell death. Currently, chloroquine is still 
available in many countries across the tropics, even though National Malaria 
Programmes and the WHO endorse artemisinin combination therapies.  
As part of efforts to find a replacement for chloroquine, Chinese and French 
researchers independently created piperaquine in the 1960s 55,56. The molecule 
belongs to the same 4-aminoquinoline class of compounds and was potent against 
circulating, multi-drug resistant parasites. Piperaquine monotherapy was used for 
prophylaxis and acute treatment throughout the later 1960s and 70s, in particular 
replacing chloroquine in China 56. Despite reports of resistance, piperaquine was 
used in China through the mid-90s. Apparently resistance to piperaquine is unstable, 
as sensitivity returned quickly after monotherapy was replaced. As interest in 
artemisinins increased through the 1990s, piperaquine was explored as a potential 
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partner drug. Dihydroartemisinin-piperaquine (DP) was rolled out in the 2000s. DP 
was effective against multi-drug resistant strains in Southeast Asia, but recent 
evidence shows efficacy in the Greater Mekong Subregion (GMS) is declining 
dangerously. As with chloroquine, piperaquine is expected to interfere with haem 
detoxification in the digestive vacuole.  
Shortly after the war, another 4-aminoquinoline, amodiaquine, was 
synthesised as part of a new chemical scheme to create aminoalkylphenols by 
American chemists Burckhalter et al 57,58. In 1946, amodiaquine was created, and 
from shortly thereafter, it was used to treat patients. In the body, amodiaquine is 
metabolised to desethylamodiaquine, which kills the parasite presumably by a 
similar haem-mediated cytotoxic mechanism as cross-resistance with piperaquine 
has been reported 59. However, the WHO withdrew its recommendation for 
amodiaquine prophylaxis in the 1990s because of complications with liver toxicity 
and agranulocytosis. In 2008, amodiaquine was re-approved as a partner drug in 
ACT cocktails when paired with artesunate. Artesunate-amodiaquine (AS-AQ) is 
commonly used throughout Africa 59.  
  Project 523 in China discovered another 4-aminoquinoline, naphthoquine, in 
1986 60. While naphthoquine has never been used as monotherapy, current studies 
are examining potential efficacy as a partner drug in future ACT cocktails 61. Very 
little is known about how it functions.  
 
 
1.4.3 8-Aminoquinolines: primaquine 
 
 Though the first 8-aminoquinoline, plasmochin, was synthesised in 1925, the 
most noteworthy 8-aminoquinoline is primaquine. Primaquine was discovered in 
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1946 by American chemistry Robert Elderfield at Columbia University 62,63. 
Primaquine is most useful in killing the relapsing liver stage parasites in Plasmodium 
vivax and Plasmodium ovale infections, but the drug is also a potent gametocytocide. 
Primaquine cannot be used for chemoprophylaxis but remains in use for relapsing 
infections. To date, primaquine is the only approved compound that targets these 
liver stages; preserving its efficacy is crucial.  
 During the Korean War, Army scientists experimented with administering 
primaquine as a combination therapy with chloroquine to treat P. vivax infections 
with great success 62. Uniquely, primaquine is contraindicated for use in patients 
with glucose-6-phosphate dehydrogenase (G6PD) deficiency as the drug causes 
dangerous haemolysis 64.  
 
 
1.4.4 Antifolates: sulfadoxine and pyrimethamine 
 
 Sulfadoxine and pyrimethamine are two antimalarials of great importance 
even though resistance evolves very quickly. Pyrimethamine was first discovered in 
the 1940s by Gertrude Elion in the United States 65. Elion sought to exploit 
biochemical differences between organisms in her effort to design drugs. In the case 
of pyrimethamine, Elion took aim at differences in metabolism and DNA replication. 
For her work on pyrimethamine and several other key drugs, Elion shared the Nobel 
Prize in Chemistry in 1988.  
 Pyrimethamine inhibits dihydrofolate reductase (DHFR) and interferes with 
folate biosynthesis. Folate is required for nucleotide biosynthesis and DNA 
methylation. Around the same time, sulfadoxine was discovered and shown to inhibit 
dihydropteroate synthase (DHPS) 65. DHPS lies in the same synthetic cascade as 
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DHFR; therefore, sulfadoxine and pyrimethamine synergise when used together. 
This combination therapy (SP) was rolled out as chloroquine resistance began to 
sweep through the tropics as a promising alternative therapy. However, resistance to 
SP evolved even faster 66. Even though parasites harbouring the mutations required 
for resistance to both drugs are globally prevalent, SP is used in intermittent 
preventative treatment in pregnant women and infants (IPTp and IPTi). IPTp and 
IPTi were officially recommended by the WHO in 2010 after several years of study 
and debate 67. Both involve administering a full round of SP treatment to 
asymptomatic pregnant mothers and newborns in endemic areas to prevent infection 
during and shortly after the pregnancy, even when resistance-causing mutations 
approach 50% prevalence. In these areas, SP is not used to treat clinical infections, 
and the prophylactic benefit of administering SP in the context of IPTi and IPTp 
outweighs continuing to select for resistance-causing mutations. Infection of the 
placenta interferes with the flow of nutrients to the foetus and frequently results in 
spontaneous abortion or stillbirth. Around the same time, research primarily led by 
Sir Brian Greenwood and Prof Alassane Dicko examined the efficacy of 
prophylactic administration of SP-amodiaquine in high transmission areas during the 
dry season to reduce the human infectious reservoir heading into the wet season 68–70. 
This work turned into what is now called Seasonal Malaria Chemoprevention 
(SMC), which is used across the Sahel and has saved hundreds of thousands of lives 
over the last five years. For his contributions to this work, Dicko was awarded the 
Africa Prize by the Royal Society in 2017. Current work aims to combine SMC and 
IPTp/IPTi with the RTS,S vaccine.  
 Sulfadoxine and pyrimethamine are unique amongst antimalarials because 
the mechanisms of action and resistance are known. As mentioned above, the drugs 
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are substrate analogues that specifically inhibit Plasmodium isoforms of DHPS and 
DHFR, respectively. Several structures of these enzymes have been resolved in 
complex with drugs and small molecule cofactors, indicating precisely how the 
drugs interact with the catalytic machinery 71–73. These drugs select variants of dhps 
and dhfr with mutations that sterically block drug molecules from accessing their 
binding pockets. In vivo, the evolution of resistance to SP is complicated, but 
canonically involves variants at codons 437, 540, and 581 in dhps and 51, 59, and 
108 in dhfr, though other haplotypes associated with clinical treatment failure have 
been observed 74. Crystal structures of some of these mutant proteins have been 
solved and provide insight into how the structural changes prevent drug access 71,72.  
Haplotypes vary by continent, indicating resistance has arisen independently 66.  
 Other antifolates have seen usage in the clinic and laboratory, including 
WR99210 and proguanil. WR99210 is a potent inhibitor of P. falciparum DHFR and 
is used commonly in transfection studies, though is too toxic for use in humans. 
Human DHFR can complement loss of P. falciparum DHFR activity and rescue 
parasite growth in the presence of WR99210 in culture 75. Proguanil is used as a 
combination with atovaquone, and its active metabolite cycloguanil inhibits 
Plasmodium DHFR. Though these drugs are all active against falciparum, vivax and 
knowlesi, there are differences in sensitivity between species 76. Potency against 
ovale spp. and malariae remains to be characterised.    
 
 
1.4.5 Antimicrobials: doxycycline, clindamycin, and azithromycin 
 
 Though tetracyclines, macrolides, and lincosamides were all originally 
developed for prokaryotic bacterial infections, some have potency against protozoa. 
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Tetracyclines were originally discovered in the 1940s, and in 1950, initial trials in 
consenting human volunteers indicated doxycycline may have anti-falciparum and 
anti-vivax properties 77,78. Just like with the antifolates, tetracycline use was revisited 
by health authorities as chloroquine resistance began to spread in the 1960s. In 
addition to tetracyclines, macrolides and lincosamides were also considered, and 
clindamycin and azithromycin were found to have antimalarial properties 79. In 1985, 
the CDC formally recommended the use of doxycycline for chemoprophylaxis 77. 
Recommendations to include clindamycin and azithromycin followed thereafter. 
 These drugs are not recommended for treatment of acute clinical infections 
because they exhibit delayed action. In bacteria, these three classes target ribosomes 
and block protein synthesis. In Plasmodium, these drugs target the bacteria-like 
organelle called the apicoplast. The apicoplast is a four-membrane organelle in the 
parasite cytoplasm derived from an evolutionary endosymbiotic engulfment of a red 
alga80. This prokaryotic alga had prokaryotic ribosomal machinery, which the 
apicoplast retained. These ancient ribosomes are susceptible to antibiotics in the 
same way as bacteria81. However, unlike bacteria, the parasite also has eukaryotic 
ribosomes, which do the bulk of the protein synthesis in the cell. Parasites can 
survive one entire lifecycle without a functional apicoplast 81. Because the apicoplast 
in these treated parasites is not functional, it cannot replicate and segregate properly 
into the daughter parasites. Therefore, these next-generation parasites lack an 
apicoplast and are not viable. Interestingly, in vitro antibiotic-mediated cytotoxicity 
can be overcome by supplementing the parasites with isopentenyl pyrophosphate 
(IPP) 82. In the asexual stage, the only essential function of the apicoplast is to 
produce IPP for use in post-translational protein prenylation. Replacing this 
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metabolite in culture medium allows parasites to grow without an apicoplast, 
indefinitely 82.  
 Therefore, except at micromolar concentrations of drug, parasites replicate 
normally in the presence of antibiotics over one life cycle. This “delayed death 
effect” renders antibiotics unsuitable for treating acute infections where rapidly 
reducing peripheral parasitaemia is required 81. However, they do work well as 
prophylaxis when any infection is in the liver-stage or asymptomatic and peripheral 
parasitameia is very low. I.V. quinine and doxycycline is used in some cases as a 
rescue therapy for complicated malaria patients. Some prophylactic failures and 
putative markers for doxycycline resistance have been reported, but these in vitro 
experiments were not performed to look at the delayed death effect exerted by 
doxycycline 83–87. Therefore these data are difficult to interpret. It is not clear how a 
difference in EC50 to a 48-hour exposure of doxcycyline translates to the accepted 
96-hour EC50.  
 
 
1.4.6 Endoperoxides: Artemisinins and Synthetic Ozonides 
 
 Though artemisinin was not properly extracted and identified until the 
twentieth century, records show Chinese herbal practitioners had been using 
preparations of the qinghao plant (Artemisia annua) to treat a variety of ailments for 
nearly 2000 years 88. The active metabolite, dihydroartemisinin, was only discovered 
in the 1970s by scientists led by Tu Youyou under Project 523 in China. These 
scientists also created the more stable versions of the artemisinin pro-drug 
artemether and artesunate. After the Cultural Revolution, Chinese science was 
opened to the West, and publications in the 1990s began to describe the efficacy of 
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artesunate, artemether, and dihydroartemisinin as superior to chloroquine and 
quinine 88. Nicholas White, Keith Arnold, and others were early European 
champions of the artemisinins and helped bring the drugs to the global marketplace .  
 Artemisinin and its derivatives are unique molecules possessing a hallmark 
endoperoxide bridge in a sesquiterpene lactone tricyclic ring. These molecules are 
highly potent against P. falciparum, P. knowlesi, and P. vivax but their efficacy 
against P. ovale spp. and P. malariae remains to be characterised. So far, the 
mechanism of action of artemisinin is unclear, though its cytotoxic effect is largely 
believed to result from overwhelming oxidative stress caused by opening of the 
endoperoxide, forming reactive radical oxygen atoms. Parasites treated with 
artemisinin in vitro display increased levels of total ubiquitylation, consistent with 
systemic protein damage and turnover 89. Studies have suggested that haemoglobin 
metabolism catalyses the activation of the endoperoxide, but this remains to be 
validated and clarified 90. It is accepted that, though all asexual stages are susceptible 
to artemisinin, there is a period of hypersensitivity in the very early ring stage, which 
gives way to a period of relative insensitivity that arcs back towards sensitivity in the 
trophozoite phase. The schizont stage is again relatively insensitive. Throughout the 
lifecycle, potency of artemisinin, as determined by 6-hour pulses of drug, ranges 
from approximately 1 nM to greater than 100 nM 91. Artemisinins show variable 
activity against male and female gametocytes, seeming to only inhibit male 
gametocytes 92.  
 In the clinic, artemisinin monotherapy was used briefly in the late 1990s 
before it was condemned by the WHO in 2006. Even so, monotherapies are still 
available in many endemic countries 3. The recommended treatment guidelines since 
then specify that artemisinin should be used in combination with another, longer-
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lasting drug in a three-day artemisinin combination therapy (ACT). Currently the 
most common ACTs available are mefloquine-artesunate (MA; Artequin), 
artemether-lumefantrine (AL; Coartem), artesunate-amodiaquine (AS-AQ; 
Camoquin), and dihydroartemisinin-piperaquine (DP; Artekin). Other formulations 
include amodiaquine and pyronaridine. ACTs remain effective throughout Africa, 
though there are recent reports of concerning treatment failure 93–96. However, in 
Southeast Asia, artemisinin resistance is well established, and there are increasing 
reports of partner drug failure. Efficacy in South America remains high. Preliminary 
evidence indicates that the basis for reduced artemisinin susceptibility in Africa, 
where it occurs, differs from that in Southeast Asia 93. Further discussion of 
artemisinin resistance can be found in Section 1.5.3.1. Currently, the TRAC II 
project in Southeast Asia is examining the safety and efficacy of triple ACT 
formulations. Other proposed interventions include a six-day sequential ACT 
regimen with two different ACT formulations, though compliance may be low 97.  
 Several synthetic endoperoxide compounds based on the chemical scaffold of 
artemisinin are currently at various stages of the development pipeline. The most 
promising candidates include OZ277 and OZ439. These compounds are so far 
tolerated well and are highly effective against parasites 98. One report indicates 
OZ277 may be susceptible to K13(C580Y)-mediated cross-resistance with 
dihydroartemisinin as determined by the ring-stage survival assay (Section 1.6), 
though OZ439 is effective against these strains in this assay format 99,100. This assay 
format may not be appropriate for the synthetic compounds because the RSA was 
designed for artemisinin, which displays a very short, six-hour half-life, and these 
ozonides have a much longer half-life. Further work is needed to move these 
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compounds to market, but their high potency and long half-life represent promising 
developments in a much-needed space of malaria control efforts.  
 
 
1.5 Genetic and molecular mechanisms of antimalarial resistance 
 
 Despite our best efforts to eradicate malaria, the malaria parasite has kept 
pace, tuning its genome to block or circumvent drug action (Fig 5). Over the last 
several decades, molecular tools such as whole genome sequencing and PCR have 
allowed researchers to comb through the parasite genome to study changes during 
drug pressure in vitro and in vivo. These studies have quantified the parasite’s basal 
mutation rate at approximately 1 x 10-10 – 1 x 10-9 per base per parasite division 
101,102. However, these genome-wide estimates are extrapolated from the analysis of 
mutations and recombination in specific gene families rate, and some studies show 
this rate varies based on the parasite strain103–105. Given that parasite burdens can 
exceed 1 x 109 in a typical acute infection, individual mutations are constantly 
arising and may be selected based on the fitness costs of the mutation and drug 
pressure 101. For this reason, drug resistance can develop unexpectedly and expand 
suddenly and rapidly. Clinical resistance has been observed for nearly every 
antimalarial drug ever rolled out. Understanding the molecular changes in the 
parasite that underpin resistance has helped scientists track resistance and design 
novel chemotherapies. This section will only discuss quinine, mefloquine, 
lumefantrine, chloroquine, piperaquine, doxycycline and clindamycin, and 
artemisinin because these are the only drugs that are discussed extensively in this 
thesis and therefore warrant a detailed introduction. A brief discussion of other 
common antimalarials can be found above. 
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Figure 5 Timeline of the emergence of parasite resistance to frontline chemotherapies 
Plasmodium falciparum has evolved resistance to nearly every drug that has been introduced for 
treating human infections. The length of the coloured bars indicates the approximate duration of use 
of each annotatd chemotherapy. The edges of the bars indicate the approximate dates of introduction 
and withdrawal. A fading bar indicates waning use of the given chemotherapy. Black arrows indicate 
the first reports of parasite resistance to the compound in humans. The specific years indicated by 
these black arrows are referenced in the following sections.   
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1.5.1 Resistance to aryl-amino alcohols 
1.5.1.1 Quinine Resistance 
 
 Despite its first recorded use dating back to the 1600s, the first clinically 
confirmed quinine resistance occurred in the early 1900s. In 1907, Arthur Neiva first 
observed quinine-resistant infections in workers returning from construction teams 
working on the “The Devil’s Railway” deep in the Amazon Rainforest in Brazil 43. 
These observations were later confirmed and reported in Germany by Bernhard 
Nocht and Heinrich Werner in 1910 as workers stationed in Brazil were ordered 
back to Hamburg, infirm 43. Concerns about quinine resistance persisted and 
worsened throughout the 1910s as the First World War erupted across Europe. 
Although sparse, military records indicate that one to two million soldiers across 
Allied and Axis powers were affected. As the War continued, quinine efficacy 
declined dramatically, particularly on the Eastern Balkan front. Due to the lack of 
understanding and tools at the time, it is not clear if these parasites were of a similar 
genetic background or susceptibility profile as those reported in Brazil earlier 
41,43,106. Particularly in the Brazil context, at least some of these quinine-resistant 
cases were diagnosed as multiple infections. It is possible that the same was true in 
the War theatres – indeed most of the relapsing cases which presented in hospital 
were P. vivax 106. Although quinine does not kill vivax hypnozoites, these 
documented cases of recrudescence suggested clinical treatment failure as they 
occurred too soon for reinfection with P. falciparum or P. vivax relapse106.  
 Since the War, quinine use, and resistance, has declined and to date is mostly 
confined to rare occurrences in South America and Southeast Asia. Domestic cases 
in Africa are very rare, and quinine retains efficacy on the continent. Consequently, 
quinine is considered frontline chemotherapy for treatment of severe malaria and 
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multi-drug resistant infections, typically in combination with an antibiotic or 
antifolate 107,108.  
 
 
1.5.1.2 Mefloquine Resistance 
 
 As described previously, mefloquine was discovered by the US Army in the 
mid-1960s, trialed, and rolled out several years later 44. However, within a few years 
of use, resistance was reported in the Thai-Cambodian border region in the Greater 
Mekong Subregion. By 1990, researchers reported a 30% treatment failure rate with 
mefloquine monotherapy 109. Since then, resistance has been reported in South 
America and sporadically in West Africa, possibly due to less common use 110–112. 
Shortly after the initial detection and report of mefloquine resistance moving through 
the GMS, trials of combination therapy with artesunate showed the progression of 
resistance could be halted and mefloquine efficacy rescued, presumably because the 
burden of parasite density reduction is mainly accomplished by the fast-acting 
artemisinin with support and long-term protection from mefloquine 109. Currently, 
mefloquine-artesunate combination therapy enjoys widespread success throughout 
Africa and South America, though the combination is failing in Southeast Asia94,113–
119. 
 
 
1.5.1.3 Lumefantrine Resistance 
 
 Where mefloquine was discovered by the Americans, lumefantrine, and a 
host of other drugs, was discovered by the Chinese in an analogous clandestine  
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project around the same time in 1976 120. Unlike quinine and mefloquine, 
lumefantrine has never been used as a monotherapy and has only been 
coadministered with the artemisinin-derivative artemether as Coartem (artemether-
lumefantrine, AL). Therefore, it is difficult to obtain direct evidence of resistance in 
vivo. As noted previously, artemisinin combination therapies in general, and 
Coartem specifically, have been widely successful outside of the Greater Mekong 
Subregion 121–123. Evidence of resistance outside this region, particularly in East 
Africa where AL is frontline under some national malaria control programs, is 
limited and, in some cases, controversial, though cannot be ignored and demands 
further investigation 93,124–130.  
 
 
1.5.1.4 Mechanism of resistance to aryl-amino alcohols 
 
So far, decreased susceptibility to aryl-amino alcohols has been linked to 
genomic amplifications of the pfmdr1 gene. This gene was first identified in 
falciparum in 1989 by Wilson et al following a search for orthologues of the multi-
drug resistance transporters found in mammalian organisms. This seminal study 
followed on the back of work in 1987 showing chloroquine-resistant (CQR) parasites 
accumulated dramatically less chloroquine than sensitive parasites 131. This 
accumulation and CQR phenotype could be reversed with Verapamil, which had 
previously been shown to block the release of anticancer drugs from tumour cells via 
MDR-dependent pathways, suggesting an underlying efflux mechanism in CQR 
parasites 131. Therefore, Wilson et al identified the two orthologues of the 
mammalian mdr: pfmdr1 and pfmdr2, which share 59% homology 132. Northern 
blotting revealed mdr1 was overexpressed in their mefloquine-resistant parasite, 
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whereas mdr2 was not. On the basis of chloroquine sensitivity, subsequent 
comparative studies identified copy-number variations in CQ-sensitive and -resistant 
strains without a clear trend delineating the two phenotype classes 132–134.  
Pfmdr1 encodes a P-glycoprotein family protein, Pgh1, which is localised to 
the digestive vacuole in P. falciparum 135. Several years later in 1994, Cowman et al 
also experimentally derived mefloquine-resistant parasites in vitro on a CQR 
background and showed these parasites overexpressed mdr1. Interestingly, this CNV 
also correlated in this study with potentiation of chloroquine and cross-resistance to 
quinine and the related molecule, halofantrine 136. Several studies from the late 
1990s well into the 2000s continued to question and redefine the role of PfMDR1 in 
modulating drug sensitivity 137,138. Transfection studies suggested that mutations in 
the C-terminal region of the protein encoding S1034C, N1042D, and D1246Y could, 
together, modulate susceptibility to mefloquine and quinine 137,139. Parasites 
harbouring pfmdr1 copy number variants were also shown to have reduced 
susceptibility to lumefantrine, mefloquine, and quinine 140. However, the prevalence 
of these SNPs and CNVs is highly-region specific. Recent genome editing using zinc 
finger nucleases clarified the role of certain globally prevalent mutations in 
modulating sensitivity to frontline chemotherapies. Specifically, N86 reduces 
susceptibility to lumefantrine and mefloquine but may potentiate quinine, whereas 
N86Y causes parasites to become less sensitive to chloroquine 8.  
Synthesizing these results and the current understanding about the complex 
dynamics in multidrug-resistant parasites, Veiga et al propose that PfMDR1(N86) 
weakly imports lumefantrine into the DV away from its cytosolic target where it is 
protonated and sequestered, whereas the N86Y mutant cannot import lumefantrine 
and thus increases the effective cytosolic drug concentration (Fig 7) 141. This may 
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make sense because lumefantrine and mefloquine do partly accumulate in the DV142. 
However, this mechanism does not account for differences observed in quinine 
susceptibility. At this point, it is difficult to speculate how PfMDR1 affects 
mefloquine and quinine activity because very little is known about their mechanisms 
of action in the cell. A recent study showed that mefloquine may inhibit the 80S 
ribosome, though further work is required (Fig 7)143. With the arrival of molecular 
forward and reverse genetic tools for Plasmodium, these important mechanisms will 
likely begin to be unravelled. 
 
 
1.5.2 Resistance to 4-aminoquinolines 
 This section will only discuss the 4-aminoquinolines chloroquine and 
piperaquine, because the 8-aminoquinolines were not used in the work described by 
this thesis. A brief discussion of these other related compounds is included above. 
 
 
1.5.2.1 Chloroquine Resistance 
 
 Chloroquine enjoyed widespread use during and after World War II until the 
late-1950s when pockets of resistance emerged along the Thai-Cambodian border 
and in Northern South America. These pockets quickly spread into tracks of 
resistance that began to sweep across both regions. By 1960, chloroquine-resistant 
(CQR) infections were documented and confirmed in Colombia, Venezuela, 
Thailand, and Cambodia, ultimately reaching Africa in the late 70s 144 (Fig 6). By the 
mid-80s, resistant strains dominated Sub-Saharan tropical Africa 144,145. At the height  
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Figure 6 Spread of chloroquine- and DHA-Piperaquine-resistant genotypes over geographic 
areas 
The top panel depicts how chloroquine-resistant genotypes encoding PfCRT(K76T) spread across the 
world over time, emanating from Southeast Asia beginning in 1957. The bottom panel describes how 
a single lineage of parasites resistant to dihydroartemisinin-piperaquine combination therapy 
harbouring K13(C580Y) and plasmepsin II amplification is spreading around the Greater Mekong 
Subregion along Cambodia’s borders. These figures are adapted from data presented by Packard et al 
and Imwong et al respectively.   
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of the resistance crisis, childhood (under the age of 10) mortality was up nearly 6-
fold in some parts of Africa, and no cheap, effective alternatives were available 146.  
 
 
1.5.2.2 Mechanism of resistance to chloroquine 
 
 Chloroquine resistance likely arose independently several times, first in the 
Greater Mekong Subregion, then in South America, the outlying Pacific Rim, and 
East Africa, rather than sweeping around the tropics as a single genetic lineage 147. 
That this process took decades is interesting. The antifolates sulfadoxine and 
pyrimethamine, which were intended as replacements for CQ, failed as acute clinical 
therapies very quickly because the parasite was able to evolve point mutations to 
sterically block access to the drug-binding pocket on their target enzymes. When a 
drug retains its efficacy for many years, this indicates that the underlying mechanism 
of action and resistance may be complicated at the subcellular level or cause a 
significant fitness deficit.  
 Initially, investigators believed there was a “chloroquine receptor” that 
mediated the drug’s cytotoxicity and resistance after detailed reports of host cell 
membrane involvement and collapsed digestive vacuoles, a phenomenon called 
“clumping”. At the time, studies had shown that chloroquine accumulated in the 
acidic digestive vacuole 148. These initial investigations were particularly difficult 
because there was no in vitro culture system for P. falciparum. Once Trager and 
Jensen described the successful, long-term passage of P. falciparum in human 
erythrocytes in 1976, the field of molecular parasitology began in earnest, starting 
with attempts to unravel chloroquine resistance 149.  
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 In 1980, Chou et al proposed ferriprotoporphyrin IX as a candidate 
chloroquine receptor150. The group showed chloroquine binds ferriprotoporphyrin IX 
(FP), which is naturally produced by the parasite during haemoglobin degradation in 
vitro and accelerates FP-mediated cell lysis 150. They proposed that, while FP is 
naturally produced and inherently toxic to cells, there is a factor in the cell that 
further modifies FP into malaria pigment and mitigates its cytotoxicity. It followed 
that CQ interacts with FP and forms stable FP-CQ complexes that retain cytotoxicity 
and cannot be sequestered as nontoxic complexes 150–152.  
 D.C. Warhurst countered with an alternative view that chloroquine is carried 
down a pH gradient in the cytoplasm towards the acidolysosome 42. There, CQ 
blocks haemoglobin degradation and starves parasites of amino acids. This view is 
consistent with known cytotoxicity in mammalian cells that lack FP but fails to 
explain multi-fold differences in sensitivity between parasites and mammalian cells.  
 Through the vigorous debate on mechanisms of action, it was clear that 
chloroquine targeted the digestive vacuole and resistant parasites retained 
dramatically less chloroquine, despite normal accumulation kinetics 131,153. As stated 
in Section 1.5.1.3, investigators looked for mechanisms of drug efflux and identified 
pfmdr1, an orthologue of the mammalian chemotherapy efflux gene, and observed 
that the calcium channel blocker Verapamil potentiated chloroquine accumulation 
and sensitivity specifically in CQR strains, just like in drug-resistant cancer cells 
131,154. As mentioned above, field studies in the late 1990s provided mixed evidence 
linking mutations in pfmdr1 to chloroquine susceptibility 155. Later work argued 
against a resistance mechanism involving expulsion of CQ from the cell, but 
confirmed accumulation defects in the digestive vacuole, suggesting Verapamil 
targeted mutant-PfMDR1 154–156.  
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 At the end of the century, field and genetic studies identified a strong genetic 
selection on a region of chromosome 7 corresponding to pfcg2 157,158. Transgenic 
experiments ruled out a role for this protein but showed mutations in the 
neighbouring pfcrt gene may determine chloroquine sensitivity 159,160. Field work 
then confirmed the association of a locus, PfCRT(K76), with chloroquine resistance 
around the world. While K76T is the major causal allele, K76I and K76N have also 
been observed in the laboratory and correlated with reduced susceptibility to 
chloroquine 159,161. Interestingly, this mutation was found on diverged backgrounds, 
and mutations in pfmdr1 and pfcg2 did not improve the association, corroborating 
evidence that these genes are not predictive in determining the resistance status, 
though pfmdr1 may be involved in fine tuning resistance in some parasite 
backgrounds 155.  
 Subsequent genetic investigation has revealed that PfCRT is a 
transmembrane protein located in the digestive vacuole membrane, like PfMDR1 159.  
Sequence analysis indicates that the protein has 10 transmembrane domains and 
shares homology with known membrane channels and transporters. Despite a decade 
of intense work, the native function of PfCRT remains unclear. Several roles have 
been proposed including export of haemoglobin-derived peptides to the cytosol and 
as an ion channel or proton pump 162,163. Mutations predicted to have inactivating, 
steric consequences on protein folding which cause hypersensitivity to CQ have been 
shown to cause the DV to swell, supporting a role for the wild type protein in 
transporting some natural substrate towards the cytosol 163. As described above, CQ 
is known to diffuse into the DV where it is protonated and trapped in the acidic 
environment. The globally prevalent K76T mutation likely enhances the activity of 
the transporter or reduces its specificity, allowing the efflux of protonated, charged 
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chloroquine, and thereby reduces intra-DV CQ levels to a sub-therapeutic 
concentration 163,164. Indeed, an earlier study in Xenopus oocytes showed mutant 
PfCRT could transport non-protonated CQ whereas wild type PfCRT could not 164. 
The identification of mutations which increase sensitivity of already-sensitive strains 
suggests the wild type protein has the ability to export small amounts of protonated  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 Schematic representation of the mechanism of lumefantrine, mefloquine, and 
chloroquine action and resistance 
Chloroquine and lumefantrine are believed to inhibit parasite haemoglobin detoxification by similar 
processes. Chloroquine diffuses into the digestive vacuole where it is spontaneously diprotonated in 
the acidic environment into HCQ2+ which blocks haem detoxification. Wild type PfCRT is incapable 
of effluxing the charged chloroquine molecule. The mutant PfCRT(K76T) molecule, which confers 
chloroquine resistance, is capable of pumping protonated chloroquine out of the vacuole, thus 
reducing the effective concentration of HCQ2+ in the digestive vacuole. Lumefantrine is believed to 
be pumped into the vacuole by PfMDR1 where it is similarly protonated to HLUM+, which interferes 
with haem detoxification. PfMDR(N86Y) is believed to block the import of LUM into the digestive 
vacuole. However, lumefantrine in the cytosol may still inhibit an essential process which explains 
why N86Y only confers reduced parasite susceptibility to lumefantrine. Mefloquine sensitivity 
follows a similar trend and may inhibit the 80S ribosome in the cytosol. These data are adapted from 
Veiga et al141 and Wong et al143.  
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CQ to the cytosol at steady state, and any mutations which inactivate the protein 
would cause super-lethal accumulation of CQ in the DV (Fig 7). Still, further 
investigation is required to improve our understanding of how this complex process 
occurs and elucidate any involvement of other factors in tuning CQR phenotypes. 
 A similar mechanism may be involved in mediating amodiaquine resistance 
as PfCRT(K76T) has been reported to be associated with clinical treatment failure in 
patients in the Greater Middle East treated with amodiaquine monotherapy 165,166. 
Additionally, mutant CRT, albeit with a different mutation encoding H95P, is 
associated with loss of amodiaquine sensitivity in P. berghei 167. Further 
investigation will be required to unravel the mechanisms mediating amodiaquine 
resistance and its underlying mechanism of action. 
 
 
1.5.2.3 Piperaquine Resistance 
 
 Currently, piperaquine is used in combination with artemisinin as 
dihydroartemisinin-piperaquine, though it was previously used as a monotherapy in 
China from the 1960s until reports of resistance in the 1980s 168,169. 
Dihydroartemisinin-piperaquine combination therapy (DP) has found success where 
other ACTs have started to fail, namely in the Greater Mekong Subregion. However, 
as early as 2010, PCR-corrected trials indicated that failure rates to DP were as high 
as 25% in some parts of Cambodia 170,171. Efficacy of DP has continued to decline, 
and recent reports suggest a single artemisinin- and piperaquine-resistant P. 
falciparum lineage may be sweeping across the GMS 172,173. To date, there have been 
no reports of piperaquine failure outside of the GMS.  
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1.5.2.4 Mechanism of resistance to piperaquine 
 
Unfortunately, there are no culture-adapted clinical isolates from the 1980s 
when resistance to piperaquine monotherapy in China was first reported. Ex vivo 
studies of piperaquine-resistant parasites in the late 1990s, largely carried out by one 
group led by H Yang, suggested cross-resistance to chloroquine and piperaquine 169. 
Indeed, the piperaquine molecule is also a weak base and shares a quinoline structure 
with chloroquine. However, a more recent study of 280 isolates from French 
travellers reported that chloroquine and piperaquine resistance are not linked and that 
any early associations were simply co-occurences 174.  
Early attempts to generate a piperaquine-resistant parasite in vitro succeeded 
and identified a novel SNP in pfcrt encoding C101F, deamplification of pfmdr1, and 
a novel amplification on chromosome 5 in two independent clones 175. Both clones 
displayed decreased accumulation of the drug in the parasite. However, this 
resistance was unstable and reverted in the absence of piperaquine pressure. Recent 
in vitro investigation and genome editing definitively showed this C101F mutation 
in PfCRT could mediate piperaquine resistance 176. This data provides insight into a 
mechanism of piperaquine action in the haem detoxification process much like 
chloroquine. A mutant PfCRT could pump the drug out of the DV. However, this 
causative mutation has not yet been observed in the field 177.  
A recent phenotype-genotype association study conducted by Benoit 
Witkowski showed ex vivo piperaquine sensitivity is associated with plasmepsin II 
copy number. Plasmepsin II is a haemoglobinase localised to the parasite DV 178,179. 
Parasites with duplicated plasmepsin II displayed 100-fold greater survival than 
parasites harbouring single copies of the gene in the novel Piperaquine Survival 
Assay 180. Another study of isolates from Cambodia re-identified this duplication and 
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also associated a novel mutation encoding E415G in Exonuclease I with reduced 
piperaquine susceptibility 181. While polymorphisms in Plasmepsin II seem 
consistent with what is known and proposed about piperaquine’s mechanism of 
action, mutations in Exonuclease I are harder to explain. However, a recent study by 
Andrew Lee and David Fidock showed that Cambodian parasites lacking ExoI 
displayed a mild mutator phenotype. To date, no polymorphisms in plasmepsin II or 
exoI have been detected in parasites outside of Southeast Asia, though these markers 
have been used to track resistance throughout the GMS 172. However, currently there 
are fears of a parasite lineage bearing plasmepsin II CNVs and pfk13 mutations 
sweeping across the GMS, entrenching artemisinin and piperaquine resistance. 
Further work is needed to examine how these and other mutations may impact 
piperaquine accumulation and action.  
 
 
1.5.3 Resistance to artemisinins 
 As described above, artemisinin combination therapies (ACT) are used 
universally around the world in malaria endemic regions. The artemisinin component 
of ACT is one of several molecules but all are metabolised in vivo into 
dihydroartemisinin. These compounds have high potency on the early ring stage of 
P. falciparum and rapidly reduce peripheral parasitaemia. However, due to the 
dramatic differences in stage-specific cytotoxicity, parasites of other stages by not be 
completely killed off by the time the drug is completely degraded in the body.  
 ACTs have had excellent success worldwide since their deployment in the 
mid 1990s—however widely reported resistance in Southeast Asia threatens their 
global efficacy 182. Noedl and Dondorp first reported clinical treatment failures in 
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Western Cambodia along the Cambodian-Thai border in 2008 and 2009 183,184. Since 
then, treatment failures have been reported widely across Mekong, and as mentioned 
above, some fear the spread of a single, multi-drug resistant strain across the region 
3,172. To date, ACTs remain highly effective throughout Africa and South America. 
One study in the New England Journal of Medicine in July 2017 described the 
emergence of an artemisinin-resistant parasite in Equatorial Guinea in a Chinese 
worker 185. In vitro culture adaptation and examination showed this parasite had an 
elevated ring-stage survival phenotype similar to but less dramatic than parasites of 
Southeast Asian origin. While this report is certainly concerning, the mutations in 
the parasite genome noted in this report have never been observed previously nor 
observed since, either in Africa or the GMS. Several recent studies of imported P. 
falciparum malaria cases in Europe suggest that ACT efficacy may be declining in 
sub-Saharan Africa. These studies beg continued investigation.  
 Interestingly, when artesunate was first used as a monotherapy in the late 
1990s, nearly one in five patients had recrudescent parasitaemia. Even when 
artemisinin is administered for seven days, one in ten patients display recrudescent 
parasitaemia 186. This sparks an interesting debate as to whether the treatment failure 
observed in Southeast Asia is truly artemisinin resistance or just partner drug failure. 
The consensus in the field is that the ring-stage survival phenotype quantified in the 
lab is indicative of clinical treatment outcome, though this association needs to be 
further investigated.  
Currently, extended ACT regimens and triple ACTs (combinations of three 
drugs) are under examination for their efficacy in regions with multi-drug resistant 
parasites. Additionally, synthetic endoperoxides with longer in vivo half-lives are 
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under development and show great promise, particularly on these artemisinin-
resistant strains.  
 
 
1.5.3.1 Mechanism of resistance to artemisinins 
 
 So far, very little is known about how the falciparum parasite tunes its 
biology to evade artemisinins. Artemisinins have remarkably short, 2-5-hour half-
lives both in the body and in vitro 187. As a result, it is inappropriate to study 
resistance over a 48-hour lifecycle like chloroquine. Instead, small windows of the 
lifecycle should be examined. A seminal work by Witkowski et al in 2013 showed 
that a 6-hour pulse of 700 nM dihydroartemisinin administered to cultures of early 
ring-stage P. falciparum parasites distinguished between slow-clearing parasites 
from Pailin, Cambodia and sensitive, normally-clearing parasites from Ratanakiri, 
Cambodia 188. This in vitro correlation with clinical phenotype laid the foundations 
of the subsequent efforts to understand this ring-stage phenomenon. A later study by 
Klonis et al showed an oscillating artemisinin sensitivity profile of the 3D7 isolate 
across a 48-hour lifecycle 91 (Fig 8). This work revealed a period of hypersensitivity 
in the first few hours of the lifecycle immediately followed by a brief period of 
relative resistance in the late ring/early trophozoite stage, which progresses back 
towards sensitivity in the trophozoite stage. The basis of this early ring-stage 
hypersensitivity and thereby resistance is the subject of intense investigation.  
It has been long proposed that the haem-derived iron atoms activate the 
endoperoxide in dihydroartemisinin. This therefore would support a mechanism of 
resistance involving altered haemoglobin uptake or degradation. 
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Figure 8 Comparison of time-dependent relationship between haemoglobin uptake and 
artemisinin resistance 
Overlaid data, derived from Klonis et al (DHA EC50’s) and Elliott et al (haemoglobin content), show 
how parasite sensitivity to artemisinin seems to negatively correlate with haemoglobin content. 
Parasites are more susceptible to artemisinin when there is less haemoglobin in the parasite cell. 
These studies were conducted by different laboratories making it difficult to directly compare the 
exact temporal relationship between artemisinin susceptibility and haemoglobin content. However, as 
haemoglobin is degraded in the trophozoite stage, haem and haemazoin may activate artemisinin’s 
endoperoxide. Interestingly, the period hypersensitivity in the ring-stage does not correlate with 
haemoglobin content as even by microscopy, there is little to no haemoglobin in the parasite cell.  
 
Indeed, several studies have shown that interfering with haemoglobin degradation by 
knocking out falcipain proteases or treating cells with protease inhibitors 
dramatically affects parasite susceptibility to artemisinins90,189,190. However, 
questions remain regarding how haemoglobin degradation could affect cells in the 
first few hours of life when the digestive vacuole is still forming, and studies have 
shown that there is virtually no haemoglobin in the parasite at this stage191 (Fig 8).  
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Figure 9 Protein map of pfkelch13 and hkeap1 
A schematic representation of PfKelch13 protein, the confirmed modulator of artemisinin resistance 
in vitro and in vivo, and its human orthologue, hKEAP1. PfKelch13 (K13) and KEAP1 both have a 6-
bladed -propeller kelch-domain at their C-terminus as well as a BTB/POZ domain upstream of this 
propeller domain. In the context of the BTB/POZ dimerization domain, the propeller domain 
mediates interactions with ubiquitylation machinery in KEAP1. The BACK domain may help orient 
substrates. K13 lacks the BACK domain but contains an approximately 200 amino acid N-terminal 
sequence with little homology to KEAP1 or other mammalian factors.  
 
 
Clinical resistance has been linked to several mutations in pfkelch13, which 
produces the Kelch13 (K13) protein, with the C580Y mutation being the most 
common K13 mutation in Southeast Asia. On the molecular level, K13 is a WD40-
repeat containing factor, which shares some homology with the KEAP1 
transcriptional regulator in mammalian cells (Fig 9). KEAP1 regulates the NRF2 
transcription factor, which activates stress response and cell survival pathways.  
However, K13 does not seem to be involved directly in transcriptional 
regulation. Instead, a recent study localised K13 to a conspicuous cytoplasmic 
compartment closely apposed to the digestive vacuole 192.  
Multi-omic investigation suggests that cells expressing K13 mutations 
associated with artemisinin resistance seem to have a more robust oxidative stress 
response, consistent with the proposed mechanism of artemisinin-mediated 
cytotoxicity. These cells display elevated levels of glutathione, an important 
antioxidant, lower abundance of haemoglobin-derived peptides, and a transcriptional 
response tuned towards expression of mitochondrial redox factors 193,194. 
Artemisinin-treated parasites also display significantly increased global 
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ubiquitylation, consistent with a response involving the ubiquitin-proteasome system 
and increased protein turnover 89,195. 
The only mechanistic information on K13-mediated protection comes from a 
2015 study by Mbengue et al 196. In this work, the authors propose that K13 
regulates PI3K, which produces the lipid signalling molecule phosphatidylinositol-3-
phosphate (PI3P). They show that parasites with K13 mutations have elevated levels 
of PI3P, and artificial induction of PI3P in the absence of K13 mutations 
phenocopies the K13(C580Y)-mediated ring-stage protection from artemisinins. 
PI3P localises to the digestive vacuole and apicoplast membranes, though it is 
known to participate in a wide variety of intracellular processes in other organisms 
196–199. One 2018 study published by Bhattacharjee et al, also from this laboratory, 
demonstrated that K13 localises to PI3P-labeled vesicles and structures emanating 
from the endoplasmic reticulum, which increase in number during artemisinin-
induced stress 200 (Fig 10). Apparently, these vesicles contain exported proteins, 
namely PfEMP1, an important family of cytoadhesion molecules that are secreted to 
the red cell surface and mediates virulence. In their study, K13 copurifies with these 
factors and many other factors involved in proteostasis. Additionally, red cells 
infected with parasites expressing resistance-associated pfkelch13 mutations have 
different cytoadherence properties. However, a previous study in 2016 by six 
prominent laboratories each independently confirmed that no PI3P could be detected 
in the ER, and PI3P does not have a role in export to the red cell, which questions 
these results 201. Additionally the cryoimmunoelectron micrographs presented as 
strong evidence in Bhattacharjee’s work seem to show both PI3P and K13 signal 
essentially everywhere inside and outside of the parasite and red cell in DHA-treated 
samples suggesting that these antibodies may also recognise off-target epitopes 200.  
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Another recent work addressed the mechanisms underlying artemisinin-
induced dormancy 202. Zhang et al demonstrated that artemisinin stress causes BiP, 
an ER-resident chaperone, to mediate PK4 dimerisation in the ER membrane. This 
dimerised PK4 phosphorylates and activates eukaryotic initiation factor 2a (eIF2), 
which induces translational repression. Normally, eIF2 is only phosphorylated in 
schizonts in preparation for cytokinesis and egress. However, in parasites with K13 
mutations associated with artemisinin resistance, PK4 either remains phosphorylated 
or is prematurely phosphorylated in early ring-stage parasites. By extension, these 
cells exhibit a type of dormancy in the early ring-stage that allows them to evade 
some of artemisinin’s cytotoxicity and propagate into the next cycle. Chemically 
inhibiting PK4 restores sensitivity in artemisinin-resistant strains 202 (Fig 10). 
The Zhang study revealed important information about the mechanisms of 
dormancy, but do not clarify how the parasite resumes its normal growth. Around the 
same time, a third paper by Duvalsaint et al examined the role of phytohormones and 
isoprenoids in enabling the parasite to resume its growth after artemisinin-induced 
dormancy 203. This work showed that apicoplast-derived isoprenes were required for 
exiting the artemisinin-induced dormant state.  
A number of other factors have been proposed to be involved in modulating 
drug response and be associated with clinical treatment failure. Some of these 
proteins include Ubp1 and AP2µ, which are the subjects of this thesis, as well as 
ATP6, the SERCA calcium pump 204–208. The role of ATP6 has been seriously 
questioned lately, and there is no evidence of association with resistance in the field 
120,209–211. It is likely that the mechanism of artemisinin resistance is subtle because 
only a fraction of “resistant” parasites actually survive to the next cycle after 
artemisinin exposure. From the evidence presented so far, it probably involves some  
 62 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 Schematic representation of artemisinin response and resistance mechanisms 
Artemisinin exposure is believed to induce a type of dormancy in Plasmodium falciparum. How the 
cell recovers from this dormancy and the characteristics of this dormancy are mostly unknown. K13 
mutations cause resistance either by enhancing the ability of parasite cells to endure artemisinin-
induced stress or escape ART-induced dormancy. Two mechanisms have been offered: induction of 
ER stress response and translational dormancy factors BiP, PK4, and eIF2 as well as a PI3P-
dependent hypervesiculation and export of key virulence factors. Reduced parasite susceptibility to 
artemisinin has been reported in the absence of K13 mutations. However, it is unclear how this would 
occur.   
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modulation of protein synthesis and turnover centred at the ER and may require 
additional antioxidant cofactors or signalling molecules. Overall, considerable study 
is still required to elucidate the mechanisms of artemisinin activation, action, and 
resistance in order to preserve their efficacy worldwide.  
 
1.6 Evaluation and Surveillance of Drug Resistance 
Currently, surveillance of drug resistance predominantly relies on active case 
detection and reporting through drug efficacy studies in the field and in vitro or ex 
vivo assessment of drug susceptibility of parasite isolates in the lab.  
 Evaluation of drug efficacy in the field involves treating symptomatic 
patients with a frontline chemotherapy and monitoring these patients’ clinical and 
parasitological responses over 4 to 6 weeks. Namely, investigators examine 
progression of clinical symptoms, resolution of peripheral, acute parasitaemia, and 
long-term protection from reinfection or recrudescence. The sum of these indicators 
provides evidence of early treatment failure, late treatment failure, delayed 
clearance, and adequate clinical and parasitological response. While blood smears 
are taken and read in the field for microscopic diagnosis of infection and treatment 
monitoring, peripheral blood samples are usually taken as filter paper blood spots or 
venous blood samples for subsequent PCR-based investigation of parasite clearance 
and molecular markers of drug resistance. PCR and Sanger Sequencing are also used 
to separate new infections or multi-species infections from parasite recrudescence 
after treatment. This genotyping across a region can provide insights into the spread 
of resistance-associated parasite genetic haplotypes.  
 In the lab, cryopreserved or live samples of infected blood can be cultured 
and examined for ex vivo drug susceptibility. Some of these isolates may be adapted  
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Figure 11 Common antimalarial drug sensitivity assays 
Schematic representation of common antimalarial drug sensitivity assays. The 48-hour and 96-hour 
assays involve exposing parasites to serial dilutions of compounds in 96 well plates for the stated 
length of time beginning when parasites are in the ring stage. After the stated time, these plates are 
frozen, thawed, and lysed. Parasite growth is quantitated by proxy with SYBR-Green, which stains 
DNA. Total DNA correlates with parasite proliferation. Short exposure assays (third assay) involve 
exposing parasites to fixed concentrations or serial dilutions of a chemotherapy for 4 to 6 hours. 
Drugs are then washed off and parasite growth is assessed directly by live cell FACS using SYBR 
Green and MitoTracker Deep Red (MTDR), which stains total parasite DNA and mitochondria of live 
cells.  
 
 
to long-term in vitro culture and used for advanced genetic or molecular research, 
including genome editing. Three main assay formats are used to examine drug 
susceptibility in the lab: 48-hour dose response, pulsed dose response, and single 
pulse survival (Fig 11). The type of assay and the method of assay readout chosen 
depends on the drug under examination. Drugs with half-lives like chloroquine or 
pyrimethamine are assayed using the 48-hour approach. This is because these drugs 
remain at a near constant concentration in the body over a single parasite lifecycle. 
Quantitating the reduction in parasitaemia over a single lifecycle provides insight 
into how the parasites will be cleared over multiple days in vivo. However, this 48-
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hour format is not appropriate for drugs with shorter half-lives. In particular, 
artemisinins are exceptionally unstable and rapidly degrade in the body and in 
culture. Therefore a 48-hour exposure is not physiologically relevant. Witkowski et 
al first described a pulsed assay format where parasites are exposed to the 
artemisinin compound for 6 hours, which more closely resembles the in vivo half-life 
of the drug, and then extensively washed 212. Shorter pulses have also been explored 
for artemisinins with equal ability to discriminate resistant and sensitive parasite 
populations 213. Incorporation of serial dilutions of a drug either in a pulsed or 48-
hour exposure format allows investigators to determine EC50 or EC90. In general, a 
FACS-based readout using a live/dead stain like MitoTracker and a DNA stain like 
SYBR Green provides a reproducible and robust quantitation of parasite survival. 
However, FACS machines are expensive to maintain and may not be available. In 
this case, SYBR Green-based quantitation of parasite proliferation in a plate reader is 
an affordable and high-throughput. However, this method is sensitive to the exact 
concentration of parasite material in each well—evaporation or sample loss will lead 
to overcounting of parasite DNA—whereas FACS counts the same number of gate-
stopping events per sample. In practice, the difference is small, though FACS is 
particularly useful when looking at artemisinins because these drugs render a 
subpopulation of cells pyknotic whereby they are nonreplicative but still retain 
DNA. SYBR Green methods will count these parasites as alive, whereas FACS with 
MitoTracker will not.  
 When carried out in the ring stage, the pulsed assay format, also known as 
the ring-stage survival assay (RSA), is the only validated assay for examining the 
sensitivity of a given parasite isolate or strain to artemisinin. With clinical parasite 
isolates, the ex vivo RSA survival (percentage of cells surviving the drug pulse) 
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correlates well with in vivo parasite clearance and clinical outcome. However, it is 
not clear whether elevated survival rates in this assay format are good predictors of 
clinical outcome (i.e. would a novel mutation identified in the laboratory be 
clinically relevant?). Additionally, this assay does not capture important aspects of 
host environment during ring-stage infection, namely environmental temperature 
(Fever conditions). Ring-stage resistance must occur in the context of hyperthermic 
conditions, and the RSA is only performed at 37C. Therefore, while the RSA is the 
best assay we currently have to examine parasite sensitivity to artemisinin, there is 
clear room for improvement, and it will be important to understand how predictive 
the RSA survival rates are of clinical outcome. 
 For antimicrobial agents such as doxcycyline and azithromycin, in vitro 
studies of parasite susceptibility require longer 96-hour exposures because these 
agents exert cytotoxic effects on second-generation parasites. In general, the assay 
formats described here are robust and basic parameters can be manipulated to 
provide an optimised readout of parasite survival. 
 This thesis uses EC50 to refer to the concentration of a compound required to 
reduce parasite growth by 50% with respect to a solvent-treated control. Though it 
may seem pedantic, it is important to distinguish cytocidal and cytostatic killing 
when studying the cytotoxicity of compounds in live cells. Because the assays in this 
thesis quantify cellular proliferation, it is inappropriate to use IC50, which 
canonically refers to inhibition of a specific pathway or enzyme.  
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1.7 Endocytosis in P. falciparum 
 
 Many of the most common antimalarial drugs leverage the malaria parasite’s 
dependence on haemoglobin. Despite its importance to drug action and broader 
parasite biology, relatively little is known about how malaria parasites sample their 
extracellular and intraerythrocyte environments.   
The term endocytosis encompasses any mechanism of uptake of material 
from the extracellular space and takes many forms in higher order eukaryotes214. 
Broadly, there are three types of endocytosis: phagocytosis, pinocytosis, and 
receptor-mediated endocytosis (Fig 12)214. Phagocytosis describes the active, ATP-
dependent process of invagination and uptake of molecules other than solutes from 
outside the cell through a structure called the cytostome. This is commonly 
associated with the behaviour of macrophages engulfing entire diseased or disease-
causing cells, but also includes the uptake of macromolecules, excluding solutes. 
Pinocytosis is also an ATP-dependent process but only concerns the uptake of 
extracellular fluid and solutes214. Receptor-mediated endocytosis (RME) is a  
 
 
 
 
 
 
 
 
Figure 12 Three types of endocytosis in eukaryotes 
Three major pathways for endocytosis exist in eukaryotes. Phagocytosis involves the uptake of solid 
particles from an extracellular space, including other cells and proteins. By contrast, macropinocytosis 
allows cells to sample soluble, dissolved small molecules in the extracellular space. Receptor-
mediated endocytosis refers to the uptake of extracellular ligands via interaction with ligand-specific, 
transmembrane receptors.  
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specialised mechanism, which internalises receptor-bound cargo and therefore is a 
cargo-specific process. RME is a highly regulated process and encompasses a wide 
variety of uptake pathways across eukaryote cells. All RME pathways involve a 
controlled invagination of the plasma membrane around a critical mass of cargo-
bound receptors214. This invagination is directed by several factors including a coat 
protein, which polymerises into a cage-like structure on the cytoplasmic face of the 
budding membrane215. Via ATP-dependent membrane scission, the membrane 
droplet is cleaved from the plasma membrane and trafficked into early endosomal 
compartments or hydrolytic lysosomes. The cargo molecule is dissociated from the 
receptor molecule, and the receptor molecule is, in some cases, shuttled back to the 
plasma membrane216. All of these processes originate at the plasma membrane and 
therefore differ from transcytosis, which describes the budding and traffic of 
membrane bound vesicles between organelles inside the cell214.  
 Mechanisms of endocytosis in Plasmodium are generally unclear. To date, 
the study of endocytosis revolves around the examination of haemoglobin uptake. 
The parasite engulfs an enormous amount of haemoglobin from the host erythrocyte 
cytoplasm during the asexual lifecycle. It is not immediately clear if this is by a 
continuous, dedicated phagocytic process or simply one major phagocytic event, 
which happens to ingest a large volume of haemoglobin, since the erythrocyte 
cytoplasm contains so much of it. A seminal study by Elliott et al in 2007 showed 
the parasite has four separate pathways for haemoglobin uptake, which take place 
over different stages of the asexual cycle 191 (Fig 13). They major mechanism is what 
the authors describe as the “Big Gulp.” They time this process to occur between 
hours 6 and 30 of development and describe it as the invagination of a single, 
massive vacuole, formed during the developmental “folding” of the very-early  
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Figure 13 Several distinct pathways for haemoglobin uptake 
During Plasmodium falciparum development, the parasite cell ingests haemoglobin through four 
major means. The Big Gulp is a large endocytic event mediated by unknown factors occurring in the 
ring stage. Throughout the asexual cycle small vesicles, cytostomal tubules, and phagotrophs also 
mediate uptake. Phagotrophs are similar to The Big Gulp but is actin-independent. 
 
parasite into the canonical ring shape observed by Giemsa staining. This process 
seems to be actin independent and accounts for nearly 95% of the haemoglobin 
uptake. Other mechanisms of haemoglobin ingestion include small haemoglobin-
containing vesicles, which can be observed budding from the cytostome by electron 
microscopy before, during, and after the Big Gulp; cystostomal tubules, which form  
direct channels from the cytostome into the cytoplasm; and phagotrophs, which 
define large haemoglobin-containing vesicles 191.  
 Though clathrin heavy chain is encoded in the parasite genome, it has not yet  
been characterised, so the involvement of clathrin in haemoglobin endocytosis is 
unknown. However, by electron microscopy, haemoglobin-containing vesicles seem 
to be too small to be consistent with clathrin-coated vesicles in higher-order 
eukaryotes191. In 2010, Bakar et al recapitulated some of these results and showed 
that the parasite does not begin to sample the host cell cytoplasm until the mid-ring 
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stage 217. This group also showed haemoglobin is first internalised into small 
vesicular structures that then coalesce into the digestive vacuole.  
The role of actin in parasite endocytosis is subject to some debate. The 
original Elliott study suggested the Big Gulp is not affected by actin inhibitors and 
that only some of the mechanisms of endocytic uptake were actin-dependent191. 
However, multiple studies have shown that interfering with actin dynamics does 
seem to affect haemoglobin levels in the cell and digestive vacuole size, leading to 
the conclusion that an actomyosin motor is somehow required in the traffic of 
haemoglobin-containing endocytic vesicles to the digestive vacuole 191,217–220. 
Another study recently suggested that Dyn1, a dynamin family member, is required 
for cleaving vesicles from the plasma membrane for parasite endocytic sampling of 
the erythrocyte cytosol, much like in other eukaryotes 220.  
Through all of this work, it is still not clear what factors mediate these 
different pathways of haemoglobin uptake and whether they all proceed via the 
cytosome. It is also not clear if there are any receptor-mediated pathways. Across 
nearly all eukaryotic taxa, the AP-2 adaptor protein complex mediates clathrin-
dependent endocytosis from the plasma membrane to the early endosome 
compartment of specialised cargo molecules, including the transferrin receptor. An 
early study in 1986 reported that the parasite produces a transferrin receptor, which 
allows the parasite to ingest ferric iron bound to transferrin 221. However, a later 
study in 1992 showed that parasites did not take up transferrin, suggesting any 
encoded transferrin receptor is either dispensable or behaves in an unknown way 222. 
Therefore, to date, the only mechanistic insights into endocytic processes in the 
parasite exist in the context of haemoglobin uptake, which seems to largely be an 
active, but non-specific sampling of the erythrocyte cytosol. A detailed  
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Figure 14 Overview of adaptor protein complexes 
Eukaryotes have several adaptor protein complexes that mediate compartment-to-compartment 
vesicular traffic. AP-1 mediates Golgi-to-endosome traffic, AP-2 plasma membrane endocytosis, and 
AP-3 intra-endosomal traffic. AP-1, AP2, and AP-3 functionality is conserved across eukaryotes. AP-
4 and AP-5 are not necessarily found in all eukaryotes and are involved in specialised traffic in the 
Golgi and endosomal network. COPI and COPII (not pictured) mediate traffic between the ER and 
the Golgi.   
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characterisation of clathrin heavy chain and the transferrin receptor are necessary to 
further elucidate potential roles of canonical endocytic machinery in the parasite.  
 
 
1.8 Adaptor Protein Complexes 
 
 Where endocytosis refers to the process of moving material from the 
extracellular space into the cell, transcytosis refers to a similar process, which moves 
material from compartment to compartment within the cell. In many cases, this cargo 
shuttling is mediated by specialised adaptor protein complexes that recognise cargo 
molecules and coat proteins223. These complexes and their associated traffic define 
major cargo highways in the cell.  
The adaptor protein complexes are composed of the four heterotetrameric 
complexes, AP-1-AP-4, and the heterohexameric AP-5 which associate with clathrin 
or another coat protein to direct intracellular vesicular traffic 224 (Fig 14). Not all 
eukaryotes have all five complexes, but all sequenced organisms have AP-1, AP-2, 
and AP-3, reflecting their evolutionary functional importance214,223. AP-1 traffics 
between the trans-Golgi network (TGN) and endosomes. AP-2 canonically mediates 
endocytosis of bound cargo from the plasma membrane to the early endosome. AP-3 
moves cargo from the early endosome further along the endosomal system to 
multivesicular bodies, late endosomes, or lysosome-like organelles. AP-1-AP-3 all 
interact with clathrin cages 224. AP-4 resembles AP-1 in that it traffics from the 
trans-Golgi to the endosomal network, but it has functionally diverged and is utilised 
in unique, cell type-specific pathways, such as neural signalling and polarised 
intracellular traffic. Notably, AP-4-containing vesicles do not utilise a clathrin coat 
224,225. AP-5 is the most recently discovered complex in the adaptor complex family. 
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Like AP-4, AP-5 does not seem to associate with clathrin and is also localised to the 
TGN. Although it is expressed throughout mammalian development and is essential 
for cell survival, its trafficking destination and cargo are still unknown 225,226. The 
monomeric GGA proteins are also clathrin adaptins, share some homology with the 
gamma subunits of the APs, and participate in similar trafficking pathways. 
However, these are well outside the scope of this thesis and will not be discussed or 
reviewed. 
 Architecturally, the adaptor protein complexes are heterotetramers consisting 
of two large (/ ) , one medium (µ), and one small subunit () (Fig 15). The 
large subunits are made of a large trunk domain consisting primarily of a twisting L-  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15 Architecture of adaptor protein complex core 
(Top panel) The adaptor protein complexes are heterotetrameric complexes consisting of large 
(subunits that provide architectural support and interact with the coat protein and vesicle 
membrane via appendage domains. The structure of these appendages have not been resolved and 
therefore are not depicted. The µ subunit interacts with the cargo molecules, and  provides 
regulatory and structural functionality. µ resides in a saddle formed by the large subunits. (Bottom 
panel) A list of the expected components of each adaptor protein complex and the respective P. 
falciparum gene identifiers. No gene for AP-2has been annotated in the P. falciparum genome.   
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shaped, -helical solenoid connected to an appendage, “ear” domain by a protease-
sensitive linker 224,227. The trunk domains of each large subunit are primarily 
structural and make contacts with each other and the µ and  subunits. The ear 
appendages are more functional and are responsible for interaction with the coat 
protein and other factors 227. The L-shaped curvature of the superhelical trunks form 
pockets that cradle  and µ subunits within the assembled complex 227,228.  
 The  subunit shares structural homology with the N-terminal domain of the 
µ subunit 228. The overall function of within an AP complex remains under 
investigation. It is probably involved in complex stability. Mutations in this subunit 
in the context of most adaptor complexes have been linked with developmental  
pathologies in humans 229,230. The µ subunit is directly responsible for cargo binding 
on the C-terminal domain of the subunit and harbours phosphoregulatory sites on the 
flexible linker bridging the N- and C-terminal domains. Structurally, µ sits in a  
saddle formed by the two large subunits until a cargo molecule is present, at which 
point, the µ subunit undergoes a large translocation and rests “open” on the solvent-
exposed surface of large,  subunit 227,228. The µ and  subunits directly bind C-
terminal dileucine (D/ExxxLL) and tyrosine-hydrophobic (Yxx) sorting motifs. µ 
also interacts with phospholipids.  
 Mechanistically, the adaptor complex weakly associates with 
phosphatidylinositol-labelled membranes, with the lipid type specific to each  
complex. Phosphorylation of a threonine residue on the linker in the µ subunit 
triggers a conformational change, which enables the µ and  subunits to interact with 
cargo molecules 231,232. These cargo-loaded complexes interact with other factors  
involved in the budding process including the coat protein. The budding process 
continues as the coat polymerises around the budding vesicle until dynamin cleaves 
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the neck of the invagination, forming the free vesicle and resealing the parental 
membrane 231. A large number of other factors including auxulin, epsin, AP180, and 
amphiphysins are recruited to the sites of the initial invagination after cargo 
recognition and binding. These factors are complex-specific and regulate how the 
budding process proceeds and where the vesicle ultimately goes.  
 The adaptor protein complexes and clathrin support the late secretory 
pathway and endocytosis between the trans-Golgi, cell surface, and endosomal 
network as described. Upstream of these pathways, the coatomer complexes COPI 
and COPII mediate anterograde and retrograde traffic between the endoplasmic 
reticulum and the cis-Golgi233. COPI also mediates traffic within the Golgi. Unlike 
the adaptor protein complexes, COPI and COPII both aggregate and interact with 
cargo molecules and act as vesicular coats233.  
 Though these processes are reasonably well defined in mammalian cells, it is 
unclear how this canon translates to Apicomplexans. Apicomplexa are, at least for 
some of their lifecycles, intracellular and exist within a parasitophorous vacuole and 
have unique organelles in the post-Golgi secretory pathway. Cargo will need to get 
to these organelles, and it is possible that traditional Golgi-to-endosome sorting 
pathways have been redirected towards these organelles. In Toxoplasma gondii, ap-1 
has been shown to target to the apical secretory organelles from the TGN, and 
limited evidence suggests the same may be true in Plasmodium falciparum 234,235. In 
Dictyostelium, the large  subunit of AP-1 plays a dual role in  AP-2 236. Though no 
additional studies of adaptins in Apicomplexa have been reported, this may suggest 
an evolutionary multi-purposing of some adaptins in multiple adaptor complexes as a 
result of genome streamlining.  
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 AP-2 in Plasmodium has been implicated in artemisinin resistance in the 
field and in rodent model studies 204–206,208. In 2007, Hunt et al evolved an 
artemisinin-resistant P. chabaudi malaria parasite by a series of sequential drug 
selections and in vivo crosses208. Genome sequencing identified a mutation of 
interest in the pfap2mu gene, encoding PcAP-2µ(I568T). Subsequent analysis of P. 
falciparum parasites from patients in East Africa identified evidence of selective 
pressure on a separate mutation of interest encoding PfAP-2µ(S160N), and 
preliminary reverse genetics work suggested this mutation may alter parasites 
susceptibility to several drugs205. These studies argued a putative mechanism in 
haemoglobin endocytosis by homology with mammalian AP-2, which performs 
receptor-mediated endocytosis from the plasma membrane, but how receptor-
mediated endocytosis could occur in the context of a double membrane at the 
parasite periphery is unclear. Specific investigations of these putative factors are 
needed to determine the nature and extent of their involvement in endocytic events.  
 
 
1.9 Roles of ubiquitin and ubiquitin turnover P. falciparum 
 
 Ubiquitin, as its name suggests, is involved in nearly every process in the 
cell. The small, 76-amino-acid protein is a post-translational modification, ligated 
onto lysine sidechains of a protein target via an enzymatic ubiquitylation cascade. 
Ubiquitylation is a dynamic and reversible process, and understanding how ubiquitin 
ligation and removal occurs throughout the parasite is important as artemisinin 
susceptibility has been linked to ubiquitylation and protein turnover.  
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1.9.1 Ubiquitin conjugation is a dynamic process 
 
 Generally, ubiquitylation is catalyzed by a cascade of ubiquitin-activating E1, 
ubiquitin-conjugating E2, and ubiquitin-ligating E3 enzymes237. An E1 first 
generates an activated, ubiquitin adenylate through ATP hydrolysis. The E1 then 
transfers this ubiquitin intermediate to a cysteine side chain in the E2 active site via a 
transthioesterification reaction. With the help of one or more E3 enzymes, the C-  
terminus of ubiquitin is finally covalently ligated to the -NH3 of the target lysine 
side chain on the substrate (Fig 16).  
 The final step of the ubiquitin ligation cascade occurs through one of two 
mechanisms depending on the ligation domain of the E3 protein. HECT 
(Homologous to the E6-AP Carboxyl Terminus) domain-containing E3s catalyse a  
transthioesterification between the E2 active cysteine and a cysteine in their active 
site, and subsequently, ligate ubiquitin to the target protein. In contrast, RING 
(Really Interesting New Gene) domain-containing E3s never covalently possess 
ubiquitin but rather guide direct ligation of ubiquitin from the E2 cysteine to the 
target lysine.  
Despite the differences in the molecular size of each modification, 
ubiquitylation is a dynamic modification like acetylation, phosphorylation, and 
methylation, and like methylation, a substrate can be mono- or polyubiquitylated. In 
all cases, ubiquitylation begins with ligation to a lysine side chain of the target 
protein by one of the mechanisms previously discussed. Successive ubiquitylation 
can then form chains on different and alternating lysine side chains of the previous 
ubiquitin (K6, K11, K29, K48, K63 etc.).  
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Figure 16 Conjugation and cleavage of ubiquitin chains from target substrates 
Conjugation and cleavage of ubiquitin chains from a target substrate requires several enzymatic steps. 
E1 ubiquitin-activating, E2 ubiquitin-conjugating, and E3 ubiquitin-ligating enzymes all work in 
concert to retrieve free ubiquitin from solution and covalently attach it to the -NH3 of a lysine 
sidechain of a target protein in an ATP-dependent process. The specificity of this reaction is derived 
by combinatorial diversity resulting from the pairing of E2 and E3 enzymes into a catalytic 
holoenzyme. Removal of ubiquitin requires the activity of a deubiquitinase (DUB) which catalyses a 
hydrolysis reaction to cleave the thioester linking ubiquitin and a substrate sidechain. Ubiquitin 
conjugation and cleavage is involved in cell signaling, chromatic modification, and protein turnover.    
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In the cell, the degree and type of ubiquitylation determines the fate of the 
ubiquitylated substrate. Polyubiquitylation on K48 always marks a protein for 
proteolysis by the 26S proteasome 237. K63-linked polyubiquitin chains are involved, 
in humans, in intracellular targeting and transportation of vesicles, inflammation, and 
other tasks 237,238. Other types of polyubiquitylation, including branched chains and 
monoubiquitylation, are much less well understood 239,240.  
Much of the substrate specificity of the ubiquitin ligation cascade is believed 
to be derived from the E3 enzyme interactions with the target protein. Although 
many HECT-type E3 ubiquitin ligases function as monomers to receive ubiquitin 
from an E2 and modify a target protein, evidence now indicates that many E3’s form 
E2n:E3n multisubunit complexes. These modular complexes take advantage of 
combinatorial diversity to allow a single E3 to toggle between substrates or poly- 
and monoubiquitylation of the same substrate 241. The Plasmodium falciparum 
genome is reported to encode 8 E1s, 14 E2s, and 54 E3s 195.  
 Recent work suggests that nearly half of the proteome may be ubiquitylated, 
with overall ubiquitylation peaking in the trophozoite stage 242. Mass spectrometry 
on P. falciparum whole ubiquitome extracts reveals components of nearly every 
cellular process ranging from chromatin structure to transcription factors to redox 
metabolism maybe ubiquitylated 242. A large number of factors identified in this 
screen are currently of no putative function.   
 There is also considerable interest in ubiquitin-like modifiers including 
SUMO and Nedd8. These proteins are conjugated to target factors in mechanistically 
similar ways, and some machinery has been identified in falciparum, leading to the 
speculation that they are actively involved in regulation of the parasite cell. 
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However, these related systems are beyond the scope of this thesis and will not be 
discussed further. 
As mentioned above, ubiquitylation and protein turnover has been linked to 
artemisinin susceptibility. In particular, K13 is a proposed E3 ligase scaffold factor, 
mediating substrate-ligase interaction 196. Additionally, recent work has associated 
mutations in an E2 (PF3D7_1243700) and HECT H3 (PF3D7_0826100) with 
artemisinin resistance in a GWAS study of 45 parasites from Senegal, but these data 
require further evaluation 243,244.  
 
 
1.9.2 Deubiquitylation as a process, exploitable for cell survival 
  
 Just as ubiquitin monomers are ligated to target proteins and polymerised by 
an E1-E2-E3 cascade, ubiquitin monomers can be removed from proteins or poly-Ub 
chains by specialised proteases called ubiquitin hydrolases (Fig 16). These enzymes 
hydrolyse the isopeptide bond formed between the target lysine side chain and C-
terminal Gly76. The foundational mechanistic biology is well reviewed by 
Wilkinson, but there are two general classes of cysteine hydrolases that operate on 
ubiquitylated substrates: ubiquitin C-terminal hydrolases (UCH-family) and 
ubiquitin-specific proteases (USP/UBP-family) 245. UCH-family proteases resemble 
papain proteases and prefer substrates with single ubiquitin modifications or with 
flexible linkers between the globular domain of the target protein and the isopeptide 
bond. In contrast, UBP-family members prefer polyubiquitylated substrates 245.  
 In general, these factors, and UBPs in particular, play an important role in the 
ubiquitin-proteasome system. Since the majority of cellular energy is devoted to 
protein synthesis and recycling, it makes sense that the cell would aim to limit 
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unnecessary turnover. UBPs remove ubiquitin monomers from proteins destined for 
degradation immediately before entry into the proteasome to preserve a free 
ubiquitin pool. Proteasome activity, and the turnover of this ubiquitin pool, has been 
linked with rates of protein synthesis. Therefore, DUBs have been explored as 
possible drug targets for diseases involving immortal or rapidly dividing cells, 
including many cancers 246,247.  
 Very little is known about how deubiquitylation occurs in Plasmodium spp 
248. To date, only one deubiquitinase (DUB) has been characterised. In 2010, 
Artavanis et al presented the first structural and biochemical characterisation of 
PfUCHL3 (PF3D7_1460400) with and without an ubiquitin substrate bound to the 
active site 249,250. PfUCHL3 is unique in that it is has dual specificity for ubiquitin 
and Nedd8 and is the only deNeddylase in the parasite genome, by inference with 
sequence homology to other taxa. Additionally, PfUCHL3 has similar activity in 
vitro as compared to the human orthologue. 
 The proteasome and DUB system is known to have redundancies in other 
organisms. Therefore, though some DUBs are chemotherapy targets, some may be 
dispensable. The high-resolution structure provided by Artavanis highlights 
important differences between the P. falciparum protein and the human orthologue 
indicating that at least some hydrolases may be druggable. Additionally, ectopically 
overexpressing a catalytically dead mutant of PfUCHL3 in cells is lethal, indicating 
the protein may be essential, though this may be due to a dominant negative effect 
250. Artvanis did not undertake a cell biology approach to examine localisation or 
factors that may interact with PfUCHL3. This work provides a platform into the 
functional characterisation of other P. falciparum DUBs, but to date no other studies 
have been published.  
 82 
 In P. falciparum, components of the DUB/proteasome system have been 
linked to drug resistance. Proteasome inhibitors have been shown to be cytotoxic on 
their own and synergise with artemisinins, supporting a mechanism of action of 
artemisinin involving oxidative insult and resistance requiring an enhanced stress 
response. The DUB Ubp1 has been linked in multiple studies in Plasmodium 
chabaudi and Plasmodium falciparum to artemisinin and chloroquine resistance 
205,208,251–253. Pfubp1 potentially encodes a 416 kDa polypeptide over three exons. 
The C-terminal third of PfUbp1 shares some homology with USP7/HAUSP in 
humans, which is widely targeted by chemotherapies (Fig 17). USP7 regulates 
Mdm2, which regulates p53, a well-characterised tumour suppressor 246. In this case, 
USP7 prevents Mdm2 from being degraded, rather than being a general hydrolase 
targeting polyubiquitin chains at the proteasome. Whether PfUbp1 shares functional 
homology with USP7 and whether the mutations of interest identified in this gene 
have any functional and clinical relevance remains to be investigated.   
 General protein turnover and recycling are only two of the important cellular 
roles of deubiquitylation activity. DUBs are also important components of protein 
quality control at the ER and protein import into the apicoplast (Fig 18). Both of 
these roles involve ubiquitylation of a substrate, unfolding of the polypeptide, and 
feeding into a protein channel. In the case of ER-associated degradation (ERAD), 
misfolded proteins are first recognised in the ER lumen, where these polypeptides 
are recognised by an E2-E3 complex made up of PfUbc7 and PF14_0215 in P. 
falciparum and polyubiquitylated 254. The ubiquitin polymer is then recognised by 
chaperones, which guide the protein to the 26S proteasome in the cytosol where the 
protein is unfolded and degraded, and the ubiquitin polymer is disassembled by 
DUBs.  
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Figure 17 Structure of USP7 catalytic core 
The crystal structure of the catalytic core of USP7 (pink, RCSB: 5KYD) provides insights into how 
recognition and hydrolysis of ubiquitin (green) occurs. The ubiquitin molecule docks into a pocket 
formed by b sheets which form a hand-like structure. The C-terminus of ubiquitin does not have 
secondary structure and extends through a scissor-like catalytic pocket made up of C223, H464, and 
D481. H464 and D481 provide electrostatic stabilisation and help to orient the incoming ubiquitin tail 
with respect to the catalytic cysteine, C223. The reactive sulfhydryl group of C223 catalyses a 
hydrolysis reaction to cleave the thioester linking Gly76 of ubiquitin to a target lysine sidechain.  
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 This system is adapted to the import of proteins across the unusual 4-
membrane structure of the apicoplast. The apicoplast is the relict plastid organelle in 
the parasite most likely acquired through a symbiotic engulfment of a photosynthetic  
red alga. In recent years, studies have revealed that some proteins are localised in 
specific membranes or lumens of this 4-membrane structure, suggesting a functional 
significance of this structure rather than just evolutionary coincidence 255,256. To 
facilitate this sub-compartment-specific targeting, each membrane has a specialised 
“doorway” to the next lumen 256,257. The mechanism by which cargo is first delivered 
through the outermost membrane is unknown, however a 2009 study by Spork et al 
indicated that a modified ERAD pushes proteins through the second outermost 
membrane 257. CDC48, a AAA-type ATPase partners with Der1p, a membrane 
channel, to force proteins through this membrane with the help of an ubiquitylation 
cascade leading to the linearisation of the polypeptide. Proteins are then refolded on 
the other side of the channel. In Toxoplasma gondii, this process makes use of a 
special, apicoplast-localised ubiquitin molecule 256. Apicoplast-localised DUBs 
remove this specialised ubiquitin immediately before translocation. 
Each ubiquitylation process requires a deubiquitylation step, at some point. 
We know that ubiquitylation also plays key roles in regulating endocytosis, 
propagating signal transduction, and modifying chromatin architecture, but at this 
point, nothing has been published to shed light on these pathways and how they 
might be similar, different, or druggable when compared with the widely studied 
mechanisms and machinery of the higher order eukaryotes. 
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Figure 18 Two major roles for deubiquitylation in the Plasmodium falciparum cell 
Ubiquitin plays many roles in the cell as it is added to and removed from substrates. Two major 
DUB-catalysed processes include ER-associated degradation (ERAD) and membrane translocation of 
proteins in the apicoplast. Unfolded or damaged material in the ER must be exported and degraded in 
the cytosol (top panel). Polyubiquitin marks on damaged or unfolded material are recognised by a 
retrotranslocator in the ER membrane which facilitates the moving of this material to the cytosol 
where DUBs recycle ubiquitin before the protein is degraded. Moving proteins across the second 
apicoplast membrane involves a similar reaction where an apicoplast-specific ubiquitin molecule is 
attached to a target protein. The protein is unfolded, translocated, and refolded. Before translocation, 
DUBs hydrolyse and recycle this plastid ubiquitin.  
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1.10 Genome editing strategies in Plasmodium falciparum 
 
 Merging the study of these molecular markers in vitro and in the field is 
imperative to unravel the complicated narrative of drug resistance. Molecular 
epidemiology work has and continues to produce highly important data about the 
competitive dynamics of alleles in parasite populations throughout space and time. 
However, if this work is not directed at the right mutations, the data being generated 
can be meaningless. The actual roles and impacts of the mutations must be studied in 
vitro to inform this epidemiology work. Since the adaptation of transfection 
techniques to Plasmodium in 1995, genetic experiments in P. falciparum have been 
largely confined to episomal overexpression of factors of interest or single-crossover 
integration of transgenes. Unfortunately, Plasmodium parasites do not have the 
endogenous machinery to facilitate RNAi, and many other genetic tools typically 
deployed in eukaryotic systems similarly break down 258,259. While episomal and 
single-crossover experiments generated valuable insights into parasite biology, both 
approaches have their limitations.  
 Episomal overexpression necessarily competes with expression from the 
genomic locus.  In particular, across a population of cells, expression levels can vary 
dramatically depending on how many copies of the plasmid a give cell retains and  
propagates. For certain factors, the presence these additional copies can conceivably 
confuse genetic regulatory mechanisms and lead to artificial phenotypes. This 
approach is not appropriate for studying drug resistance factors because each cell 
represents a mixed population, with some molecules harbouring the mutation of 
interest and some not. While any phenotype observed should be attributable to the 
mutation, it is possible mutant molecules may exert an artificial dominant negative 
effect. Lastly, timing of transcription can be problematic because promoters are not 
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Figure 19 Overview of the attB/attP integration system 
Integrating transgenes into cell genomes through the attB/attP recombination system requires a 
plasmid-derived recombination template and an integrase enzyme. The plasmid containing the 
transgene will insert into the cell genome during replication when the integrase enzyme directs single-
crossover recombination at the attB and attP sites. attB is typically included on the plasmid, and attP 
is typically included in the cell genome.   
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Figure 20 Overview of Zinc Finger Nuclease-mediated Genome Editing 
Zinc finger nucleases (ZFNs) are one of several enzymes that can be programmed to introduce double 
strand breaks at sites in a target cell genome. ZFNs consist of several tandem zinc finger domains 
fused to the catalytic domain of the FokI endonuclease. Each zinc finger recognizes a single triplet 
DNA sequence, and thus ZFNs can be directed to nearly any locus in a genome. Specificity results 
from using several zinc fingers in tandem to reduce the changes of off-target cleavage. One ZFN is 
designed to recognise sequences upstream and downstream of the target site. The FokI domains 
dimerise and induce a double strand break when their respective tandem zinc fingers recongise their 
respective genomic sequences. A plasmid-based repair template with homology upstream and 
downstream of the ZFN-induced break allows the parasite to repair the chromosomal break, thus 
integrating the desired transgene or mutation.   
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Figure 21 Overview of Cas9-mediated genome editing 
Like ZFN-mediate editing, Cas9-mediated editing relies on a nuclease (Cas9) to induce a double 
strand break at a programmed location in a target genome. A plasmid-encoded small guide RNA 
(sgRNA), transcribed under the control of an endogenous promoter, forms a ribonucleoprotein 
complex with Cas9 and thus has specificity for a specific chromosomal locus. In theory, Cas9 will 
only induce cuts at a protospacer adjacent motif (PAM; consensus: NGG) when docked with a 
sgRNA and when this complex has found its chromosomal target. The induced break can be repaired 
with a plasmid-derived homology template as described for ZFNs.    
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well defined in Plasmodium spp. The use of validated promoters such as the 
calmodulin promoter is tempting and generally suitable for looking at protein 
localisation, but overexpression or expression at inappropriate times in the cell cycle 
can also cause issues with interpreting any phenotype observed.  
Single-crossover integration was pioneered in part by David Fidock’s 
laboratory in 2006 with the successful adaptation of the mycobacteriophage Bxb1 
integrase and attB/attP recombination handles to P. falciparum (Fig 19)260,261. This 
system allows integration of transgenes into the genomes of strains harbouring an 
attB handle in a non-essential locus. Single-crossover integration overcomes the 
issues of expression variation and growth defections due to unequal segregation of 
plasmids across a population of cells, but these modifications have a known 
tendency to revert to their wild type genotype over long-term culture. Cells still 
express the wild type, endogenous locus, and stage-specific expression of the 
transgene can still be problematic. Knockout studies using single-crossover 
approaches aimed at disrupting the endogenous locus led to the characterisation of 
many genes as essential, though we now know some of these results are incorrect, 
and the original integration was likely unsuccessful. These limitations, as they 
pertain to drug resistance studies, are summarised in our previous work conducted by 
Gisela Henriques and meant throughput was very low, as a single modification could 
take months to generate.  
 Despite its global importance, Plasmodium falciparum remained a relatively 
intractable organism for functional genetics work until 2014 when Straimer et al 
described the adaptation of zinc finger nucleases (ZFNs) 262 (Fig 20). ZFNs are 
custom, sequence-specific endonucleases which dimerise and induce double-strand 
breaks at any genomic locus of interest. Specifically, they make use of a split 
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cleavage domain of FokI endonuclease, each half fused to multiple Zinc Finger 
Proteins, which individually recognise triplet DNA sequences on one strand of the 
genome. The two halves dimerise when the ZFPs recognise their target sequences on 
each strand, catalysing a double strand break. Interestingly, Plasmodium spp. lack 
the canonical non-homologous end joining pathway common across other taxa and 
therefore rely on homology directed repair to join severed or damaged chromosomes 
262,263. A custom ZFN is deployed with a DNA template that is homologous to both 
sides of the broken chromosome, with the desired modification sandwiched between 
these homology arms. ZFNs enabled a surgical-style approach to genome 
manipulation where one could examine the impacts of individual nucleotide changes. 
Immediately, the role of the K13(C580Y) variant in modulating parasite sensitivity 
to artemisinin was confirmed. Though they are reliable, ZFNs are highly expensive 
and therefore not suitable for genome-wide manipulation.  
Shortly thereafter, two groups announced the adaptation of the CRISPR-Cas9 
genome editing technology to P. falciparum (Fig 21)263,264. Cas9 is a bacterially-
derived endonuclease that forms a complex with a short, single-stranded guide RNA 
molecule (sgRNA), which is homologous to a region of the genome265. This 
ribonucleoprotein is an active nuclease capable of inducing double strand breaks at, 
theoretically, any locus immediately upstream of a so-called protospacer adjacent 
motif (PAM), defined for Cas9 as any NGG trinucleotide in the genome. Different 
Cas nucleases have different PAM motifs265. Like ZFNs, a homology template can 
be supplied to repair the double strand break and introduce genetic elements or 
mutations of interest. The adaption of Cas9 editing to Plasmodium falciparum has 
led to a new dawn in functional genetic characterisation in the parasite. Cas9 has 
already been paired with the split-Cre recombinase system for inducible 
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modification of the genome and conditional knockout studies as described in other 
systems 266. Currently two systems for driving sgRNA transcription exist. One, 
described by Ghorbal et al, relies on the endogenous but poorly characterised 
falciparum U6 promoter 263. The second, described by Wagner et al, leverages the 
T7 system widely used in bacterial and protein expression work 264. Transfected 
parasites express T7 polymerase, seemingly without consequence, in addition to 
Cas9. Currently, it is unclear if either system represents a distinct advantage. 
Although initially hailed as a highly-efficient system for genome editing, 
transgenesis with CRISPR-Cas9 has been slow because many sgRNA guides do not 
target the genome well. A high-throughput examination of guide activity is required 
to optimise a predictive activity algorithm resembling the Doench Root algorithm 
currently used in higher order eukaryotes 267. While NGG sites are sparse in certain 
genes given the AT-richness of the parasite genome and manual guide optimisation 
may be needed to achieve a transgenic line, Cas9 editing is still a cheap and 
potentially scalable way to approach the genome  
Recent work has identified another Cas-like nuclease called Cpf1 that 
recognises the motif TTN268. Though Cas9 is still the predominant RNA-guided 
nuclease in the field, this new PAM motif is much more common in the P. 
falciparum genome, meaning that Cpf1 may enable more accessible manipulation of 
the genome.  
Overall, these genetic techniques present new tools to continue to interrogate 
Plasmodium biology. Currently, we now have single-crossover integration, ZFNs, 
Cas9, and episomal expression systems to introduce mutations, knockout and 
knockdown elements, and reporter tags. In this thesis, this recombineering toolbox 
will be used to validate the involvement of mutations in the AP-2 adaptor complex 
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µ-subunit (µ2) and Ubp1 ubiquitin hydrolase in the parasite drug response and 
interrogate the biology of these two important molecules. Eukaryotic biology is 
widely conserved, but there are important differences between pathogens and host 
cells, which both mediate the virulence of these organisms and may represent 
exploitable vulnerabilities.   
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Chapter 2 
General Aims 
 
 
The broad aim of this work is to better understand how proteins associated with drug 
resistance and parasite survival function in the cell and contribute to the overall 
phenomenon of artemisinin resistance and ACT treatment failure currently observed 
in patients with uncomplicated Plasmodium falciparum infections across the tropics.  
Specifically, this project aims to: 
1. Examine ongoing evidence of directional selection in the pfap2mu and 
pfubp1 genes in field isolates from East Africa using full and partial PCR-
based gene amplification strategies and Sanger sequencing. If the 
pfap2mu(S160N) variant is involved in modulating parasite susceptibility to 
artemisinin combination therapies, I expect that the prevalence of this 
mutation will have increased since 2009. The samples for this analysis 
originate from the sample Kenyan village that we previously studied, and the 
local ACT formulation has not changed in the intervening years. If the 
haplotypes identified in pfubp1 in 2009 are related to drug susceptibility, I 
would expect reduced diversity in this gene and the emergence of a 
dominant, alternate haplotype.    
2. Validate the involvement of mutations in pfap2mu and pfubp1 in determining 
antimalarial sensitivity via CRISPR-Cas9-mediated transgenesis in 
laboratory strains. Namely, the orthologues of mutations identified in a 
rodent model of artemisinin resistance encoding µ2(I592T), Ubp1(V3275F), 
and Ubp1(V3306F) are expected to modulate parasite susceptibility to 
artemisinin. These Ubp1 mutations may also impact parasite susceptibility to 
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chloroquine, as they first arose during chloroquine selection. The µ2(S160N) 
variant discovered in P. falciparum clinical infections may have effects on 
sensitivity to artemisinin or frontline chemotherapy partner drugs, if it is 
actually involved in drug sensitivity in Kenya. 
3. Determine and compare the molecular and cell biology of the AP-2 adaptor 
protein complex and the Ubp1 deubiquitinase to those established for the 
human counterparts using in vitro approaches including protein localisation, 
genetic disruption, and mass spectrometry. The AP-2 complex is expected to 
be peripherally located in the parasite cell in association with clathrin, as in 
nearly all eukaryotes, and Ubp1 is expected to be localised to the nucleus, 
like its USP7 orthologue in higher order eukaryotes. 
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Chapter 3 
Materials and Methods 
 
 
3.1 Bacteriological Methods 
3.1.1 Bacteriological Media 
 
LB media was used for plasmid transformation and plasmid preparations. 
This media consists of 1% (w/v) bacto-tryptone, 0.5% (w/v) yeast extract, and 1.0% 
(w/v) NaCl in deionized water. Dissolved media was then sterilized by autoclaving 
for 20 minutes at 121°C and 15 psi. The sterile media was supplemented with 
antibiotics for selection as required by the particular plasmid transformed or cell line 
cultured.  
Solid media (LB) for plate culture consisted of 1.0% (w/v) bacto-tryptone, 
0.5% (w/v) yeast extract, 1.0% (w/v) NaCl, and 1.5% (w/v) agar in deionized water. 
This solution was autoclaved, cooled below 60°C, augmented with antibiotics, and 
poured into sterile Petri plates. 
 
Table 1 Antibiotics and concentrations used for cell culture 
Antibiotic Liquid Medium Conc. Solid Medium Conc. 
Ampicillin 50µg/mL 100µg/mL 
Chloramphenicol 25µg/mL 25µg/mL 
Kanamycin 10µg/mL 10µg/mL 
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3.1.2 Bacteriological Strains 
 
The following strains of Escherichia coli were used in this work as described.  
 
Table 2 E. coli strains used for DNA plasmid preparation 
 
Strain Source Genotype Antibiotic Resistance 
XL-10 Gold 
Agilent / 
reprepared as 
below 
TetrΔ(mcrA)183, Δ(mcrCB-
hsdSMR-mrr)173, endA1, 
supE44, thi-1, recA1, gyrA96, 
relA1, lac Hte [F ́ proAB 
lacIqZΔM15 Tn10 (Tetr) Amy 
Camr] 
Chloramphenicol 
Stellar Takara 
F-, endA1, supE44, thi-1, 
recA1, rel A1, gyrA96, 
phoA, Φ80d, lacZΔ M15, 
Δ (lacZYA - argF) U169, Δ 
(mrr - hsdRMS - mcrBC), 
ΔmcrA, λ- 
None 
 
3.1.3 Competent Cell Preparations 
Cells were made competent by calcium chloride treatment. First, cells were 
transformed, restreaked, and incubated on LB plates at 37°C overnight. Then a 100 
mL flask with LB media was spiked with 2.2 mL of a salt solution consisting of 0.44 
M MgCl2, 0.44 M MgSO4, and 0.11 M KCl, inoculated with 3 colonies from the 
restreak plate, and grown in a 37°C shaker until 0.4-0.6 OD600. The cell culture was 
then chilled on ice for 10 minutes, and the cells were harvested by centrifugation at 
2000 rpm at 4°C for 7 minutes. The cell pellet was resuspended in 30 mL of 
prechilled FB solution (10 mM PIPES, 250 mM KCl, 15 mM CaCl2). The 
resuspended pellet was incubated on ice for an additional 10 minutes. The cells were 
harvested from the calcium chloride treatment by centrifugation at 2000 rpm at 4°C 
for 7 minutes. The cell pellet was then resuspended in 8 mL of cold FB solution. 
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This resuspension was augmented with 0.5 mL of DMSO. After an additional 10 
minute incubation on ice, these cells were aliquoted into sterile Eppendorf tubes, 
flash frozen using liquid nitrogen, and stored at -80°C. 
 
 
3.2 DNA Methods 
3.2.1 Custom Primer Processing 
 
Desalted custom primers were purchased from Integrated DNA 
Technologies® (Coralville, IA). The lyophilized primers were centrifuged upon 
arrival and resuspended in TE(10,0.1) (10 mM Tris-Cl, pH 8.0, 0.1 mM EDTA) to 
100 µM stock concentration. 10 µM working aliquots of primer were diluted from 
this stock in TE(10,0.1) and stored at -20°C. A full list of primers used in this thesis 
is included in Appendix V. 
 
 
3.2.2 Phenol/Chloroform Extractions 
 
Phenol/Chloroform extractions are a technique used to purify nucleic acid 
away from proteins. This purification is typically performed during a plasmid 
preparation to remove contaminating cellular proteins or enzymes added during the 
purification process such as RNaseA. Phenol/Chloroform is a 1:1 (v/v) mixture of 
phenol equilibrated in TE(10,0.1) and 100% chloroform. To extract a sample, 1 
volume of premixed phenol/chloroform was added to the sample. The sample was 
then vortexed for 10-15 seconds and spun down at 13.3K rpm. The top, aqueous 
phase contains the extracted nucleic acids, and proteins are in the lower, organic 
phase. The aqueous phase is removed for further purification. This process is 
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repeated for a total of 2 extractions followed by 1 extraction with 500 µL of 100% 
chloroform to remove contaminating proteins and phenol.  
 
 
3.2.3 Ethanol Precipitation of DNA 
 
Ethanol precipitation is a common molecular biology technique used to 
concentrate DNA and perform buffer exchange or to sterilise DNA before 
transfection. 0.1 volumes of 3M sodium acetate pH 5.2 is added to the sample along 
with 2.5 volumes 100% ethanol. The solution is incubated at -20°C for 10-20 
minutes and centrifuged at 13.3K rpm at 4°C for 30 minutes. The liquid is aspirated, 
and the pellet is resuspended in 1 ml of 75% (v/v) ethanol in water. This is incubated 
at -20°C for 10 minutes to draw salts out of the DNA pellet, and the DNA is 
reharvested by centrifugation. The liquid is again aspirated, and the DNA pellet is 
left to air-dry before resuspension in an appropriate volume of sterile TE(10,0.1). 
 
 
3.2.4 Agarose Gel Electrophoresis 
 
Agarose gel electrophoresis is one of the most ubiquitous biology laboratory 
techniques and is used to separate DNA fragments based on their size. Typical 
agarose gels were made with 1-2% (w/v) HGT agarose in 30 mL of 0.5xTBE (45 
mM Tris base, 45 mM boric acid, 1.5 mM EDTA). Heating the solution for 90-120 
seconds in a microwave dissolved the agarose solid. When the solution was no 
longer steaming, 1.5 µL of 10 µg/mL ethidium bromide was added, and the solution 
was mixed. The solution was then poured into a gel-casting block, well combs were 
inserted, and the gel was incubated at room temperature for 30-45 minutes.  
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To separate a sample of DNA fragments, 6x gel loading buffer (0.25% (w/v) 
bromophenol blue, 0.25% (w/v) xylene cyanol, 30% (w/v) glycerol) was added to 
the sample to a final 1x concentration. The polymerized gel was lowered into an 
electrophoresis box filled with 0.5 x TBE such that the running buffer covered the 
top of the gel. The samples were added to the lanes alongside a reference molecular 
weight marker. The gel was electrophoresed at 125V power for approximately 40 
minutes. For the best separation, the gel agarose percentage should correspond to the 
size of fragments being separated. Fragments between 500 bp-1000 bp were best 
separated with a 1.2-1.5% gel. Smaller fragments required a higher percentage 
agarose gel and larger fragments were separated with a lower percentage gel.  
 
 
3.2.5 Native Polyacrylamide Gel Electrophoresis (PAGE) 
 
 
Native PAGE gels are most useful for separating DNA fragments less than 
500 bp. These gels were prepared by first filling a BioRad Mini-Protean® gel casting 
block with stacked plates. Plates were assembled such that the back glass is 
separated from the front glass with two plastic spacers. The gel mixture was 
prepared by adding 25 mL of 30% 40:1 acrylamide, 3.75 mL 10 x TBE to 42.5 mL 
of deionized water. This solution was mixed and deaerated under a vacuum for 2-5 
minutes, swirling occasionally. After deaeration, 300 µL of 25% (w/v) ammonium 
persulfate and 75µL TEMED was added to the deaerated solution. This solution was 
quickly taken up with a 60 mL syringe and injected through a luer valve into the 
filled PAGE gel casting block. This solution was added to the height of the front 
glass plates. Gel combs were then inserted rapidly into the plates before the gel 
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solution polymerizes. The casting block was incubated at room temperature for 30-
60 minutes. The casting block was then disassembled, and the polymerized gels were 
wrapped in wet towels and stored at 4°C until use.  
 
 
3.2.6 PCR Amplification of gene fragments 
 
 Polymerase Chain Reaction (PCR) was used to amplify gene fragments for 
downstream sequencing or cloning. In brief, a standard reaction consisted of either 1 
x ThermoPol Reaction Buffer or 1 x NH4 Buffer, 4 mM MgCl2, 0.25 mM dNTPs, 
0.5 µM forward and reverse primers, and 0.5 units of BioTaq polymerase in 25 µl 
total volume. HotFirePol master mix was used for pfubp1 gene fragments based on 
optimisation performed by previous members of our laboratory, and amplicons for 
downstream cloning applications were generated with 1 x CloneAmp mix (Takara). 
These reactions were performed with 0.5 µM primers in a 25 µl reaction. In the case 
of nested PCR reactions, 1 µl of the Nest 1 reaction was used as a template for a 25 
µl Nest 2 reaction. Thermocycling settings were optimised for each amplification but 
generally based on the following generic cycling and manufacturer’s 
recommendations for elongation and denaturation temperatures:  
 
 3𝑚 𝑎𝑡 95𝑜𝐶 → 18 − 35 × (30𝑠 𝑎𝑡 95𝑜𝐶 → 30𝑠 𝑎𝑡 𝑇𝑚 − 5𝑜𝐶 →
1𝑚𝑖𝑛
1𝐾𝑏𝑝
 65 − 75𝑜𝐶) 
5𝑚 𝑎𝑡 65 − 75𝑜𝐶 
 
 
 
Extension products were confirmed by gel electrophoresis on a 1-2 % (w/v) agarose 
gel. Products for cloning were extracted with the QiaQuick kit by the manufacturer’s 
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protocol or phenol/chloroform extraction and ethanol precipitation. Custom primers 
were designed to have less than 60% GC content and a Tm between 50-60°C and 
were ordered from IDT®.  
Several other polymerases were used in the production of this thesis. These 
polyermases were Q5 Polymerase (New England BioLabs), Pfu (made 
recombinantly in Prof Song Tan’s laboratory at Penn State University), and 
PfuTurbo (Stratagene), and each polymerase was used according to the 
manufacturer’s guidelines or methods specified here.  
 
 
3.2.7 Cycle sequencing of double-stranded DNA 
 
 For cycle sequencing of PCR products, excess primers and dNTPs were 
removed from PCR reactions prior to sequencing. Briefly, 5 µl of the PCR reaction 
were combined with 3 units of Exonuclease I (ThermoFisher) and 1 unit of FastAP 
Alkaline Phosphatase (ThermoFisher) in 1 x FastAP buffer and water to 10 µl. The 
reaction was incubated at 37°C for 60 minutes followed by 72°C for 15 minutes. 1-5 
µl of this cleaned reaction was added to a sequencing reaction containing 1 mM 
sequencing primer, 1 x sequencing buffer, and 0.5 µl of BigDye V3.1 in 10 µl total 
volume. For sequencing plasmid DNA, 50 ng of plasmid was included instead of the 
cleaned-up PCR reaction. The cycle sequencing reaction was thermocycled as 
follows:  
 
 
 1𝑚 𝑎𝑡 96𝑜𝐶 → 25 × (30𝑠 𝑎𝑡 96𝑜𝐶 → 30𝑠  𝑎𝑡 50𝑜𝐶 → 4m at 60𝑜𝐶) 
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This cycle sequencing reaction was EDTA/Ethanol precipitated by the 
manufacturer’s protocol and submitted for capillary sequencing at LSHTM on a ABI 
3730 platform or to Source BioScience (Cambridge, UK). Sequence data were 
analysed using a variety of bioinformatic tools in the Geneious version 9.1 software 
package.   
 
 
3.2.8 Cloning of DNA fragments 
  
 Plasmids were assembled using a variety of cloning methods. In summary, 
DNA fragments were cloned either by traditional sticky-ended cloning, inFusion 
cloning (Clontech), or sequence-and-ligation-independent cloning (SLIC). Cloning 
protocols are described below. Each ligation or plasmid assembly reaction was 
transformed into 50 µl of XL-10 Gold ultracompetent cells (Agilent) and plated onto 
LB agar media supplemented with 100 µg/ml ampicillin. Colony PCR was 
performed to screen transformants for successful integration of the insert fragment, 
and screened colonies were restreaked. Selected clones were used to inoculate 5 ml 
LB cultures supplemented with 50 µg/ml ampicillin which were grown overnight at 
37°C. Plasmids were harvested from these cultures with a Qiagen Miniprep kit and 
restricted mapped. Sanger sequencing was performed to confirm the sequence of the 
insert.  
 
 
3.2.8.1 Preparation of Vector and Insert DNA for Sticky-Ended Ligation 
 
 Vector and insert DNA for sticky-ended ligation were prepared by digestion 
of the corresponding parent DNA sources (plasmid or PCR product) with two 
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restriction endonucleases. The reactions consisted of 0.5-1 µg DNA, 1 x NEB Buffer 
compatible with both enzymes, 0.1 mg/mL BSA, 5 mM DTT, 0.5-1.0 units of each 
restriction enzyme in deionized water to 30 µL total volume. The reaction was 
typically carried out at 37°C for 1-2 hours. All enzymes were purchased from New 
England Biolabs and were used according to the manufacturer’s recommendations. 
After incubation, the reactions were analyzed by agarose gel electrophoresis. 
In the event that two enzymes could not be used simultaneously in a double 
digest, a sequential digest was performed. In this case, the enzyme that requires a 
lower salt concentration was added in its corresponding buffer for 1 hour. Then, the 
reaction conditions were either adjusted via addition of 5 M NaCl to enable the 
second enzyme to become active, or the reactions were phenol/chloroform extracted, 
ethanol precipitated, and resuspended with the second enzyme in different buffer 
conditions.  
 
 
3.2.8.2 Preparation of Vector and Insert DNA for Blunt-Ended Ligation 
 
Some ligations had to be performed using blunt-ended fragments from PCR 
reactions. In this case, the purified PCR product had to be kinased because PCR does 
not attach the required 5’ phosphate groups to enable ligation with a 3’ hydroxyl 
group. The kinase reaction consisted of 1 x PNK Buffer, 5 mM ATP, 3 mM DTT, 
15µL PCR product, and 5 units T4 Polynucleotide Kinase in deionized water to 30 
µL. This reaction was incubated at 37°C for 15 minutes. The kinased product was 
then isolated by gel electrophoresis and gel extraction.  
Blunt ended vectors were produced by digestion with an endonuclease such 
as EcoRV that produced a blunt end. The digestion was performed the same way as 
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the digestions for sticky-ended ligation. After the digestion was performed, 0.1 units 
of calf intestinal phosphatase (CIP) were added to the reaction. The reaction was 
then incubated at 50°C for 45 minutes. The dephosphorylated vector fragment was 
then purified via gel electrophoresis and gel extraction.   
 
 
3.2.8.3 Agarose Gel Extraction of DNA 
 
Once vector or insert DNA was digested, separated with gel electrophoresis, 
and visualized with a UV transilluminator to confirm the presence of the correct 
fragments, the fragments were excised from the gel using a clean razor blade. These 
gel slices were placed into an eppendorf tube filter assembly. This assembly 
consisted of a 0.5 mL Eppendorf tube with a hole poked into the bottom that was 
covered with glass wool inserted into a 1.75 mL Eppendorf tube. The gel slice was 
placed into the 0.5 mL tube and spun at 7000 rpm for 3 minutes. The DNA fragment 
previously contained in the gel slice eluted through the filter and is collected into the 
1.75 mL tube. This extraction method typically recovers between 50-70% of the 
material in the gel.  
 
 
3.2.8.4 Blunt and Sticky Ended Ligations 
 
To ligate insert and vector fragments into a plasmid, the isolated insert and 
vector DNA was added at an approximately 3:1 molar ratio with 5 mM DTT, 1 x T4 
Ligase Buffer, ligase and deionized water to 10 µL. For sticky ended ligations, 40 
units of T4 DNA ligase were used whereas for blunt ended ligations, 750 units of T4 
DNA ligase were used. The ligation reaction was incubated at room temperature for 
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15-30 minutes before transformation into E. coli. A separate ligation reaction always 
set up only containing the vector DNA to determine the cloning bias (ratio of 
colonies on vector only plate to vector and insert plate). This negative control and 
the cloning bias help determine the quality of the vector and insert preparations. 
 
 
3.2.8.5 Plasmid Transformation 
 
Ligation mixtures or purified plasmid DNA was transformed into E. coli 
either during subcloning or for protein expression. During subcloning, 2 µL of each 
ligation reaction were added to 100 µL of competent cells. When transforming 
purified plasmid, 0.1 ng of DNA were added to the cell mixture. In each case, the 
cells were then incubated on ice for 15 minutes. Following this incubation, the cells 
were heat shocked at 42°C for 30 seconds. 500 µL of sterile LB media were then 
added, and the cell suspension was then incubated in a 37°C shaker for 15 minutes. 
Following this incubation, 300 µL of the cell suspension were plated onto LB plates 
containing the appropriate antibiotics for selecting colonies with the correct plasmid. 
 
 
3.2.8.6 Colony PCR 
 
During subcloning, after transformation, several clones from the vector and 
insert plate were screened using colony PCR to detect whether they contained the 
desired insert. To perform this screening, each clone selected was resuspended in 
100 µL of deionized water and restreaked onto a new LB plate containing the 
appropriate antibiotic. These cell suspensions were then vortex for 10-15 seconds 
and used as PCR templates. Primers were selected to amplify around the inserted 
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DNA fragment. PCR was performed using 1 µL of cell suspension in a PCR master 
mix containing 1 x ThermoPol buffer, 0.26 mM dNTPs, 0.5 µM forward and reverse 
primers, 1 unit of Pfu polymerase, and water to 20 µL. The standard thermocycling 
conditions are:  
 3𝑚 𝑎𝑡 95𝑜𝐶 → 25 × (30𝑠 𝑎𝑡 95𝑜𝐶 → 30𝑠 𝑎𝑡 𝑇𝑚 − 10𝑜𝐶 →
1𝑚𝑖𝑛
1𝐾𝑏𝑝
 75𝑜𝐶) 
 
These PCR reactions were analysed with gel electrophoresis, and clones that 
produced the desired product were selected for plasmid preparation. Single clones 
from the restreak plates of these clones were used to inoculate flasks of 5 mL LB 
media with 50 µg/mL of ampicillin. These flasks were grown overnight in a 37°C 
shaker. 
 
 
3.2.8.7 Site-Directed Mutagenesis  
 
This mutagenesis method was designed from Stratagene’s QuikChange 
mutagenesis protocol. Custom, complementary primers were designed to have a new 
DNA sequence, and therefore mismatches (often swapping out codons), at the site of 
mutagenesis flanked by ten or more bases complementary to the template sequence. 
The primers are also designed to introduce or remove a restriction site around the 
mutagenized region to facilitate plasmid identification during downstream cloning 
experiments. The reaction consists of combining 5 ng template DNA, 1 x PfuTurbo 
reaction buffer, 0.2 mM dNTPs, 0.2 mM forward and reverse primers, and 1 unit 
PfuTurbo in deionized water to 25 µL. A linear amplification was then performed 
using the following thermocycler settings:  
 108 
 
 
 3𝑚 𝑎𝑡 95𝑜𝐶 → 18 − 35 × (30𝑠 𝑎𝑡 95𝑜𝐶 → 30𝑠 𝑎𝑡 𝑇𝑚 − 5𝑜𝐶 →
1𝑚𝑖𝑛
1𝐾𝑏𝑝
 65𝑜𝐶) 
5𝑚 𝑎𝑡 65𝑜𝐶 
 
Afterwards, 2 µL of the reaction were removed and stored in a sterile 
Eppendorf tube. 20 units of DpnI restriction enzyme were then added to the 
remaining 23 µL of the reaction mix. The reaction mix was then incubated at 37°C 
for 1 hour. DpnI will digest methylated DNA. Because the template plasmid DNA 
was isolated from E. coli with dam methylase, the unmutated template will be 
methylated and cut. PCR does not methylate DNA so the mutated PCR product will 
not be cut. After the 1 hour incubation, 2 µL of the digested sample were 
transformed into E. coli alongside the 2 µL of undigested sample and plated onto 
TYE plates with ampicillin overnight. The majority of the clones screened from the 
digested plate should contain the desired mutation because the DpnI treatment 
should eliminate most of the parent plasmid.  
Colony PCR primers were selected to flank the mutation site and produce a 
fragment less than 500 bp. In addition to screening clones from the digested plate, 
the parent plasmid should be included in the colony PCR experiment to provide a 
negative control for comparison. After thermocycling during colony PCR, 10 µL of 
the reaction were combined with 2 µL of 6xGLB and run on a Native PAGE gel to 
screen for clones that may have multiple insertions of the mutagenesis primer. This 
problem occurs relatively frequently during mutagenesis with Q5 and several other 
polymerases and is an going area of investigation. The PCR products were compared 
to the product amplified from the parent. Each product should be the same size. 
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Colonies that produced fragments larger than the parent product likely contained 
primer insertions.  
The remaining 10 µL from the colony PCR reaction including the reaction on 
the parent template were digested with the appropriate restriction enzyme for the site 
either introduced or removed during the mutagenesis. Colonies that do not have 
primer insertion and produce the correct fragments after this restriction digest likely 
have the desired mutations and were selected for plasmid preparation, restriction 
mapping, and sequencing.  
 
 
3.3 Protein and Fixed Cell Methods 
3.3.1 Preparation of cell extracts 
 
 This protocol is for analysis of small amounts of protein (i.e. not preparative-scale 
immunoprecipitation). 5 ml of cell culture at 5% haematocrit and 5% parasitaemia was 
transferred to a 50 ml conical centrifuge tube. Infected erythryocytes were harvested by 
centrifugation at 800 g for 5 min at RT. Culture media was aspirated, and the cells were 
washed in 50 ml of sterile PBS and again centrifuged. The washed cells were washed again 
in 10 ml PBS and then lysed in 10 pellet volumes of 0.15% (w/v) saponin in PBS. After 5 
minutes incubation at 4oC, parasites were harvested away from lysed cell debris by 
centrifugation at 13K RPM for 10 minutes at 4oC. Parasites were then washed repeatedly by 
centrifugation at 13K RPM for 2 minutes in sterile, cold PBS containing protease inhibitors 
until the wash supernatant was clear, indicating the majority of red cell debris and 
haemoglobin had been removed. These harvested parasites were resuspended to 50% (w/v) 
in PBS with inhibitors and stored on ice until further manipulation or flash frozen in liquid 
nitrogen.  
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To prepare whole cell extracts, the washed saponin-treated parasite pellet was 
resuspended in 4-6 volumes of cold lysis buffer. Lysis conditions vary by the protein under 
study and aims of the experiment but generally consist of variations on a standard lysis 
buffer (20 mM HEPES, 100 mM NaCl, 0.5% Triton X-100, 1 mM PMSF, 1xRoche protease 
inhibitors, pH 7.4) or RIPA buffer (10 mM Tris, 150 mM NaCl, 1% (v/v) Triton X-100, 
0.1% (v/v) sodium deoxycholate, 0.1% (w/v) SDS, 1 mM PMSF, 2 mM EDTA, 1 x Roche 
protease inhibitors, pH 7.5). Parasite lysis was allowed to proceed for 30 minutes on ice, and 
a soluble extract was prepared by spinning this lysate at 13K RPM for 30 minutes at 4°C. If 
late trophozoites or schizonts were being studied, 0.5 ul of BaseMuncher (Expedeon Ltd.; 
San Diego, CA) was added to the lysis reaction to digest nucleic acids, which make the 
extraction thick and difficult to manipulate and interferes with lysis. After centrifugation, 
the soluble supernatant was removed into a separate tube on ice, and the insoluble pellet was 
washed 3 times in 1 ml cold lysis buffer to remove residual soluble factors. The insoluble 
pellet was then resuspended in lysis buffer to the original extraction volume and stored on 
ice. Equal amounts of each sample were mixed with 5xPGLB (250 mM Tris, 10% (w/v) 
SDS, 5 mM EDTA, 10 mM DTT, 30% glycerol, 0.05 mg/ml bromophenol blue, pH 6.8) to 
1xPGLB, boiled at 95C for 1-3 minutes, centrigued to remove haemazoin, and loaded on an 
SDS-PAGE gel for further analysis. 
 
 
3.3.2 SDS-PAGE Electrophoresis 
 
One of the most common techniques for protein analysis is sodium dodecyl sulfate 
polyacrylamide gel electrophoresis, or SDS-PAGE. This technique uses a modification of 
Native DNA PAGE electrophoresis to denature proteins into their primary sequence and 
separate them based on size. 18% (w/v) SDS-PAGE gels were prepared by first stacking 
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glass gel plate assemblies into a BioRad Mini-Protean® gel-casting block in the same way 
as for Native PAGE gels. The separating gel solution consisted of 18% (w/v) acrylamide 
(30:0.5 acrylamide:bis-acrylamide), and 0.75 M Tris-Cl, pH8.8 in deionized water. This 
solution was deaerated under a vacuum for 5-10 minutes. Then SDS was added to 0.1% 
(w/v).  
Polymerization was initiated by addition of 240 µL of 25% (w/v) ammonium 
persulfate and 60 µL of TEMED. The casting block was filled approximately 70% with this 
solution using a 60 mL syringe and a luer valve. Water-saturated butanol was poured over 
top of this separating layer. After incubation for 1 hour at room temperature, the butanol was 
removed and washing off with ethanol and water. A 5% (w/v) stacking gel was then mixed, 
poured on top of the separating gel, and incubated at room temperature once the well combs 
were inserted. This gel consisted of 5% (w/v) acrylamide (10:0.5 acrylamide:bis-
acrylamide), 0.1 M Bis-Tris, pH 6.8, and 0.1% (w/v) SDS. This solution was prepared in the 
same way as the separating gel solution. After this final incubation the gels were stored like 
Native PAGE gels. 
Samples were analyzed on these gels by first mixing the sample with an equal 
volume of PAGE gel loading buffer (PGLB) and boiled for 1-3 minutes to further denature 
the proteins. While the sample was denaturing, a pre-cast gel was fitted into a Mini-Protean 
II® Electrophoresis Cell, and the cell was filled with protein gel running buffer (10 mM 
Tris, 76 mM glycine, 0.02% (w/v) SDS). After boiling, 10 µL of sample were added to each 
lane along with protein molecular weight standards for size comparison. The gel was 
electrophoresed at a constant 20W for 10 minutes. The gel was either used for western 
blotting or silver staining. Additionally, 4-12% TruPAGE gels (Sigma) and 3-8% Tris 
Acetate gel (LifeTech) were used in this thesis, where noted. 
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3.3.3 Western Blotting 
 
To detect protein levels with greater sensitivity than coomassie staining and identify 
specific factors in cell extracts or pulldowns, Western Blotting was performed. Proteins 
separated by SDS-PAGE were transferred to a nitrocellulose membrane (Amersham 
Hybond ECL®) in a Bio-Rad Turbo Blot according to manufacturer’s guidelines.  
 Afterwards, the SDS-PAGE gel was stained with Coomassie to show that the proteins 
successfully transferred out of the gel, or the membrane was stained with Ponceau S and 
destained with TBS. The membrane was equilibrated in 1xTBS (25 mM Tris, pH 8.0, 0.15 
M NaCl) for 5 minutes. The equilibrated membrane was then incubated in blocking buffer 
containing 5% (w/v) nonfat dry milk in 1xTBS for 30-60 minutes. The membrane was then 
subjected to a solution containing a dilution of primary antibody in blocking solution for 1 
hour. The membrane was then washed with TBST (25 mM Tris, pH 8.0, 0.15 M NaCl, 0.1% 
Tween 20) for five minutes. The membrane was washed two more times with TBST to 
remove non-specifically or unbound antibody. The gel was then incubated in a dilution of an 
HRP-conjugated secondary antibody in blocking solution for 1 hour. The membrane was 
washed three more times with TBST. To visualize the immunostained proteins, the protein 
side of the membrane was covered with 1 mL of a 1:1 mixture of Pierce ECL detection 
solutions 1 and 2 for 5 minutes. Excess solution was poured off, and the gel was wrapped in 
clear plastic before exposure to X-Ray film and development. 
 
 
 
3.3.4 Cryomilling and Immunoprecipitation 
 
Because AP2µ was curiously insoluble under most mild-lysis conditions suitable for 
pulldowns, I turned to the novel cryomilling technique of performing near-detergent-free 
lysis. In this technique, parasites are harvested by saponin lysis and flash frozen in PBS. 
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These frozen blocks are then pulverised at very high pressure in a bead mill, generating a 
fine powder which can be lysed with buffer containing minimal to no detergent. This lysate 
is then used for immunoprecipitation as above. This technique has been used to study a 
variety of factors in other organisms, including endocytic factors, with excellent success. In 
particular, this technique is known to identify more specific interacting factors than 
traditional lysis and immunoprecipitation techniques, however it requires a considerable 
amount of material, typically more than 5 mg of total protein. This technique was performed 
under the guidance of Dr Martin Zoltner and Prof Mark Field at the University of Dundee.  
For cryomilling, lysate preparation, and immunoprecipitation, Plasmodium 
falciparum cultures were grown to approximately 8% parasitaemia in 5% 
haematocrit in approximately 6 L of complete medium. These infected red cells were 
then harvested by centrifugation when parasites were in the trophozoite stage and 
lysed with 0.15% (w/v) saponin in PBS at 4oC. Trophozoites were harvested by 
centrifugation at 13K RPM for 5 minutes at 4oC and washed several times with cold 
PBS to remove haemoglobin and red cell debris. The washed, packed parasites were 
resuspended to 50% density in PBS, flash frozen in liquid nitrogen, and stored at -
80oC. This process was repeated until 6-8 ml of resuspended parasites had been 
stored.  
These frozen blocks were taken out of the tubes and placed into the ball 
chamber of a cryomill (Retsch). The frozen parasites were milled under 7 cycles of 3 
minutes cooling and 3 minutes milling. The milled powder was then carefully 
removed from the ball chamber and stored in a 50 ml tube in liquid nitrogen. All 
steps were performed at or below -80oC to prevent parasite material from thawing.  
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Figure 22 Cryomilling workflow 
In preparation for cryomilling, 6-8 ml of saponin-lysed parasites (50% (w/v) in PBS) were isolated 
and flash frozen as small pellets in liquid nitrogen. These pellets were pulverised in a Rescht ball mill 
at liquid nitrogen temperatures and lysed under low-detergent conditions for immunoprecipitation and 
mass spectrometry. 6-8 L of cell culture typically produced 40 ml of parasite “powder”, which was 
sufficient for 6-10 proteomics-scale pulldowns (each requiring 300 mg of ground material).  
 
To optimise immunoprecipitation conditions, 50 mg of parasite powder was 
removed and mixed with 1 ml of pre-cooled test extraction buffer and resuspended 
by gentle pipetting on ice. The resuspension was then sonicated on ice for 4x(3 sec 
on/10 sec off) at 30% amplitude). The lysate was then cleared by centrifugation at 
18.5K RPM for 20 minutes at 4oC. 1 ml of the lysate was then added to 40 µl pre-
equilibrated anti-HA magnetic beads (ThermoFisher) or anti-GFP magnetic 
DynaBeads (Field Lab) and rotated at 4oC for 1h. The beads were then magnetised 
and unbound material was removed. The beads were then washed with extraction 
buffer 3 times to remove unbound material. The beads were then centrifuged to 
remove residual buffer. Bound material was then eluted by resuspending the beads 
with 30 µl LDS-loading buffer (Invitrogen) without reducing agent and incubating 
for 10 minutes at 70oC. Eluted material was then isolated by centrifuging and 
magnetising the beads and removing the supernatant. Reducing agent (Invitrogen) 
was added to the supernatant, and the samples were incubated for 10 minutes at 
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70oC. Eluted material was then analysed by electrophoresis on a 4-12% gradient 
polyacrylamide gel and silver staining. Additionally, soluble and insoluble extract 
and bead flowthrough samples were examined for target protein content by western 
blotting.  
At preparative scale, the above protocol was repeated with 300 mg of parasite 
powder and 240 µl, split over six tubes. Sonication was performed at 35% amplitude 
for a total of 12 cycles. During the final wash, the beads were combined into one 
tube, and bound material was eluted in 90 µl. The final eluted fraction was 
concentrated with a speed-vac to 30 µl and run 1 cm into a gel. The gel lane was 
excised and submitted to the University of Dundee Proteomics Facility for analysis.  
 
TLCK stock (10 mM in 1 mM citric acid – unstable at higher pH) 
 
Test extract buffers: 
A. 20 mM HEPES, 100 mM NaCl, 0.1% (w/v) Brij58, 0.1 mM TLCK, protease 
inhibitors, pH 7.4 
B. 20 mM HEPES, 100 mM NaCl, 0.5% (w/v) CHAPS, 0.1 mM TLCK, protease 
inhibitors, pH 7.4 
C. 20 mM HEPES, 100 mM NaCl, 0.1% (v/v) Tween-20, 0.1 mM TLCK, 
protease inhibitors, pH 7.4 
D. 20 mM HEPES, 100 mM NaCl, 0.1% (v/v) Triton X-100, 0.1 mM TLCK, 
protease inhibitors, pH 7.4 
E. 20 mM HEPES, 250 mM NaCl, 0.1% (w/v) CHAPS, 1 mM MgCl2, 10 mM 
CaCl2, 0.1 mM TLCK, protease inhbitors, pH 7.4 
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3.3.5 Analysis of tryptic peptides by Mass Spectrometry 
 
 Eluted immunopurified proteins were detected by tandem LC-MS/MS liquid 
chromatography mass spectrometry at the University of Dundee Proteomics Facility. 
Samples were analysed on an UltiMate 3000 RSLCnano System (Thermo Scientific) in line 
with a LTQ OrbiTrap Velos Pro (Thermo Scientific). Resulting spectra were mapped with 
MaxQuant R1.5 to the 3D7 reference proteome downloaded from PlasmoDB and MaxQuant 
common contaminants database. The minimum peptide length was set to 6 amino acids, and 
the false discovery rate was set to 0.01 as calculated against a reversed proteome.  
 
 
3.3.6 Protein localisation by immunofluorescence 
 
To examine the subcellular localisation of the factors discussed in this thesis, indirect 
immunofluorescence assays were performed. Localisation of factors of interest were 
examined at all stages of the asexual parasite lifecycle. Cells were first cultured to 3-5% 
parasitaemia under the culture conditions described above. While this is not critical, it 
makes observing parasites under the microscope easier and more parasites can be imaged in 
a single frame, though higher parasitaemias should generally be avoided because the cells 
may be starving or stressed in culture, which may affect the localisation of the factor or 
other cellular markers.  
For thin-smear IFAs, once the culture was at a sufficient parasite density, blood 
smears were prepared on glass slides. These smears were quickly dried under cool air to 
avoid heat fixing the cells. Small circles (approximately 1 cm diameter) were drawn on the 
dried smear with a hydrophobic PAP pen for each antibody combination to be examined and 
allowed to dry briefly at room temperature. Cells inside each circle were fixed with 4% 
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paraformaldehyde in PBS for 10 minutes at room temperature in a humidified chamber. The 
fixative was then aspirated, and the cells were washed in PBS four times. Washing was done 
by pipetting PBS into the circle and aspirating after 3-5 minutes. Then cells were 
permeabilised with 0.1% (v/v) Triton X-100 in PBS for 10 minutes and similarly washed. 
Cells were then blocked for 1 hour at room temperature with 3% (w/v) BSA in PBS 
supplemented with 0.1% (v/v) Tween20. Primary antibodies were then added in blocking 
solution for 1 hour at room temperature or overnight at 4oC. Primary antibody solution was 
then removed and washed off four times and replaced with secondary antibody solution in 
the same modified blocking buffer for 1 hour at room temperature. Secondary antibody 
solution was then aspirated, the cells were washed four times, and a cover slip was mounted 
in VectaShield with DAPI. The cover slip was then sealed to the slide with nail varnish. 
Importantly, each antibody stock solution was centrifuged at 13K RPM for 2 minutes at 4°C 
before preparing each dilution. This significantly reduced the amount of background 
fluorescence and floating, fluorescent debris that interfered with imaging. Slides were 
imaged several hours later using either an epifluorescence, confocal, or super-resolution 
microscope as described in the text and below.  
For IFAs performed in suspension, 10-20 µl of infected erythrocytes were washed 
once in sterile PBS and fixed for 30 minutes in 10 volumes PBS containing 4% (w/v) 
formaldehyde and 0.0075% (v/v) EM-grade glutaraldehyde at 37 oC with gentle shaking. 
After fixation, the cells were harvested by centrifugation at 5K RPM for 30 seconds, and 
fixative was replaced with 1 ml quench and permeabilisation buffer (0.1% (v/v) Triton X-
100, 125 mM glycine in PBS) for 10 minutes.  Blocking and antibody staining was 
performed as above. During the final washing step after incubation with the secondary 
antibody, DAPI was added to the PBS washing solution. Finally, 2-3 µl of cells resuspended 
to 50% density in PBS were dropped onto glass slides coated in 2% PEI. A cover slip was 
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applied and sealed onto the slide. These cells were imaged as described.  
 
 
3.3.7 Fluorescent labelling of intracellular lipids 
 
For the imaging of neutral lipids, LipidTOX Green and Nile Red stains were used. 
Neutral lipids are present in several structures within the cell throughout organelle and 
vesicular membranes as well as in lipid compartments near the digestive vacuole. These 
stains are unique in that they are incompatible with detergents, which disrupt the fluorescent 
stains at any concentration. To stain and image these lipids on their own or in conjunction 
with antibodies, the protocol described above was used, except the permeabilisation step 
was omitted and Tween20 was excluded from all buffers. Dilutions of the lipid stains were 
incubated on the cells after the secondary antibodies for 3 hours at room temperature and 
washed off with PBS. Cover slips were mounted in VectaShield with DAPI, sealed, and 
immediately imaged by epifluorescence microscopy. The omission of the permeabilisation 
step was critical because little to no signal was observed even when Tween20 was omitted 
from the buffers. Lipid staining could only be observed when the permeabilisation step was 
also omitted. Permeabilisation is optional for immunofluorescence work, though it may 
increase the fluorescent signal observed for low abundance proteins.  
 
 
3.3.8 Antibodies 
 
Below is a list of all the antibodies described in this thesis, the origin organism, and source. 
All antigens refer to Plasmodium falciparum proteins, except where noted.  
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Table 3 Antibodies used in this thesis 
Antigen  Species Origin 
ACP Rabbit Geoff McFadden Laboratory 
AMA1 Rabbit Mike Blackman Laboratory 
BiP Rat Tony Holder Laboratory 
CDC48 Rabbit Jude Przyborski Laboratory 
Clathrin Heavy Chain  Rabbit Frances Brodsky Laboratory 
ERD2 Rabbit Kasturi Haldar (MR4) 
EXP2 Mouse Mike Blackman Laboratory 
GAP45 Rabbit Anthony Holder Laboratory 
GAP50 Rabbit Judith Green Laboratory 
GFP Rabbit Anthony Holder Laboratory (IFA) 
GFP Mouse Commercial, Sigma (Western Blot) 
HA Rat Commercial, Sigma (3F10 clone) 
K13 Mouse David Fidock Laboratory 
MSP1 Mouse Mike Blackman Laboratory 
Plasmepsin II  Mouse Daniel Goldberg Laboratory (MR4) 
Plasmepsin V  Mouse Daniel Goldberg Laboratory (MR4) 
Rab5A Rabbit Gordon Langsley Laboratory 
Rab5B Rabbit Gordon Langsley Laboratory 
Rab7 Rabbit Gordon Langsley Laboratory 
Rab11A Rabbit Gordon Langsley Laboratory 
RON4 Mouse David Baker Laboratory 
 
 
3.4 In vitro Cell Culture Methods 
3.4.1 Cell subculturing 
3.4.1.1 Plasmodium falciparum cell culture 
 
 Plasmodium falciparum parasites were cultured in human erythrocytes donated from 
the NHS Blood Bank in London, UK. The blood type was typically AB+, though we receive 
whatever the Blood Bank has available. If whole blood is provided, cells are washed twice 
with RPMI 1640 (Gibco) medium to remove the Buffy coat and resuspended to 50% 
haematocrit in RPMI. If red blood cells are provided, the blood is washed once in RPMI and 
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similarly resuspended.  
The culture conditions for falciparum cells is determined based on the parasite line. 
For lines that are well-adapted to suspension culture like 3D7, Dd2, and Cam3.II 
derivatives, parasitised red blood cells were maintained in RPMI 1640 supplemented with 
Albumax II, 1% (v/v) L-glutamine, and 40 µg/ml gentamycin sulphate at 4% haematocrit 
between 0.5% and 10% parasitaemia. For parasite lines isolated from patients and recently 
adapted to culture, parasitised cells were maintained in the same culture medium 
supplemented with 5% (v/v) heat-inactivated AB+ human serum and grown at 2% 
haematocrit between 1% and 5% parasitaemia. All cells were maintained at 37°C in 2% O2, 
3% CO2, 95% N2 atmospheric conditions. Parasitaemia was determined by staining 
methanol-fixed thin blood smears on glass slides with 10% (v/v) Giemsa in PBS for 5-10 
minutes and counting under a light microscope with a graticule.  
 
Table 4 List of compounds used in this thesis 
Compound Abbrev. Origin Application 
Working 
Concentration 
Compound 2 C2 Moon Lab 
Reversible PfPKG 
inhibitor; parasite 
synchronisation 
10 µM 
Dihydroartemisinin DHA MMV 
Drug Susceptibility 
Assays 
- 
Chloroquine CQ MMV 
Drug Susceptibility 
Assays 
- 
Quinine QN MMV 
Drug Susceptibility 
Assays 
- 
Lumefantrine LUM MMV 
Drug Susceptibility 
Assays 
- 
Piperaquine PIP MMV 
Drug Susceptibility 
Assays 
- 
Mefloquine MEF MMV 
Drug Susceptibility 
Assays 
- 
Brefeldin A BFA Conway Lab 
Trafficking inhibitor; 
protein localisation 
disruption 
5 µg/ml 
Rapamycin RAP Baker Lab 
FKBP/FRB 
dimerisation 
induction; activation 
of DiCre 
10 nM 
WR99210 WR MMV 
Selection of 
transgenic parasites 
2.5 nM 
Blasticidin-S BSD Sigma Selection of 2 µg/ml 
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transgenic parasites 
FT827 - 
Forma 
Therapeutics 
Experimental PfUbp1 
inhibitor 
- 
FT671 - 
Forma 
Therapeutics 
Experimental PfUbp1 
inhibitor 
- 
HBX19818 HBX MedChemExpress 
Experimental PfUbp1 
inhibitor 
- 
 
All compounds used during the culture of Plasmodium falciparum in thesis are listed with their 
abbreviations which may appear in this text, as well as their source, application, and working 
concentration. Where no working concentration is listed, the compound was used in serial dilutions.  
For subculturing cells, infected cells were harvested by centrifugation at 600g for 3 
minutes with slow brake in a conical tube. The spent media was aspirated, and the culture 
was reseeded typically at a 1:10-1:50 dilution in fresh, uninfected blood.  
Parasite strains were frozen using Glycerolyte and thawed by a 12% (w/v), 1.6% 
(w/v) two-step NaCl protocol as described in Methods in Malaria Research 269. 
Table 4 provides a list of all compounds used in this thesis, their source, and 
their working concentration, where appropriate. 
 
3.4.1.2 Plasmodium knowlesi cell culture 
 
 Plasmodium knowlesi was cultured similarly to Plasmodium falciparum. 
Parasitised red blood cells were maintained in RPMI 1640 supplemented with 
Albumax II, 1% (v/v) L-glutamine, 40 µg/ml gentamycin sulphate, and 10% (v/v) 
horse serum at 2% haematocrit. All cells were maintained at 37°C in 2% O2, 3% 
CO2, 95% N2 atmospheric conditions. To synchronise cultures, schizonts were 
enriched on a 55% Nycodenz cushion by centrifugation at 900 g for 10 minutes and 
allowed to reinvade fresh red cells for 1-3 hours. Schizonts which had not undergone 
egress were removed by a subsequent Nycodenz enrichment and discarded. 
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3.4.1.3 HeLa cell culture 
 
In this study, the localisation of PfAP2µ and PfK13 were examined in HeLa cells. 
Live HeLa cells were obtained from the Polly Roy laboratory at LSHTM and cultured as 
adherent cells in tissue culture-treated flat-bottom flasks. Cells were maintained in DMEM 
supplemented with 10% (v/v) fetal bovine serum and 1xPen-Strep (100 units/ml penicillin; 
0.1 mg/ml streptomycin) (Sigma). HeLa cells were passaged frequently to maintain the 
culture at less than 50% confluency. Cultures were maintained at 37°C in a 5% CO2 
atmosphere.  
For passaging, growth medium was aspirated, and the cells were washed twice with 
PBS to remove serum, which inhibits trypsin. After two washes, the PBS was replaced with 
2 ml of 0.05% Trypsin-EDTA solution (Sigma), and the culture was returned to the 37°C 
incubator for 2-4 minutes. The culture flask was knocked on the bench to release the cells, 
and culture medium containing serum was added to the cell suspension to 10 ml total 
volume to quench the trypsinisation. The suspension was then centrifuged at 300g for 3 
minutes with slow brake at RT, and the cells were resuspended in 10 ml of fresh medium. 
The culture was reseeded at a 1:5 or 1:10 dilution from the stock suspension, and the 
remaining material was destroyed.  
 
 
3.4.2 Parasite synchronisation 
 
Parasite cell cultures were typically maintained as generally synchronous cultures 
with a 8-12 hour post-invasion window of synchrony. This was mainly accomplished by 
sorbitol treatment. To remove trophozoites and schizonts from ring-stage parasites in 
culture, infected red blood cells were harvested by centrifugation as described above. The 
cells were resuspended in pre-warmed 5% (w/v) D-sorbitol and incubated at 37°C for 10 
 123 
minutes. Infected cells were then re-harvested by centrifugation, and the sorbitol solution 
was aspirated as well as any remaining liquid in the original culture flask. The infected cells 
were resuspended in culture medium and returned to the original flask or subcultured as 
appropriate. The synchronisation was confirmed by Giemsa staining.  
To obtain tighter synchrony, schizonts were enriched by Percoll density-gradient 
centrifugation. For this method, cells were cultured up to 5-10% schizontaemia at 3% 
haematocrit. Parasitised cells were harvested by centrifugation and layered gently on top of 
3 ml of pre-warmed 70% Percoll solution in a 15 ml conical tube. A stock of 70% Percoll 
was prepared by mixing 7 ml Percoll, 1 ml 10xRPMI in dH2O, and 2 ml of 13.3% (w/v) 
sorbitol in PBS. The tube with schizont-infected cells layered onto the Percoll cushion was 
centrifuged at 2000g for 10 minutes at RT with slow acceleration and slow brake. Schizont-
infected cells float on top of the Percoll layer and red cells that are uninfected or infected 
with other stages will sink below the layer. The schizont layer was gently removed by 
pipetting and washed with 5 ml of warmed complete media. These enriched schizonts were 
then allowed to invade fresh red blood cells at 20% haematocrit under gentle orbital shaking 
at 37oC for 1-3 hours, after which the cells were sorbitol-synchronised to remove schizonts 
that had not yet egressed.  
To obtain highly synchronous parasites with less than a 1 hour post-invasion (HPI) 
window of synchrony, 1-3 HPI parasites were obtained as described above. These cells were 
then treated as schizonts with Compound 2, a reversible inhibitor of PKG as described by 
Taylor et al. Compound 2 can be used to reversibly delay egress for up to 4 hours without 
known detriment. Parasites blocked for greater than 4 hours typically are not viable. Once 
more than 90% of blocked parasites in the culture were highly-segmented schizonts, the 
cells were harvested by centrifugation, washed with complete medium once, resuspended to 
50% haematocrit in complete medium, and incubated under shaking conditions at 37°C. 
 124 
Cells were then sorbitol-synchronised within 30 minutes. Alternatively, highly-segmented 
schizonts could be enriched by Percoll purification and incubated with fresh red cells. In 
practice, this additional manipulation can cool the parasites and slow their growth slightly, 
which promotes asynchrony and reduces the 0-30 minute ring-stage parasitaemia. 
Compound 2 was generously provided by the David Baker laboratory.  
Plasmodium knowlesi can only be synchronised over a 55% (v/v) Nycodenz solution 
in 10 mM HEPES, pH 7.0, which behaves like Percoll. Percoll is slightly harsher, and 
knowlesi parasites do not tolerate Percoll as well as Nycodenz. After desired reinvasion has 
occured, infected cells can be re-treated with Nycodenz to remove schizonts that have not 
yet egressed. Currently, no chemical means of isolating ring-stage parasites as with sorbitol 
treatment exists for Plasmodium knowlesi, though this is under investigation.   
 
 
3.4.3 Transfection Techniques 
3.4.3.1 Plasmodium falciparum transfection by ring-stage 
electroporation 
 
For transfecting Plasmodium falciparum cells, several techniques were used 
including the classical ring-stage transfection. Using the protocol for ethanol precipitation of 
DNA described above, 150 µg of DNA per plasmid to be transfected was precipitated in a 
sterile 1.5 ml eppendorf tube under under sterile, cell culture conditions. The DNA pellet 
was air dried in the microbiology safety cabinet for one hour at room temperature and 
resuspended in 15 µl of sterile TE(10, 0.1). For this method, ring-stage cultures of 5-10% 
parasitaemia were harvested less than 20 hours post invasion. For each transfection 400 µl 
of infected red cells were equilibrated in 10 volumes of pre-warmed cytomix (25 mM 
HEPES, 120 mM KCl, 0.15 mM CaCl2, 2 mM EGTA, 5 mM MgCl2, 10 mM 
K2HPO4/KH2PO4, pH 7.6) and harvested by centrifugation at 600g for 3 minutes at RT with 
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slow brake. 300 µl of equilibrated infected cells were combined with the resuspended, 
sterile DNA and added to a 2 mm transfection cuvette (BioRad) and mixed well by 
pipetting. The cells were then shocked in a BioRad Gene Pulser II using 0.31 kV, 950 µF, 
and maximum capacitance settings. The shocked cells were immediately placed into 1 ml of 
warm culture medium. 2-4 hours later, the transfected cells were washed once with culture 
medium to remove lysed cells and debris before being returned to a standard 10 ml culture. 
Drug selection was applied from 24 hours after transfection. Parasites typically took 3-5 
weeks to recover after drug selection.  
 
 
3.4.3.2 Plasmodium falciparum transfection by spontaneous DNA 
uptake 
 
Another transfection technique used in this study was the spontaneous DNA uptake 
method. DNA was precipitated and resuspended as described above. For each transfection 
500 µl of fresh uninfected red cells were equilibrated in 10 volumes of cold cytomix (25 
mM HEPES, 120 mM KCl, 0.15 mM CaCl2, 2 mM EGTA, 5 mM MgCl2, 10 mM 
K2HPO4/KH2PO4, pH 7.6) and harvested by centrifugation at 2000g for 3 minutes at RT with 
slow brake. 400 µl of equilibrated cells were combined with the resuspended, sterile DNA, 
pipetted into a 2 mm cuvette, and incubated on ice for 15-30 minutes. Afterwards, the cells 
were then shocked in a BioRad Gene Pulser II using 8 square waves consisting 365V for 1 
ms each, separated by 100 ms. The shocked cells washed several times with RPMI to 
remove cell debris and warmed in 2 ml of complete medium. 10 µl of Percoll-enriched 
schizonts were then added to these cells and allowed to reinvade for 3 hours with gentle 
orbital shaking at 37°C. 8 ml of medium was then added to the culture, and drug selection 
was begun 48 hours later. 
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Though it has not been extensively examined, this technique seems to be 
approximately as efficient as the ring-stage transfection. Parasites typically recover from 
drug selection approximately 4 weeks after transfection. Method 3.4.3.1 and 3.4.3.3 directly 
shock the parasite, whereas this method is comparatively gentle. This method was used to 
successfully transfect the HL1402 clinical isolate where the other two methods failed. This 
supports the general theory that clinical isolates are less robust parasites in culture and 
sensitive to perturbations, including electroporation, which are tolerated by standard 
laboratory lines.  
 
 
3.4.3.3 Plasmodium falciparum transfection by Nucleofection 
 
Nucleofection on the Amaxa 4D-Nucleofector platform from Lonza differs from the 
other two transfection methods described above because it requires the most stringent 
synchronisation of the three methods. The machine is proprietary so the actual mechanism 
of transfection is unclear, but the system transfects 10 µg of DNA into 10 µl of enriched, 
highly synchronous schizonts, which are moments away from egress. This system 
outperforms the other two methods because transfectants are recovered two weeks after 
transfection rather than four weeks and it requires significantly less DNA per transfection. 
However, the other two methods can accommodate relatively asynchronous parasites, 
whereas Nucleofection requires a 30-60 minute post-invasion window of synchrony, which 
can take several weeks to achieve. 
Briefly, parasites were synchronised tightly as described above to a 1-2 hour post-
invasion window of synchrony. In the trophozoite stage, Compound 2 was applied, and 
highly segmented schizonts were isolated by Percoll enrichment at the end of the lifecycle. 
The lifecycle progression was monitored closely by Giemsa staining. After enrichment, the 
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schizonts were washed in pre-warmed media once and then mixed with 100 µl of Lonza P3 
Primary Cell solution premixed with the proprietary transfection supplement. This was then 
mixed with precipitated, sterile DNA resuspended in 10 µl of sterile TE(10, 0.1) and added 
to a Nucleofection cuvette. The cuvette was then shocked per manufacturer 
recommendations. The transfection reaction was immediately transferred to 1 ml of pre-
warmed 50% haematocrit culture and placed on an orbital shaker at 37°C. Transfection 
efficiency roughly correlates with the parasitaemia 1 hour after transfection. Parasitaemias 
of 1-5% typically indicate a successful transfection. Transfections producing 1 HPI 
parasitaemias under 1% often are successful but require 3-6 weeks to recover after drug 
selection. Three hours after transfection, the infected red cells were washed once and 
returned to a standard 10 ml culture. Drug selection was started 24 hours after transfection.  
 
Nucleofection™ and Nucleofector™ are registered trademarks of Lonza, 2018.  
 
 
3.4.3.4 Plasmodium knowlesi transfection by Nucleofection 
 
 Transfection of Plasmodium knowlesi schizonts was performed similarly 
using the Lonza Nucleofector 4D platform. Highly synchronous schizonts were 
enriched from infected red blood cells using a 55% (w/v) Nycodenz cushion and 
centrifugation. These schizonts were washed in RPMI, and 10 µl of these schizonts 
were resuspended in 100 µl of P3 Primary Cell solution and DNA as described 
above. This resuspension was added to a transfection cuvette and shocked with the 
same protocol as above. 
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 Transfected schizonts were added to fresh red blood cells in warm media and 
allowed to reinvade overnight. These transfected cells were then selected with 
pyrimethamine for five days commencing the day after transfection.   
 
3.4.3.5 Transient transfection of HeLa cells 
 
To examine the localisation of PfK13 and the µ subunit of the PfAP2 complex in 
HeLa cells, these genes were transiently transfected using Lipofectamine 3000. The 
transgenic PfAP2µ-3xHA coding sequence was PCR amplified out of genomic DNA 
prepared from the 3D7-AP2µ-3xHA-glmS parasite line created in this thesis and cloned into 
the pTriEX-3 vector (Millipore) downstream into the CMV expression cassette. The CDS of 
pfk13 was similarly cloned to create a separate construct. 
Briefly, cells were cultured to 50% confluency in a 25 cm2 flask as described above. 
The cells were then trypsinised and counted using a haemocytometer. 3x105 cells per well 
were then seeded into a 6-well plate with three 1 cm sterile round cover slips in the bottom. 
Once the cells had reached 70% confluency, 5 µg of DNA was precipitated and resuspended 
in 125 µl of DMEM, and 5 µl of P3000 reagent was added. Opti-MEM is typically used, but 
this reagent was not readily available and optimal transfection efficiency was not critical in 
these simple transient transfection and localisation experiments. According to the 
manufacturer’s guidelines, many cell lines can be transfected without this special reagent. In 
a parallel tube, 3.75 µl of Lipofectamine 3000 reagent was diluted in 125 µl of DMEM. 
Immediately before transfection, the diluted DNA was added to the diluted Lipofectamine 
reagent and incubated at room temperature for 10 minutes to allow the DNA packaging 
reaction to occur. 
Culture medium was removed from the seeded cell monolayer, and the cells were 
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washed with PBS. The packaged DNA solution was then added to the cell layer and 
incubated at 37°C for 12 hours. After 12 hours, the transfection solution was removed and 
replaced with HeLa cell medium. After 24 hours, the medium was removed, and the cells 
and cover slips were washed in place with PBS several times. PBS was then replaced with 
fixative solution (4% formaldehyde in PBS), and the same immunofluorescence protocol 
was performed as described in Section 3.3.6. 1 µl of VectaShield with DAPI was finally 
added to each coverslip. Coverslips were inverted and mounted onto a glass slide for 
imaging. µ2-HA and PfK13 were detected with the HA-specific and K13-specific antibodies 
listed in Section 3.3.11.   
 
Lipofectamine™ and Lipofectamine 3000™ are registered trademarks of Life Technologies 
(ThermoFisher Scientific), 2018.  
 
 
3.4.4 Cloning by Limiting Dilution 
 
After transgenic parasites were generated by the above techniques and genotyped, 
they were cloned by limiting dilution. Transgenic, uncloned cultures were subcultured to 2-
5% parasitaemia under standard conditions. The parasitaemia was then determined by 
counting a minimum of 400 red cells using a light microscope with a graticule and Giemsa 
staining. The cell densities of the culture and 50% haematocrit red blood cell stock were 
then determined with a disposable haemocytometer according to the manufacturer’s 
protocol. A dilutant stock was prepared by diluting the red cell stock to 2x109 cells/ml (2% 
haemtocrit) in complete media. The transgenic culture was similarly diluted. Using the 
dilutant stock, 10-fold serial dilutions were prepared to create a final solution with 1.25 
parasites/ml in 2% haematocrit. 96-well plates were seeded with 250 µl of this final dilution 
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to seed 0.33 parasites/well. In this format, a successful cloning plate will have parasites in 
approximately one third of the wells in the plate.  
One week after seeding the plate, media in each well was aspirated and replaced with 
media containing fresh red cells at 1% haematocrit. This was repeated 7 further days later, 
14 days after seeding. At day 20, this was repeated again, and parasite growth was 
determined by an LDH assay as described below. At this point 12 clones were moved to 6-
well plates and expanded for genotyping. Four successfully cloned, verified-transgenic 
parasites were further expanded and frozen. Two clones were characterised.  
 
 
3.4.5 Drug susceptibility and parasite growth assays 
 
3.4.5.1 Standard 48-hour EC50 determination 
 
For most frontline chemotherapies discussed in this thesis, a susceptibility 
profiles for various parasite lines were determined with standard 48h exposures to 
serial dilutions of the drug of interest. Briefly, ring-stage parasite cultures at 6-8 HPI 
synchrony were diluted to form a master stock at 0.5% parasitaemia in 4% 
haematocrit. Additionally, a 2x master stock of each drug of interest was prepared in 
complete medium. Serial two- or three-fold dilutions were made into complete 
medium across 8 columns of the 96-well plate, beginning in column four, with 100 
µl of 2x diluted drug in each well. Columns two and three of the plate served as 
positive and negative growth controls, and the wells in each column were filled with 
100 µl of drug-free complete medium or complete medium containing 20 µM 
chloroquine, respectively. 100 µl of the parasite master stock was added to each 
well, diluting the drug in each well to a final 1x concentration and the parasite 
culture to a final 2% haematocrit.  
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The outermost rows and columns were filled with 250 µl of sterile PBS. Over 
the course of a 48h incubation at 37°C, liquid in these wells commonly evaporates, 
which concentrates the liquid in the well in what we call the ‘edge effect’. This 
would expose the parasites to higher concentrations of drug than intended; therefore, 
these wells were omitted.  
The plate was then incubated for 48 hours at 37°C under standard culture 
atmosphere. After this incubation, the plate was frozen for 24 hours at -80°C and 
then thawed at 37°C to lyse the cells. The liquid in each well was resuspended, and 
100 µl of each well was added to a new 96-well plate containing 100 µl/well of stain 
solution (1:5000 dilution of SYBR Green (Invitrogen) in PBS). The parasite material 
and stain solution were thoroughly by pipetting, and the plate was incubated in the 
dark for at least 10 minutes. SYBR Green-labelled parasite DNA was measured on a 
SpectraMax spectrophotometer at 480 nm excitation and 520 nm emission. Parasite 
proliferation and a dose response was calculated by normalising parasite 
proliferation between the positive and negative growth controls. EC50 were 
determined using the log(inhibitor) vs growth 4 parameters non-linear regression 
analysis in Prism 7.0 (GraphPad). Z factors, originally described by Zhang et al, 
were also calculated as a quality control score to determine the robustness of the 
experiment and EC50 estimation using the following equation 
270:  
 
𝒁 = 𝟏 −  
𝟑(𝝈𝒑 + 𝝈𝒏)
𝝁𝒑 − 𝝁𝒏
 
 
 
 
where p/n and µp/µn represent the standard deviations and means of the positive 
and negative growth controls. A Z factor between 0.50 and 1 indicates a robust assay 
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and 0-0.50 indicates a poor quality assay. All assays reported in this thesis had Z 
scores greater than 0.7. 
 
3.4.5.2 Standard 96-hour EC50 determination 
 
Antibiotics like clindamycin, azithromycin, and doxycycline exert their antimalarial 
effects on second-generation parasites as described above in Section 1.4.5. 
Therefore, in order to determine parasite sensitivity to these drugs, their survival to 
serial dilutions of an antibiotic of interest must be examined after 96 hours rather 
than 48 hours. For these drugs, Method 3.3.4.1 was reproduced exactly as above 
except the assay plates were incubated for 96 hours rather than 48 hours. 
 
3.4.5.3 Ring-stage survival assay (RSA) 
 
This assay was pioneered by Benoit Witkowski and first described in 2013 as 
the only validated method of distinguishing artemisinin susceptibility phenotypes in 
parasites derived from Southeast Asia. The assay involves exposing tightly 
synchronised parasites to a 700 nM dihydroartemisinin for 6 hours. Survival in this 
assay format correlates with clinical treatment failure for parasites from this region.  
To perform this assay, Plasmodium falciparum cultures were tightly 
synchronised as described above to a 3 hour post invasion window of synchrony. A 
2x culture stock was prepared at 0.5-1% parasitaemia in 4% haematocrit and 
incubated with an equal volume of 1.4 µM dihydroartemisinin freshly prepared in 
complete medium so that parasites were exposed to 700 nM DHA in 2% 
haematocrit. The assay was performed in duplicate in 48-well plates with 500 µl per 
well. After 6 hours, infected red cells were washed by centrifugation five times with 
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1 ml of complete medium in 1.5 ml Eppendorf tubes. DHA is known to adhere to 
plastics and extensive washing has been shown to be critical. The infected cells were 
resuspended in 500 µl of medium after the final wash and reseeded in an unused 
well. After a further 66 hours, parasite proliferation was determined by FACS by 
mixing one volume of parasite culture with eight volumes of freshly prepared stain 
solution (1:1000 SYBR Green, 1:10,000 MitoTracker Deep Red in PBS). The 
stained parasites were incubated at 37°C for 30 minutes in the dark, and then 
analysed on an LSR-II flow cytometer (BD Biosciences. Ring-stage survival was 
calculated as the ratio of average parasitaemia resulting from the 6h exposure to 
DHA or DMSO.  
Multiple studies have recently demonstrated that the RSA could be modified 
to instead use a 3h or 4h pulse rather than a 6h pulse, while still retaining the ability 
to discriminate sensitive and resistant parasite RSA phenotypes. In this thesis, a 4h 
pulse was used except where noted because this considerably improves the ease of 
executing the assay as a single operator. This thesis may also use this specific 
notation when discussing RSA pulse-style assays: RSA0-3h
4h. The subscript (e.g. 0-
3h) indicates the age of the parasites when exposed to the DHA pulse, and the 
superscript (e.g. 4h) indicates the duration of the pulse.  
 
 
3.4.5.4 Lactate Dehydrogenase Assay (LDH Assay) 
 
 The lactate dehydrogenase assay, or LDH assay, measures parasite density 
and therefore proliferation by detecting active parasite LDH from live cells. LDH is 
an enzyme that catalyses conversion of lactate to pyruvate, simultaneously reducing 
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NAD+ (Nicotinamide adenine dinucleotide) to NADH. P. falciparum LDH can 
rapidly reduce 3-acetyl pyridine NAD (APAD), while erythrocytic LDH is only able 
to catalyse this reaction very slowly. In this assay cells are permeabilised in a buffer 
containing APAD, a fluorescent analogue of NAD+ and mixed with a NBT/PES 
(nitro blue tetrazolium/phenazine ethosulphate) solution, which converts APADH 
into a coloured salt that can be detected spectrophotometrically.  
 Briefly, 20 µl of parasite culture was mixed with 100 µl of reaction buffer 
(0.1% Triton X-100, 130 mM L-Lactate, 27 mM Tris-HCl, pH 9.0) supplemented 
before use with 33 µM APAD (Sigma) in a 96-well plate. To each well, 25 µl of 
NBT/PES (2.2 mM nitro blue tetrazolium, 240 μM phenazine ethosulphate in water) 
was then added, and the contents of each well were mixing thoroughly by pipetting. 
The assay plate was then incubated at 37°C for 30 minutes. Parasite proliferation 
was then measured using a SpectraMax spectrophotometer set to 650 nm.  
 While this assay can be used to perform drug dose response experiments, in 
this thesis, the reagents are more expensive than SYBR Green, and the assay 
generally produces a smaller dynamic range between parasite-positive and -negative 
samples. In this thesis, the LDH assay was used to screen limiting dilution cloning 
plates for parasite-positive wells.   
 
3.6 Microscopy Methods 
 
This thesis involves several different microscopy modalities: 
 All transgenic parasites with fluorescent tags were first screened after 
transfection under an EVoS inverted microscope for integration. For 
verifying integration and expression of these transgenes, 50 µl of standard 
cell culture was stained with Hoechst at 3 µg/ml for 20 minutes in the dark. 
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Stained cells were then washed once in PBS and resuspended to 20% 
haematocrit, and 10 µl of this suspension was sealed between a glass slide 
and 20x40 mm cover slip for imaging in on the EVoS system in a Category 3 
room.  
 Because the EVoS system is not suitable for colocalisation, live cell imaging 
and image capture was performed on a Nikon TI-3000 Eclipse inverted 
microscope. Cells were stained as above and immobilised on glass-bottom 
Ibidi µ-slides and sealed for imaging.  
 The Nikon system was also used for imaging fixed, immunostained cells 
prepared as described in Section 3.3.8.  
 All images were viewed using Fiji and Nikon Elements Advanced Research 
software packages. Z-stack images were background subtracted and 
deconvolved using the Richardson-Lucy algorithm with 8 iterations. A 
maximum Z projection was then performed and signal correlation analysis 
was performed in the Nikon software package using a standard 200x200 
pixel cell window. A minimum of 35 cells were compared for comparing 
correlational coefficients. The majority of the images presented in this text 
capture cells prepared using the thin-smear IFA method. Though many 
prominent laboratories still use this technique for examining the localisation 
of factors by IFA, this technique sacrifices cell morphology in favour of 
experimental ease and speed. In drying the thin smears, the cells are 
dehydrated causing considerable loss of cell depth, making any correlation 
between the determined localisation of two structures possibility poorly 
representative of what actually happens in the cell. Additionally, correlation 
analysis is complicated in P. falciparum because the resolution limits of 
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conventional light microscopy (approximately 0.2 m) makes discerning 
individual structures in the very small parasite cell (diameter: 1-1.5 m) 
difficult without super-resolution techniques. The presented imaging data 
should be understood with these caveats. 
 Immunoelectron Microscopy was performed by the Electron Microscopy 
Core Facility at the Washington University in St. Louis Children’s Hospital 
in conjunction with the Odom-John Laboratory.   
 
3.6.1 Immunoelectron Microscopy 
  
 P. falciparum were cultured at 37°C in 4 mL volumes in 6-well tissue culture 
dishes at 2% haematocrit until reaching 6-8% parasitaemia. Parasites were 
magnetically sorted from uninfected RBCs and ring stage parasites by passage 
through a magnetically mounted MACS LD separation column (Miltenyi Biotech, 
Germany). Parasites were collected by centrifugation and fixed for 1 h at 4ºC in 4% 
paraformaldehyde (Polysciences Inc., Warrington, PA) in 100 mM PIPES/0.5 mM 
MgCl2, pH 7.2. Samples were then embedded in 10% gelatin and infiltrated 
overnight with 2.3 M sucrose/20% polyvinyl pyrrolidone in PIPES/MgCl2 at 4ºC. 
Samples were trimmed, frozen in liquid nitrogen, and sectioned with a Leica 
Ultracut UCT7 cryo-ultramicrotome (Leica Microsystems Inc., Bannockburn, IL). 
50 nm sections were blocked with 5% fetal bovine serum (FBS)/5% normal goat 
serum (NGS) for 30 min and subsequently incubated with primary antibody for 1 h 
at room temperature (anti-PDI mouse 1:100 (1D3; Enzo Life Sciences), anti-GFP 
rabbit 1:200 (A-11122; Life Technologies), anti-GFP mouse 1:100 (11814460001; 
Roche), anti-HA rabbit 1:50 (H6908; Sigma-Aldrich), anti-Rab5a rabbit 1:50 
(Gordon Langsley) and anti-Rab5b rat 1:50 (Gordon Langsley)). Secondary 
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antibodies were added at 1:30 for 1 h at RT (12 nm Colloidal Gold AffiniPure Goat 
anti-Rabbit IgG (H+L)(111-205-144), 18 nm Colloidal Gold AffiniPure Goat anti-
Rabbit IgG (H+L)(111-215-144), 12 nm Colloidal Gold AffiniPure Goat anti-Mouse 
IgG (H+L)(115-205-146), and 18 nm Colloidal Gold AffiniPure Goat anti-Mouse 
IgG+IgM (H+L)(115-215-068) (Jackson ImmunoResearch). Sections were then 
stained with 0.3% uranyl acetate/2% methyl cellulose, and viewed on a JEOL 1200 
EX transmission electron microscope (JEOL USA Inc., Peabody, MA) equipped 
with an AMT 8 megapixel digital camera and AMT Image Capture Engine V602 
software (Advanced Microscopy Techniques, Woburn, MA). All labeling 
experiments were conducted in parallel with controls omitting the primary antibody. 
These controls were consistently negative at the concentration of colloidal gold 
conjugated secondary antibodies used in these studies. 
 
 
- - - - 
 
 
 
The molecular biology methods from this section are reproduced in part with permission 
from R. Henrici’s 2015 thesis entitled Structural and Biochemical Characterization of 
Chromatin Enzymes submitted in partial fulfillment of his BSc(Hons) from the Pennsylvania 
State University Schreyer Honors College. This thesis is available online as open-access 
without copyright.  
 
 
The in vitro cell culture methods pertaining to P. falciparum cell culture are reproduced in 
part from R. Henrici’s 2016 MPhil to PhD upgrading report entitled Manipulation of 
artemisinin and partner drug susceptibility in P. falciparum by genome editing submitted to 
the London School of Hygiene & Tropical Medicine. This document is not public, though 
available upon request.  
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Chapter 4 
Validation of AP2 µ-subunit and Ubp1 as modulators of 
antimalarial sensitivity 
 
 
 
 
4.1 Characterisations of genetic diversity in pfap2mu and pfubp1 in 
Kenya 
 
 In 2009, our laboratory analysed parasite samples from a clinical trial in 
Mbita, Kenya to examine the efficacy of artemether-lumefantrine and 
dihydroartemisinin-piperaquine in treating uncomplicated P. falciparum malaria in 
children under the age of 10 years205. As part of this study, polymorphisms in 
pfap2mu and pfubp1 were examined. These genes are new candidate markers for 
artemisinin and partner drug failure, first identified around the same time in an in 
vivo study of evolved resistance to artemisinin in Plasmodium chabaudi207,208. Three 
mutations of interest were identified in P. chabaudi between the two proteins, one in 
µ2 and two in Ubp1, and the Mbita study authors looked for evidence of selection of 
the orthologous mutations in these genes in clinical infections.  
 In this study, blood samples were taken from treated children before, during, 
and after treatment on days 0-3, 7, 14, 28, and 42 (Table 5, Fig 23). Whole-gene 
sequencing failed to identify the falciparum orthologue of the P. chabaudi mutation 
in pfap2mu encoding I592T. However, the effort did identify another non-
synonymous mutation (g.479_G>A) encoding S160N that appeared to be associated 
with recrudescent infections and day-3 parasitaemia205. Additionally, the study failed 
to identify falciparum orthologues of the P. chabaudi mutations in pfubp1, which 
would encode V3275F and V3306F, but found an association with an alternative 
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Figure 23 Patient treatment and sampling overview for 2013 field study in Kenya 
The field study in Kenya was executed as a three-day treatment and sampling regime with multiple 
follow points of patient followup and sampling after treatment. Within each day of treatment, the 
plasma concentration of the short-acting artemisinin compound rapidly spikes and wanes (solid 
orange line). This rapid bioavailability helps to quickly reduce parasitaemia. The bioavailability of the 
longer-lasting ACT partner drug rises to its maximum of the course of treatment and is detectable in 
the bloodstream up to 4-6 weeks after treatment (dotted orange line). To assess clearance of parasites 
and antimalarial efficacy, patient blood samples were taken before treatment (day 0), during each day 
of treatment (days 1, 2, and 3), and at days 7, 14, 28, and 42 after treatment had commenced. The 
bolded numbers indicate the number of samples available to analyse at each collection date.  
 
mutation in pfubp1 encoding E1528D.  
To follow up on this preliminary evidence of directional selection, the study 
authors executed another trial, this time examining artemether-lumefantrine and 
mefloquine-artesunate efficacy in the same village in 2013. The study protocol was 
similar to the 2009 study and aimed to examine these same mutations (Appendix I). 
However, due to funding issues out of our control, the study was stopped 
prematurely. Therefore, not all of the patients enrolled had blood samples drawn 
after the three-day regime. Additionally, many of the filter paper blood spots were 
lost or not returned to London by the study operators in Kenya. My work on this 
project commenced in the fall of 2015 and aimed to determine the prevalence of 
pfap2mu and pfubp1 mutations in the patient samples we did receive, which included 
both pre- and post-treatment samples. While we sequenced every sample that we 
received, we omitted samples from patients who were not followed after day 28 
post-treatment. 
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S160N that was under significant positive selection over the three day drug course (P = 0.006)65. 
Additionally, this study reported a similar association with another previously proposed marker 
of ACT failure, pfubp-1 (E1528D)56. The 2013 study aimed to foll w up on these findings. 
Furth r to objective 2 described in Ch pter 2, every sample availabl  from this study was 
analysed for these pfap2mu and pfubp-1 polymorphisms.  
4.1.1 Directional selection of variant pfap2mu alleles 
 
 According to the protocol described by Henriques et al, pfap2mu(359-1196) was 
amplified in a nested PCR reaction from DNA extracted from dried filter paper blood spots and 
sequenced by Sanger sequencing. Although 321 samples were sequenc d, 24 were excluded 
because the study was concluded early ue to insufficient funds, and several patients were not 
followed up through at least day 28 after treatment. Therefore, in total, 128 pre-treatment 
samples, 60 day 1, 59 day 2 and 3 samples, and 50 post-treatment samples were sequenced. 
These data were analysed using the same a priori hypotheses and statistical methods as in the 
2009 study to enable comparison between both data sets.   
 
 
Figure 4 2013 Study design to track parasites surviving ACT treatment 
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Table 5 Patient characteristics in 2013 Mbita ACT efficacy study 
 
 
 
 
 
 
 
 
 
 
 
 
 
Biographical and clinical characteristics of patients enroled in the clinical study for whom pre-
treatment samples were collected.  
 
 
 Given that our laboratory’s previous preliminary transgenesis efforts 
indicated that the S160N variant of pfap2mu has some effect on artemisinin 
susceptibility in cell culture, I expected that the based line prevalence of this variant 
would be higher than that detected in the 2009 study. This would be consistent with 
directional selection reported by Henriques et al, however this study was not 
designed to detect evidence of a selective sweep. Although there is very little data 
available about the prevalence, selection, or impacts of the pfubp1 variants described 
by Henrique et al and Borrmann et al, I expected the diversity of pfubp1 haplotypes 
to have decreased if this region of the gene is linked to parasite fitness or drug 
susceptibility.   
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4.1.1 Preliminary analysis of variant pfap2µ alleles 
 
 According to the protocol described by Henriques et al, pfap2mu(359-1196) 
was amplified in a nested PCR reaction from DNA extracted from dried filter paper 
blood spots and sequenced by Sanger sequencing205. Although 311 samples were 
sequenced, 24 were omitted as they were from patients without day 28 followup.  
Therefore, in total, 118 pre-treatment samples, 60 day 1, 59 day 2 and 3 
samples, and 50 post-treatment samples were sequenced and analysed. These data 
were analysed using the same protocol as in the 2009 study. 
The PCR amplification scheme used to examine this locus of interest lacked 
the sensitivity of many of the other genotyping amplifications our laboratory 
performs. Although extensive optimisation was attempted including varying primer 
sequences, thermocycling settings, and reaction composition such as divalence,  
 
 
 
 
 
 
 
 
 
Figure 24 Prevalence of S160N mutations in African patients 
Because of the low number of sample available to analyse and to facilitate comparison between 
studies, patient samples were pooled and analysed as in Henriques et al 205. Thus, the prevalence of 
the pfap2mu(S160N) variant was analysed as either pre-treatment (blue; day 0), during treatment 
(green; days 2 and 3, merged) or post-treatment (yellow; days 7-42).  
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buffer composition, and primer and template concentrations, the amplification 
sensitivity could not be significantly improved. Unfortunately, the post-treatment, 
day 2 and 3 samples were most impacted by this problem because the parasitaemia, 
and therefore extracted parasite DNA concentration, is often very low. The 
investigators of the 2009 study merged the day 2 and 3 data, recording the latest 
sequencing result for each patient, to increase their sample size; for consistency, this 
operation was performed on the 2013 data set as well.  
Between the two studies, the same trends hold (Fig 24, 26). When comparing 
all the sequenced samples from 2013 across days of treatment, there is some  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25 Within-patient selection of pfap2mu variants 
Comparison of pfap2mu genotypes in paired blood samples taken from individual patients before, and 
after ACT-treatment. Each line in the heat maps represent an individual patient. Red indicates the 
presence of the mutant S160N allele, blue the alternate S160T allele, yellow an indeterminate mixed 
genotype, and green the wild type S160S allele. Black indicates no sample was available. The panel 
on the right examines only patients for which day 0 and day 2 or day 3 sequencing data was collected 
(N = 48 patients). Ticks on the left edge of each panel indicate individual patients. 
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Figure 26 Comparison of the prevalence of pfap2mu(S160N) between 2009 and 2013 field 
studies 
A comparison of the prevalence of the mutant pfap2mu(S160N) parasite allele detected in patient 
blood samples taken before and during treatment in the 2009 and 2013 studies performed in Mbita, 
Kenya. 
  
 
evidence of positive selection for the S160N SNP. Of the pre-treatment samples, 105 
(89.0%) were wild type, 13 (11.0%) possessed the S160N mutation, 2 were mixed 
genotype, and 2 possessed the alternate S160T allele, previously observed at 
similarly low frequency in 2009. At days 2 and 3, 26.9% of sequenced samples 
possessed the mutant allele; only one patient had parasites with the alternate S160T 
allele. When examined at the individual level, the trend becomes clearer (Fig 25). In 
patients with both pre- and post-treatment samples, 12.5% had parasites with the 
S160N allele before treatment, compared to 34.3% after. In this sub-analysis, 
infections in which both genotypes were detected before treatment resolved to 
single-genotype infections with the S160N mutation after treatment.  
 Statistical calculations performed for the original study protocol determined 
that 300 patients needed to be enroled and followed for the duration of the study to 
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3 data, recording the latest sequencing result for each sample, to increase their sample size; for 
consistency, this operation was performed on the 2013 data set as well. Therefore, although the 
population level prevalence of the S160N mutation differs between each study in absolute terms, 
the overall selective pressure is still present during treatment and seems to be of the same 
magnitude. 
 Interestingly, the prevalence of the S160N mutation at the later days of PCR-confirmed 
parasite positivity (days 20-48) was lower than in 2009. Only 7 of 44 sequenced patients (15.9%) 
from the 2013 study possessed the mutant allele, compared to 7 of 28 (25%) in 2009. Although 
this difference is not statistically significant because of small sample size, it begs an interesting 
question about the fitness costs and transmissibility of this parasite genotype. One might expect a 
genetic driver of parasite survival to become more entrenched in a population after several years 
of ACT treatment. However, mefloquine-artesunate was not previously used in this setting, and 
the impacts of the introduction of this ACT are not yet clear. This underscores the common 
Figure 7 Comparison of S160 mutation prevalence between 2009 and 2013 
The prevalence of AP2mu(S160N) mutations from both the 2009 and 2013 studies compared are not significantly 
different by Pearson’s Chi Square test. 
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detect a 20% risk difference with 90% power and type I error of 0.05. Therefore, the 
current sample set is too small to calculate the statistical significance of any changes 
identified here. 
Between the two studies, the trend is similar (Fig 26). In the samples 
analysed, the S160N mutant pfap2mu allele is more prevalent in parasites detectable 
at day 3 of treatment. Interestingly, the prevalence of the mutation at the later days of 
PCR-confirmed positivity (days 20-48 after treatment) in this preliminary sample 
was lower than in 2009. Only 8 of 50 (15.9%) sequenced patients had the mutant 
allele, compared to 7 of 28 (25%) in 2009. One might expect a mutation that is under 
selection and tightly associated with treatment outcomes to increase in base 
prevalence over the four years between these studies and be present in higher 
prevalence in recrudescent infections. We have not looked for genomic evidence of a 
selective sweep, but the similar prevalence of the S160N allele determined in this 
work compared to the 2009 study suggests against a sweep.  
 
 
 
 
4.1.2 Directional selection of variant pfubp1 alleles 
 
The evidence for selection of pfubp1 genotypes during and after ACT 
treatment is more complicated. Borrmann et al associated Ubp1(E1528D) with 
artemisinin resistance in vitro by GWAS, however sequencing results from this locus 
in our 2009 study samples revealed more than 16 different haplotypes encoded 
within 30 bases upstream or downstream of the E1528 codon251. The major source of 
diversity in this region comes from several tandem KYD/E motifs, which seem to 
expand and contract as triplet motifs, shifting the reading frame by multiples of three  
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Figure 27 Haplotype diversity identified in pfubp1 at a resistance-associated locus 
14 different pfubp1 haplotypes around the E1528 residue were identified in sequenced patient 
samples. These include polymorphisms at residues 1525, 1528, and 1531 as well as indels 
immediately upstream of residue 1525. Five major haplotypes (bold) and 9 low frequency haplotypes 
(less than 2% of total samples per haplotype; grey) were identified.   
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amino acids with respect to the 3D7 reference genome. Given the degeneracy of the 
nucleotide sequence and the similarity of the amino acid translation, it is difficult to 
say with certainty where these insertions and deletions occur. Thus, interpreting the 
prevalence of any specific Asp to Glu or Glu to Asp mutations in these KYD/E 
motifs is difficult, and comparing across studies is nearly impossible unless authors 
describe how these indels were aligned in their analysis. This analysis assumes that 
any insertions or deletions occur at the 5’ end of the repetitive locus.  
Overall, my sequencing identified 13 haplotypes involving mutations at 
D1525, E1528, and E1531 as well as indels around these residues (Fig 27). More 
than 80% of the sequenced samples harboured one of five major haplotypes. 
However, 8 other low frequency haplotypes, each with less than 2% prevalence in 
pre-treatment samples, were also identified. Because there was no evidence of 
selection of these minor haplotypes, they will not be discussed further in this thesis, 
though they may be of interest for future analyses. 
When the sequences from the 2013 samples were aligned as described above 
to the reference CDS, there was no immediate evidence of selection at the E1528 
position. Approximately 15% of samples before, during, and after treatment 
contained the E1528D mutation. When the haplotype of the locus was considered as 
a unit irrespective of indels, approximately 16% of patients harboured parasites with 
the DDE (D1525, E1528D, E1531) haplotype before treatment, whereas 22% of 
samples did after. The 2009 study did not consider haplotypes but showed 10% of 
sequenced pre-treatment samples harboured E1528D, as compared with 17% after 
treatment (day 3).  
Yet when including indels in the haplotype classification, the evidence for 
E1528D becomes increasingly complicated. While the DDE haplotype (D1525,  
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Figure 28 Directional selection of pfubp1 haplotypes 
The prevalence of the five major haplotypes identified around the 1528 locus was assessed before 
treatment (day 0), during treatment (days 1 and 2/3), and after treatment (days 23-28, days 38-48). 
Samples were pooled as noted for consistency of analysis and comparison with the 2009 study by 
Henriques et al205. Haplotypes were generated by considering residues 1525, 1528, 1531 and indels 
immediately upstream of 1525 as a single unit. EEE1 therefore indicates D1525E, E1528, E1531, and 
one KYD insertion upstream of residue 1525 (Fig 27).   
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E1528D, E1531, no indels) doubles in prevalence from 3.3% before treatment to 
8.7% after treatment, it is not detected in any late-treatment failure (days 28-42) 
parasite samples, and none of the multiple other haplotypes with the E1528D 
mutation increase in prevalence during or after treatment. Instead, the EEE1 
(D1525E, E1528, E1531, with 1 KYD insertion) haplotype seems to be selected 
strongly, beginning during the three days of treatment (pre-treatment: 11.48%; day 3: 
19.6%) and continuing through several weeks post-treatment, peaking at 53.9% at 
days 28-42 after beginning the study (Fig 28). Interestingly the prevalence of the 
wild type 3D7 haplotype decreases from 63.9% before treatment to 45.7% after 
treatment and 26.9% in late treatment failure samples. It is tempting to consider 
these data as evidence of directional selection; however, we will not know until after 
the rest of the study samples are imported and analysed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29 Possible genetic mechanisms for observed pfubp1 directional selection 
A schematic representing how the EEE1 haplotype could have arisen. The EEE1 haplotype is 
considered a D1525E and a single KYD insertion, however there is no evidence of these individual 
polymorphisms. Therefore, given the degeneracy of the repeats in this region, the haplotype could 
result from a single KYE insertion around residue 1525 (third line), which would simultaneously 
introduce D1525E and the single KYD “indel” upstream of this locus.   
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An alternative possible interpretation of this data is that rather than a discrete 
KYD insertion and D1525E point mutation, a KYE insertion in the middle of that 
region is creating the haplotype (Fig 29). This makes more intuitive sense given that 
there is no evidence of selection for either the D1525E or KYD insertion 
independently. 
Unfortunately, the 2009 study was not quantitatively analysed by haplotype 
as discussed in this section, particularly with respect to the presence or absence of 
the indels. Without a full reanalysis of that data set, we can only see that 20% of the 
pre-treatment samples from 2009 had the EEE1 haplotype. Therefore, it is possible 
that a similar trend existed in 2009 but was not reported.  
 
4.1.3 Whole gene sequencing reveals minimal genetic diversity in 
pfubp1 
 Given the importance of ubiquitin hydrolases in a wide range of pathologies 
and the implication of Ubp1 in antimalarial response in both rodent and human 
studies, I sought to probe existing genetic diversity across the entire gene. The 
dynamics around the 1528 locus are interesting, but the putative C-terminal catalytic 
domain is of particular interest. Additionally, outside of this putative catalytic 
domain, the protein lacks homology with other factors. Understanding which regions 
may be conserved or polymorphic could help map functionality onto the gene and 
identify other loci of interest.  
To begin to characterise the genetic diversity along the rest of the pfubp1 
gene, a PCR-based strategy was designed to amplify and sequence the entire 10.5 kb 
coding region of the gene from randomly selected pre-treatment blood samples of 
patients who went on to either successfully clear their parasitaemia by day 3 or  
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Figure 30 Diversity topography map of pfubp1 in selected parasite samples 
The entire pfubp1 gene was sequenced from six samples from patients with fully cleared parasitaemia 
at day 3 and six samples from patients with late-day parasitaemia by PCR. The number of mutations 
per 100 base pairs was plotted along the length of the gene (top panel; red) alongside relative GC 
content per 100 base pairs (top panel; blue). The middle panel (green) depicts the sequencing 
coverage per 100 base pairs. A schematic of pfubp1 is provided which depicts the splicing 
architecture of the gene, as well as the putative catalytic DUB domain and 1528 Borrmann hotspot251. 
In. 1 and In. 2 indicate introns 1 and 2 of the pfubp1 gene. 
 
 
experience late-day treatment failure. Six parasite pfubp1 genes from each category 
were sequenced.  
Given the low complexity of many regions of the gene and the low remaining 
amounts of DNA from the finger-prick blood spots, it was not possible to obtain 
high-quality reads for the entire gene from each sample. However, it was still 
possible to identify a number of SNPs and indels along the length of the gene that 
may inform future population genetics or transgenic work (Fig 30).  
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Interestingly, most of the gene seems generally conserved between these 
parasites. As expected, there are some small expansions and contractions of low-
complexity, repetitive regions, but when SNP frequency is mapped against gene 
complexity, as measured by relative GC content, there are a few regions of higher 
complexity with variability. Higher complexity regions are not necessarily 
intrinsically functional but can be maintained if they encode important structural 
elements. One of these potentially interesting locations occurs approximately one 
quarter of the way into the gene around base 2300.  
Consistent with in silico modelling, the C-terminal region encoding the 
putative catalytic domain is mostly conserved among these 12 samples (Appendix 
IVI)208. One SNP was detected in the putative catalytic domain encoding D3496N 
just after the 3’ splice site of the second intron. At this point, it is too early to suggest 
which mutations could be interesting. The fact that one mutation is observed in such 
a small sample indicates there may be important mutation events occurring in this 
region of the gene. Unpublished recent work from others in our lab have identified 
several other mutations in this region. Work is underway to expand this 
topographical mapping of pfubp1 and to sequence the C-terminal region from a large 
sample of patients to inform future in vitro transgenic and biochemical experiments.    
 
 
4.2 Rationale for examining µ2 and Ubp1 mutations in P. falciparum  
 
 The mutations of interest in pfap2mu discussed so far in this report have been 
linked with artemisinin susceptibility either by statistical association with clinical 
treatment failure through population genetics work, computational genomics, or a 
rodent malaria study. There is no direct evidence for causation in Plasmodium 
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falciparum. Previous in vitro work in our laboratory attempted to probe the effects of 
the µ2(S160N) mutation and suggested a moderate impact on quinine sensitivity and 
a subtle effect on artemisinin susceptibility206. However, this work involved 
integrating a mutant copy of the gene under the control of the calmodulin promoter 
into the dispensable cg6 locus on the Dd2, chloroquine-resistant background. This 
approach is problematic for several reasons.  
 The first issue is that the wild type protein was not disrupted in this line. 
Therefore, in this line, mutant and wild type copies were competing for other 
components of the AP2 complex, making it is impossible to know if the phenotypes 
observed are a blend of wild type and mutant phenotypes or artefacts of this 
molecular competition. Secondly, the cam promoter is highly active and does not 
reflect the stage-specific profile of the endogenous pfap2mu promoter. The qPCR 
performed in this original transgenic work suggested abnormal expression patterns 
of the transgene compared to the endogenous locus and a high degree of variability 
in the detected expression, with minimal expression in the schizont stage. AP-2 
components are essential for cell survival in all organisms that have been examined, 
so it is unclear what effect this aberrant expression profile had on the parasite. 
Indeed, parasites overexpressing a wild type copy of pfap2mu in the cg6 cassette 
showed modified sensitivity to lumefantrine. Lastly, the examination of this 
mutation, identified in Africa, in the Dd2 parasite of Southeast Asian origin with 
chloroquine resistance is also inappropriate and complicates the interpretation of 
these data. At the time, the Dd2-attP integration system was the state of the art. 
However, now we have genome editing technologies available (Section 1.11), which 
are vastly superior. Given the potential importance of mutations in these genes, 
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mutations of interest should be re-evaluated with these tools, which represent the 
new state of the art.  
For all of these reasons, I elected to re-examine the impact of the 
pfap2mu(S160N) variant on a chloroquine-sensitive 3D7 background using the Cas9 
system to install this mutation into the endogenous pfap2mu locus. In addition to re-
examining this clinical mutation, I also examined the impacts of the mutations 
orthologous to those described by Hunt et al in pcap2mu and pcubp1, which encode 
PfAP2µ (I592T) and PfUbp1(V3275F) and PfUbp1(V3306F), respectively. Based on 
our previous data and the data presented by Hunt et al, I expected all of these 
mutations to affect parasite susceptibility to artemisinin. Additionally, the three 
orthologous mutations from the P. chabaudi study evolved in the context of multiple 
drug resistance, therefore these may contribute to parasite susceptibility to 
chloroquine. However, it is unclear from the murine drug selection regime how these 
mutations should be expected to modulate parasite susceptibility to these other 
drugs, including chloroquine. 
 
4.3 Generation of P. falciparum strains bearing µ2 mutations using 
CRISPR-Cas9 editing  
 
To validate the role of µ2 in the context of drug resistance, constructs were 
designed and created to install the S160N mutation, which was first identified in 
clinical isolates in Kenya, and the I592T mutation, which was first identified in an 
artemisinin-resistant P. chabaudi parasite.  
 Cas9 cleavage sites are defined by 20 nucleotides followed by the diguanine 
NGG protospacer adjacent motif (PAM). To design constructs to install these two 
mutations, PAM sites in the pfap2mu gene (PF3D7_1218300) were mapped using  
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A 
 
 
 
 
P. chabaudi mutation – pfap2mu(I592T) 
 
B 
 
 
 
 
 
P. falciparum Kenyan field mutation – pfap2mu(S160N) 
 
Figure 31 Schematics for manipulating pfap2mu by Cas9-mediated genome editing 
A Schematic for installing the P. falciparum orthologue of the P. chabaudi pfap2mu mutation 
encoding Pfµ2(I592T). A PAM site at the 3’ end of the gene within 15 bp of the I592 locus was 
selected. A homology repair template was designed based on the pL6 system described by Ghorbal et 
al to contain approximately 300 bp homology arms (LHR, RHR) upstream and downstream of the cut 
site as well as the I592T alternative codon and silent mutations to destroy the PAM site263. B A 
similar construct was designed to install the S160N mutation (attempt 1). A second construct was 
designed using a downstream PAM site with greater predicted activity (attempt 2). 500 bp homology 
arms were designed to increase homologous repair efficiency and the region of the CDS between this 
PAM and the S160 locus was recodonised to prevent homologous repair from occurring before the 
S160N allele was installed. For recodonisation, every other codon was replaced with the second most 
frequently used codon for the given amino acid.  
 
 
 
Reverse genetics to confirm roles of AP2 in modulating antimalarial sensitivity
AP2mu(I592T) – P. chabaudi orthologue    AP2mu(S160N) – P. falciparum field mutation
Reverse genetics to confirm roles of AP2 in modulating antimalarial sensitivity
AP2mu(I592T) – P. chabaudi orthologue    AP2mu(S160N) – P. falciparum field mutation
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Figure 32 Cas9 protospacer adjacent motifs in pfap2mu 
Annotated CDS of pfap2mu with all Cas9 protospacer adjacent motifs (PAM) marked and coloured 
by predicted activity score (Doench-Root Algorithm). A sliding colour scale from red to green 
indicates the magnitude of the score from 0 to 1.0. PAMs were identified and scored using the 
CRISPR-Cas9 tool in the Geneious R8 software package. The two pink annotations mark the 
positions of the S160 and I592 loci.  
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empirical experimentation. Factors determining sgRNA activity in Plasmodium have  
the embedded CRISPR tool in the Geneious R8 software package. The Geneious 
PAM report has limited information, namely the position of the guide on the gene, a 
predicted off-target activity score, and an on-target activity score (Fig 32). The on-
target score is produced by the Doench-Root Algorithm, hence the name DRA score, 
which was originally designed and optimised in 2014 for mammalian cells based on 
empirical experimentation. Factors determining sgRNA activity in Plasmodium have 
not yet been worked out, so the DRA score is one of the only available measures of 
possible on-target activity. Therefore, PAMs were selected that would balance 
maximising proximity to the locus of interest and DRA score, with preference given 
to proximity (Fig 32).  
A homology template was designed for each mutation that would include 
300-500 bp 5’ and 3’ arms that flank the cut site and a recodonised region that would 
integrate the mutation of interest and synonymous mutations to remove the PAM 
site. Recodonised regions including the synonymous “shield” mutations to replace 
the PAM and the mutations of interest were introduced with primers. The full 
homology template was generated by overlap PCR and cloned into the pL6 
homologous repair template plasmid (Fig 31). Two complementary, single-stranded 
oligonucleotides containing the DNA sequence of the chosen PAMs were annealed 
and ligated into the sgDNA cassette in these pL6 constructs as described by Ghorbal 
et al263.  
 The template repair plasmid and Cas9 expression plasmid were transfected 
into 3D7 parasites using the ring-stage transfection protocol described in Section 
3.4.3.1. Parasites were recovered after 24 days. PCR amplification and sequencing of 
the genomic locus showed that the I592T SNP had been successfully installed along  
 157 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33 PCR-RFLP mapping of transgenic parasites bearing pfap2mu mutations 
Successfully modified 3D7 parasites harbouring the (A) I592T, I592I, and (B) S160N mutations in 
pfap2mu were cloned by limiting dilution. The genotypes for at least two clones were confirmed by 
PCR-RFLP mapping and Sanger sequencing. Primers for PCR-RFLP mapping were outside the 5’ 
and 3’ homology arms of the plasmid-based homologous repair template so only the chromosomal 
locus would be amplified (top panel). PCR products from I592T and I592I clones were digested with 
SpeI, and PCR products from S160N clones were digested with SnaBI. The expected restriction 
fragments are annotated. SpeI site is inserted silently in the context of the mutant I592I/T transgenic 
allele, whereas the native SnaBI site is destroyed by the recodonised S160N transgene (top panel). 
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with the silent shield mutations. These parasites were then cloned by limiting 
dilution as described in Section 3.4.4 (Fig 33).  
 AP-2µ(S160N) transfectants from this first construct never recovered after 
drug selection. Despite several repeated transfections, no transgenic parasites have 
been generated using this construct, either with a wild type S160S or mutant S160N 
allele. Parasites that recovered from drug selection carry both plasmids suggesting 
this sgRNA-Cas9 ribonucleoprotein is not efficiently targeting and cleaving the 
desired locus (data not shown).  
In the design of these constructs, I had selected a Cas9 guide RNA sequence 
with emphasis on maximising the proximity of the PAM site to the mutation of 
interest with 200-300 bp homology arms. Re-examining guide sequences annotated 
by Geneious, the originally selected guide near the S160N codon, which was unable 
to efficiently direct Cas9 to the locus, had a Doench-Root predicted activity score 
(DRA) of 0.11 (11%), whereas the I592T guide that successfully generated 
transgenic parasites had a DRA score of 0.57 (57%). Given the low predicted 
activity of this S160N guide, a different guide further downstream from the S160 
locus with a 0.53 DRA score was selected, and a new homologous repair template to 
integrate this S160N mutation was designed.  
Because this new PAM site was 500 bp downstream of the S160 locus, the 
coding sequence between the PAM site and S160 codon was silently recodonised 
using the next-most-frequently-used P. falciparum codon for each amino acid271. 
Without this recodonisation, homology-driven repair could occur immediately 
around the chromosomal break without integrating the S160N mutation.  
 To also establish the technique in our laboratory and improve transfection 
efficiency, this construct was transfected along with the Cas9 expression construct 
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into 3D7 schizonts using the Nucleofection protocol described in Section 3.4.3.3. 
Parasites were then selected as above, and parasites recovered after 24 days. PCR-
RFLP mapping confirmed these parasites contained the S160N transgene. These 
parasites were also cloned by limiting dilution.  
   
4.4 In vitro characterisation of drug sensitivity profiles of transgenic P. 
falciparum lines bearing µ2 mutations 
 
 Once independent clones for both the 3D7-µ2(I592T) and 3D7-µ2(S160N) 
lines had been established, their drug sensitivity profiles were characterised using 
48h exposures to frontline antimalarials and the ring-stage survival assay, as 
described in Section 3.4.5.  
 When compared to the parental 3D7 parasite line, 3D7-µ2(S160N) displayed 
no differences in sensitivity to chloroquine, quinine, dihydroartemisinin, 
lumefantrine, piperaquine, or mefloquine in the standard 48h exposure assay format.  
 
Table 6 Nanomolar sensitivity of parasites harbouring pfap2mu mutations to frontline 
chemotherapies 
 
 
 
 
 
 
 
The nanomolar (nM) sensitivity of parasites harbouring the I592T, I592I, and S160N pfap2mu 
variants as well as the parental 3D7 parasite was characterised to chloroquine, quinine, 
dihydroartemisinin, lumefantrine, piperaquine, and mefloquine using standard 48-hour exposures 
beginning in the ring stage. Parasite proliferation was quantitated with SYBR Green DNA stain. 
EC50’s were determined using Prism v7.0 and the variable four parameter non-linear regression 
analysis. Significance was calculated using a one-way ANOVA with respect to the 3D7 parent. * 
indicates p < 0.05. Two clones (cl. 1; cl. 2) were analysed for each transgenic line. Mean of at least 
four experiments each performed in technical duplicate with standard error shown. 
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Figure 34 Sensitivity of parasites harbouring pfap2mu mutations to frontline chemotherapies 
Graphical representation of the EC50 data presented in Table 5. Displays sensitivity of transgenic 
parasites harbouring mutations in pfap2mu to 48-hour exposures to chloroquine, quinine, 
dihydroartemisinin, lumefantrine, piperaquine, and mefloquine beginning in the ring stage. Parasite 
proliferation was quantitated using the SYBR Green DNA dye as described in Section 3.4.5.1. Mean 
of at least four experiments each in technical duplicate with standard error shown. 
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This was surprising given the results of our laboratory’s previous transgenic 
work with this mutation showing significant but small increases in 
dihydroartemisinin and quinine EC50 in the same assay. The transgenic pfap2mu 
genotype was re-examined by PCR-RFLP mapping and Sanger Sequencing to rule 
out the possibility of a mistake in the original genotyping; however, these parasites 
did harbour the S160N mutation, as expected. These parasites were also fully 
sensitive to a 4-hour pulse of 700 nM dihydroartemisinin in the RSA0-3h
4h format 
validated by Yang et al213. Henriques et al reported that Dd2-AP2mu(S160N)attB was 
also fully susceptible to artemisinin in a 6-hour pulse format206.  
 However, the sensitivity profile of the transgenic line bearing the orthologous 
P. chabaudi mutation, 3D7-µ2(I592T), displayed significant differences in 
sensitivity to multiple drugs. In the 48h assay format, the I592T variant displayed 
significantly increased sensitivity to chloroquine (clone 1: 8.7  0.9 nM, clone 2: 7.4 
 0.3 nM; 3D7: 13.7  0.3 nM) and lumefantrine (clone 1: 20.9  2.1 nM, clone 2: 
21.8  1.0 nM; 3D7: 30.0  4.0 nM). There were no differences in sensitivity to 
quinine, dihydroartemisinin, piperaquine, or mefloquine. 
 As described in Section 1.6, this classic 48h drug exposure assay is 
inappropriate for assessing the sensitivity of parasite strains to dihydroartemisinin. 
This assay works well for drugs with long half-lives, but in the blood, DHA has a 
half-life of approximately 30 minutes. Therefore, continuously exposing parasites to 
artemisinin for 48 hours in a culture plate is not representative of the in vivo 
pharmacokinetics of DHA. In clinical infections, reduced susceptibility to 
artemisinins is known to occur exclusively in the ring stage of parasite development. 
In 2013, Witkowski et al combined these observations and designed the ring-stage 
survival assay (RSA0-3h
4h, Section 1.6) to examine parasite susceptibility to a 
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physiologically-relevant concentration of and exposure to DHA212. Using this assay, 
Witkowski et al differentiated fast-clearing (ART-sensitive) from slow-clearing 
(ART-resistant) parasites in ex vivo cell culture, parasites that previously seemed 
equally sensitive to artemisinin in the classic 48h exposure assay format212. The RSA 
has since become the world standard for assessing and comparing artemisinin 
sensitivity.  
When studied in the RSA0-3h
4h, the I592T parasites displayed a significant 
survival phenotype, similar to what has been reported for parasites harbouring the 
pfk13 mutations causing artemisinin resistance in Southeast Asia. These parasites 
displayed approximately 10% ring-stage survival to a 700 nM pulse of DHA. 
Ghorbal et al reported that, on the 3D7 background, the K13(C580Y) mutation 
causes a 13.5% survival in the RSA0-3h
6h assay format263. To directly compare the 
survival of the I592T clones with parasites bearing K13 mutations, I repeated the 
RSA0-3h
4h experiment with the Cam3.II-series parasites generated by the laboratory 
of David Fidock in parallel with the I592T clones.  
The Cam3.II series consists of three parasites. The original parasite 
Cam3.IIR539T is a culture-adapted clinical isolate from a patient with artemisinin-
resistant parasites of Cambodian origin. This parasite was edited using Zinc Finger 
Nucleases to generate Cam3.IIREV, which has a wild type copy of pfk13, and is 
artemisinin-sensitive262. Cam3.IIREV was then edited to install the C580Y mutation 
into pfk13, creating Cam3.IIC580Y.  
 In the RSA0-3h
4h format, the C580Y and R539T mutants displayed a 17.3% 
and 28.0% ring-stage survival phenotype; in parallel, the 3D7-µ2(I592T) parasites  
displayed an approximately 10% survival phenotype (cl 1: 11.2%; cl2: 9.3%). 
Cam3.IIREV and 3D7 displayed an approximately 2% and 1% ring-stage survival,  
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Figure 35 Sensitivity of parasites harbouring pfap2mu mutations to artemisinin in a modified 
RSA 
Sensitivity of pfap2mu mutant parasites to a 700 nM pulse of dihydroartemisinin in a modified 4-hour 
pulsed exposure RSA. Parasites expressing µ2(I592T) have a significantly elevated ring-stage 
survival (cl. 1: 11.2%; cl. 2: 9.3%) with respect to parasites expressing µ2(I592I) and the parental 
3D7 line (< 3% survival). Clones of µ2(S160N)-expressing parasites are equally sensitive to the 
parental 3D7 line. For reference, the artemisinin-resistant Cam3.II expressing K13R539T and 
Cam3.IIREV parasites are also included. 100,000 gate-stopping events were counted in each FACS 
experiment. RSA survival estimates are the mean of at least 3 experiments in each performed in 
technical duplicate, and each technical replicate was counted twice. Standard error is shown. Survival 
is defined as the ratio of SYBR-positive, MitoTracker-positive events in the DHA-treated to solvent-
treated samples. Hashed line indicates the cut off for statistical significance for multiple comparisons 
with 3D7. 
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respectively, which are well below the threshold for statistical significance (Fig 35). 
Because these data suggested the I592T mutation could cause a significant 
artemisinin-resistant phenotype similar to the validated k13 mutations affecting 
Southeast Asia, I generated an additional parasite line bearing the wild type I592I 
allele with the silent shield mutations at the PAM site to ensure the changes observed 
were strictly due to the mutation at position 592.  
 The pL6-AP2µ(I592T)-sgDNA was efficiently modified with site directed 
mutagenesis and transfected into the 3D7 background using a ring-stage transfection. 
After 4 weeks, successfully integrated parasites recovered from drug selection. 
These independent clones were isolated by limiting dilution and genotyped with 
PCR-RFLP mapping and Sanger Sequencing. Two independent clones of this 3D7- 
AP2µ(I592I) parasite line displayed no significant differences in sensitivity to any of 
the chemotherapies examined in either the 48h exposure or RSA0-3h
4h assay formats 
as compared to 3D7, supporting that the artemisinin-resistance phenotype and 
potentiation of chloroquine and lumefantrine observed is solely due to the I592T 
mutation in µ2. 
 
 
4.5 Generation of P. falciparum strains bearing Ubp1 mutations using 
CRISPR-Cas9 editing  
 
To validate the role of Ubp1 in the context of drug resistance, constructs 
were created to install the two mutations identified in the P. chabaudi rodent study 
encoding PfUbp1(V3275F) and PfUbp1(V3306F) using the pL6 system (Fig 36).  
Based on the insights from generating parasites harbouring pfap2mu mutations, 
constructs were similarly designed to target pfubp1. A PAM site was selected to 
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balance proximity to the mutation site and DRA score. The region between the cut 
site and the PAM was recodonised to include each mutation of interest. 
Inadvertently, an incorrect primer was ordered which included V3306I rather than 
V3306F, which was not realised until after the transgenic parasites were created and 
sequenced. Therefore, three mutations were designed: V3275F, V3306F, and 
V3306I.  
These constructs were transfected with pUF1-Cas9 into 3D7 using 
Nucleofection and selected as above. Parasites harbouring the Ubp1(V3306F) 
mutation are currently being generated. Successfully integrated parasites expressing 
Ubp1(V3306I) and Ubp1(V3275F) were obtained after three weeks. These parasites 
were then cloned by limiting dilution, and two clones of each construct were stored 
for further characterisation.  
 
 
 
 
 
 
 
 
 
Figure 36 Schematic for the manipulation of pfubp1 by CRISPR-Cas9 editing 
Two constructs were designed based on the pL6 system to integrate the orthologues of the P. 
chabaudi ubp1 mutations. In P. falciparum, these encode Ubp1(V3275F) and Ubp1(V3306F). An 
approximately 450 bp 5’ homology region (LHR) and 250 bp 3’ homology region (RHR) were 
designed to repair a Cas9-induced double strand break near the V3275 locus, immediately upstream 
of the 2nd intron.  
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Figure 37 PCR-RFLP mapping of transgenic parasites bearing pfubp1 mutations 
Successfully modified 3D7 parasites harbouring the (A) V3306I and (B) V3275F mutations in pfubp1 
were cloned by limiting dilution. The genotypes for at least two clones were confirmed by PCR-RFLP 
mapping and Sanger sequencing. Primers for PCR-RFLP mapping were outside the 5’ and 3’ 
homology arms of the plasmid-based homologous repair template so only the chromosomal locus 
would be amplified. PCR products from V3306I and V3275F clones were digested with HindIII (top 
panel). Both transgenic mutant clones harbour a silent HindIII site (top panel). The expected 
restriction fragments are annotated.   
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4.6 In vitro characterisation of drug sensitivity profiles of transgenic P. 
falciparum lines bearing Ubp1 mutations 
 
 Two clones each of the Ubp1(V3306I) and Ubp1(V3275F) transgenic lines 
were characterised for their sensitivity to 48-hour exposures to standard antimalarial 
drugs and the ring-stage survival assay as performed for the µ2 mutants described 
above (Table 6).  
 When compared to the parental 3D7 clone, clones harbouring the 
Ubp1(V3306I) variant were slightly less susceptible to chloroquine (clone 1: 17.3  
0.5 nM; clone 2: 16.2  0.8 nM; 3D7: 11.8  2.0 nM), quinine (clone 1: 53.3  2.5 
nM; clone 2: 47.5  2.8 nM; 3D7: 34.7  2.3 nM), and mefloquine (clone 1: 42.3  
1.6 nM; clone 2: 36.9  4.4 nM; 3D7: 31.5  2.4 nM). However, these 
Ubp1(V3306I) clones were equally susceptible to piperaquine and  
 
 
Table 7 Nanomolar sensitivity of parasites harbouring pfubp1 mutations to frontline 
chemotherapies 
 
The nanomolar (nM) sensitivity of parasites harbouring the V3275F and V3306I pfubp1 variants as 
well as the parental 3D7 parasite was characterised to chloroquine, quinine, dihydroartemisinin, 
piperaquine, and mefloquine using standard 48-hour exposures beginning in the ring stage. Parasite 
proliferation was quantitated with SYBR Green DNA stain. EC50’s were determined using Prism v7.0 
and the variable four parameter non-linear regression analysis. Significance was calculated using a 
one-way ANOVA with respect to the 3D7 parent. * indicates p < 0.05. Two clones were analysed for 
each transgenic line. Mean of at least three experiments in each performed in technical duplicate with 
standard error shown. 
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dihydroartemisinin. When examined in the ring-stage survival assay, the two 
Ubp1(V3306I)-expressing clones were as sensitive as 3D7 to a 700 nM pulse of 
DHA in the early ring stage (clone 1: 4.2% survival, clone 2: 3.7% survival). 
Lumefantrine sensitivity is not reported in this section because EC50’s could not be 
reproducibly determined. In our laboratory’s hands, lumefantrine stocks are highly 
variable, in part because the compound has very poor solubility in aqueous media. 
Future work will need to characterise the sensitivity of these lines to lumefantrine. 
 The sensitivity of two clones of the 3D7-Ubp1(V3275F) parasites to these 
antimalarials was also characterised. These clones were moderately more sensitive to 
mefloquine than the 3D7 parental strain (clone 1: 16.9  1.5 nM; clone 2: 19.7  1.9 
nM; 3D7: 31.5  2.4 nM) and similarly sensitive to chloroquine, quinine, 
dihydroartemisinin, and piperaquine.  
 In this thesis, all RSA survival estimates determined by FACS are validated 
by microscopy during the first biological replicate. When the Ubp1(V3275F) clones 
were examined by FACS after the RSA0-4h experiment described in Section 4.4, they 
displayed a 6.7% and 7.1% ring stage survival, respectively (Fig 39A). However, by 
microscopy 72 hours after the DHA pulse, the parasitaemia of the DHA-treated 
cultures was higher than that determined by FACS with a substantial proportion of 
cells looking 8-12 development hours younger (Fig39B). MitoTracker Deep Red 
does not stain ring-stage parasites well because their mitochondria are so small (Fig 
39B). Small populations of ring-stage parasites straddle the gate separating live and 
pyknotic parasites (SYBR-positive/MitoTracker-negative events). Therefore, to 
reconcile this difference in parasitaemia count, the reversible PKG inhibitor 
Compound 2, which blocks egress, was applied to DMSO- and DHA-treated 
cultures, and parasitaemia was re-examined by FACS the next day (96 HPI)272.  
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Figure 38 Sensitivity of parasites harbouring pfubp1 mutations to frontline chemotherapies 
Graphical representation of the EC50 data presented in Table 6. Displays sensitivity of transgenic 
parasites harbouring mutations in pfubp1 to 48-hour exposures to chloroquine, quinine, 
dihydroartemisinin, piperaquine, and mefloquine beginning in the ring stage. Parasite proliferation 
was quantitated using the SYBR Green DNA dye as described in Section 3.4.5.1. Mean of three 
experiments in technical duplicate with standard error shown. 
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Figure 39 Sensitivity of parasites harbouring pfubp1 mutations to artemisinin in the RSA 
 Sensitivity of pfubp1-mutant parasites to a 700 nM pulse of dihydroartemisinin in a modified 4-hour 
pulsed exposure RSA. Clones of Ubp1(V3306I)-expressing parasites are equally sensitive to the 
parental 3D7 line. B Giemsa staining of cells 48 and 72 hours after the DHA pulse reveals a 
developmental delay induced by DHA exposure (red boxes and arrows) in a subpopulation of cells.  
C Parasites expressing Ubp1(V3275F) have a significantly elevated ring-stage survival (cl. 1: 11.9%; 
cl. 2: 16.1%) with respect to parental 3D7 parasites when observed 96 hours post-invasion. 100,000 
gate-stopping events were counted in each FACS experiment. RSA survival estimates are the mean of 
at least 3 experiments in each performed in technical duplicate, and each technical replicate was 
counted twice. Standard error is shown. Survival is defined as the ratio of SYBR-positive, 
MitoTracker-positive events in the DHA-treated to solvent-treated samples.  
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Without compound 2, some of these parasites would undergo egress and invasion 
over the additional 24-hour incubation, which would artificially increase the 
recounted parasitaemia. When examined at 96 hours post-invasion by FACS, the 
Ubp1(V3275F) clones displayed a 11.9% and 14.8% ring-stage survival, 
respectively (Fig 39C). The parasitaemia of DMSO-treated cells as determined by 
FACS did not significantly change between the two time points. All parasite lines 
examined in the RSA are tightly synchronised before the DHA pulse, therefore this 
phenomenon is indicative of a DHA-induced developmental delay in a sub-
population of DHA-treated cells. When observed by Giemsa stain, there is an 
approximately 8-12 hour difference between these two populations of cells. 
Interestingly, the K13R539T parasites display a similar developmental split (data not 
shown).   
  
4.7 Discussion 
 The data presented in this chapter are the first evidence that SNPs in genes 
other than pfkelch13 can reduce parasite susceptibility to artemisinin. Specifically, 
mutations in pfap2mu and pfubp1, first identified in two evolved artemisinin-
resistant Plasmodium chabaudi clones, confer similar, though less intense, ring-stage 
survival phenotypes as compared to pfkelch13-mutant parasites. Data from a recent 
genome-wide knockout study in P. falciparum suggests both proteins are required 
for asexual replication, though their cellular roles have not yet been resolved273.  
Without functional or structural data, anticipating the impacts of the 
resistance-causing mutations described above is difficult. However, homology 
modeling of PfAP2 based on available structures of the mammalian AP2m1 
(pfap2mu sequence homologue), presented in Appendix I, reveals that the I592T 
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mutation in PfAP2 may disrupt van der Waals interactions between layered beta 
sheets in the core 2 fold. Destabilised µ2 and its role in artemisinin resistance is 
explored in Chapter 6. The same modeling predicts that the S160 residue is located 
on an unstructured loop that does not make contacts with the other AP2 complex 
subunits. There is no evidence that S160 is phosphorylated in P. falciparum. 
Therefore, it may be less surprising that the S160N mutation does not modulate 
parasite susceptibility to frontline chemotherapies. 
Additionally, homology modeling of PfUbp1 based on mammalian USP7 
(pfubp1 sequence homologue) reveals similar insights into potential functional 
consequences of the mutations studied in this Chapter. Specifically, V3275 is 
predicted to reside near the catalytic triad, three spatially grouped residues essential 
for DUB catalysis, whereas V3306 is predicted to reside in the ubiquitin binding 
pocket. The spatial accommodation of V3275F may alter the catalytic activity of the 
DUB domain by disrupting the orientation of the catalytic triad. Though there may 
be redundancy in the DUB network in the cell, Ubp1 is believed to be essential, and 
therefore it is surprising that parasites expressing Ubp1(V3275F) grow normally 
(data not shown). Experiments validating the ability of native Ubp1 to interact with 
ubiquitin are presented in Chapter 7, but a future biochemical characterisation of 
Ubp1’s DUB domain and its essentiality in the cell will be instructive.  
Unlike V3275 and the catalytic domain, many residues interact with ubiquitin 
in the binding pocket, which may offset steric consequences of mutation at V3306. 
This may explain why the V3306I mutation has no apparent phenotypic 
consequence. I have recently generated parasites expressing Ubp1(V3306F) and am 
currently characterising their drug sensitivity profile.  
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 Importantly, none of the mutations identified in the P. chabaudi study and 
linked here with artemisinin susceptibility have been identified in patient isolates, 
and the pfap2mu(S160N) variant detected in these clinical samples does not seem to 
have significant impacts on antimalarial sensitivity in the drug-sensitive 3D7 
background. Although the field data presented here suggest the S160N mutation is 
more prevalent after ACT treatment and in patients who fail ACT treatment, a larger 
sample set is necessary to have the statistical power to test these associations. 
Additionally, recent unpublished surveillance data show the S160N mutation arose 
in southwest Kenya before ACTs were introduced in the 1990s, supporting a 
different role for this mutation than in determining parasite susceptibility to ACTs. 
Further transgenic work may be required to examine the consequences of the S160N 
variant as well as variants of pfubp1 near codon 1528 detected in this thesis in other 
representative parasite backgrounds, particularly recently culture-adapted clinical 
isolates. This work has been started and a protocol for transfecting these isolates is 
established in Appendix II.  
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Chapter 5 
Functional characterisation of role of AP-2 adaptor complex and µ-
subunit in Plasmodium falciparum 
 
 
 
 
5.1 Generation of transgenic P. falciparum parasites expressing 
epitope-tagged µ2  
 
 Understanding the underlying biology of µ2 and the AP-2 complex has 
increased importance given the data presented above showing that a mutation in the 
µ subunit of AP-2 complex can modulate parasite susceptibility to artemisinin. 
Therefore, to probe the biology of this factor, the construct used to install the 
µ2(I592T) mutation into 3D7 background parasites was modified to instead install a 
triple hemagglutinin (3xHA) epitope tag onto the C-terminus of the protein with a 
short, flexible linker to expose the tag beyond the globular domain of µ2 (Fig 40A). 
The PAM site used for the I592T mutation is in close proximity to the 3’ end of the 
coding sequence and therefore was suitable for integrating this modification. 
Additionally, it is reasonable to assume this guide and homology arm combination 
targets and modifies the desired locus well because no wild type parasites could be 
detected in the bulk I592T transgenic culture by PCR-RFLP mapping (not shown).  
 In addition to the epitope tag at the 3’ end of the CDS, the inducible glmS 
ribozyme was installed into the 3’ UTR immediately after the stop codon. The glmS 
ribozyme was first identified in the glmS gene in Bacillus subtilis in 2004 by 
Winkler et al and was first used in Plasmodium falciparum by Prommana et al in 
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2013274,275. The ribozyme is an inducible element that, upon binding glucosamine 
(GlcN), rapidly forms a hairpin structure that self-cleaves. Thus, transcribed mRNA 
with the ribozyme in this configuration will have the 3’ UTR removed prior to 
translation. mRNAs which lack a 3’ UTR are degraded. The ribozyme is not 
activated in the absence of GlcN and seems to be well tolerated by the parasite, and 
the degree of activation can be controlled by the amount of GlcN added to the 
culture medium, yielding a titratable, inducible mRNA-level protein knockdown275. 
The magnitude of the knockdown seems to vary based on the protein targeted but 
generally seems to be greater than 50%.  
    As stated, the pL6-AP2µ(I592T)-sgDNA construct was modified to include 
the 3xHA-glmS elements and was transfected with pUF1-Cas9 into 3D7 using the 
spontaneous DNA uptake method and selected for a week using daily changes of 2.5 
nM WR99210 and 1.5 µM DSM-1. After 19 days, parasites were detected by 
Giemsa smear. These transgenic parasites were then cloned by limiting dilution 
(Section 3.4.4). The genotypes of two of these clones were verified by PCR 
screening and Sanger Sequencing (Fig 40B). Additionally, anti-HA western blot 
confirmed the presence of the tagged fusion protein (Fig 40B). Two clones were 
selected randomly for further characterisation. The localisation of µ2 was equivalent 
in both clones, and therefore the data presented hereinafter corresponds to clone 1.  
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Figure 40 Schematic for tagging of pfap2mu with the HA epitope and glmS ribozyme 
A Because the I592 locus is proximal to the stop codon, the pL6 construct used to introduce the I592T 
mutation was modified to introduce a triple hemagglutinin (HA) epitope tag into the CDS and the 
glmS ribozyme into the 3’ UTR immediately after the stop codon. The homology regions were the 
same as used for the I592T manipulation. The glmS ribozyme sequence was ordered as a synthetic 
gBlock from IDT. B The genotypes of two clones was confirmed by PCR screening using primers P1 
and P2 which are depicted in panel A (expected µ2-3xHA-glmS: 862 bp, WT 3D7: 568 bp). Anti-HA 
(rat, Sigma 3F10 clone, 1:5000) western blot was performed on saponin-lysed parasites from mixed 
stage cultures of clone 1 and wild type parasites to confirm the expression of the tagged fusion 
protein. 
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5.2 Examination of localisation of µ2 
 
 Given there is partial sequence homology of P. falciparum µ2 and human 
AP2m1, which mediates endocytosis, and endocytosis, at least of haemoglobin, is 
essential for intraerythrocytic parasite development (Section 1.7), I speculated that 
µ2 would be localised to the parasite periphery in the blood stage form. However, 
when examined by indirect immunofluorescence, I found the localisation of µ2 
different from what has been observed for µ2 immunostaining in nearly all other 
organisms (Fig 41)233,276–281. First examining asynchronous cultures, rather than at 
the periphery, µ2 is localised to a cytoplasmic focus in ring stages that multiplies 
during development to provide µ2-labelled compartments or structures to each 
daughter merozoite. To further probe this stage-specific localisation, parasites were 
tightly synchronised, and slides were prepared for immunofluorescence at 6-hour 
windows throughout the asexual lifecycle. These studies showed that µ2 stains a 
focus throughout the ring and trophozoite stages before multiplying and segregating 
late in development during schizogony (Fig 41). In ring stage parasites, µ2 also 
faintly stains a perinuclear ring, (Fig 41, first panel). Interestingly, in developing 
trophozoites, the µ2-defined foci seem to label a conspicuous compartment proximal 
to the digestive vacuole (Fig 41, fourth and fifth panels). In merozoites, µ2 seems 
apically oriented, between the nucleus and apical complex (Fig 41, last panel). These 
data show that µ2 is most abundant in schizonts, which is consistent with  
 
Figure 41 Localisation of µ2 during asexual development 
The localisation of µ2-3xHA was characterised by indirect immunofluorescence using anti-HA (rat, 
Sigma 3F10 clone; 1:150) and anti-rat-488 (Invitrogen; 1:150). Transgenic 3D7-µ2-3xHA parasites 
were tightly synchronised to a 2 hour post-invasion window of synchrony. Thin smears were prepared 
every 6 hours, fixed, and stained as described in Section 3.3.7. Images were acquired on a Nikon TI-
3000 inverted microscope, and post-acquisition background subtraction and deconvolution was 
performed using the Nikon Elements AR Analysis software package. Representative single cell 
windows were cropped to 200x200 pixels. Figure on next page.  
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transcriptomic data showing the expression of pfap2mu increasing during 
schizogony, and µ2 is carried into the nascent ring via the merozoites. It is important 
for the interpretation of these data to note that these components of vesicular traffic 
only assemble and are visible at “membranes of origin”, wherever the vesicle 
departs. In other eukaryotes, AP-2 and clathrin and their associated chaperone 
factors mediate cargo recognition, coat assembly, and membrane invagination and 
scission processes, before loading the vesicle onto the acto-myosin highway224. Just 
before the vesicle begins to move, these factors all disassemble282. Therefore, when 
observing trafficking components in live or fixed cells, one will never observe these 
trafficking initiation factors at the vesicle destination. In Plasmodium falciparum, µ2 
clearly stains an intracellular compartment rather than the plasma membrane, 
suggesting a different cellular role for AP-2 in P. falciparum than what is understood 
to occur in all other taxa.  
Additionally, though the localisation of the mutant µ2(I592T) was not 
examined in this study, the localisation of µ2 did not appreciably change after a ring-
stage pulse with 700 nM or 5 nM DHA when examined either immediately after the 
pulse or 24 hours later (not shown).  
 
 
5.3 Localisation of µ2 with markers of subcellular organelles 
 
 
 To better understand where µ2 is localised in the cell, correlation studies 
were undertaken. Specifically, I looked at markers of the endoplasmic reticulum, cis-
Golgi apparatus, apicoplast, mitochondria, rhoptries, and microneme due to the 
perinuclear localisation of µ2 in ring stages, and punctate, near-DV localisation 
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throughout trophozoite development, and apical orientation in schizonts (Fig 42, 43). 
Pearson’s Correlation Coefficients for co-stained images of ring and schizont stages 
are presented in Figure 45.  
The µ2 structure with faint perinuclear extension in ring stages described in 
the previous section locates adjacent to and partly overlapping with both ERD2, a 
marker of the cis-Golgi and BiP, a luminal HSP70 ER-stress chaperone (Fig 42, top 
left panel), though these species do not colocalise. In trophozoites, µ2 staining again 
partially overlaps with ER staining, though there are many BiP-labelled structures 
not labelled with µ2 (Fig 42, first row, bottom left panel).  
Given the near-DV staining, I speculated that the punctate structures were the 
apicoplast or mitochondria. The apicoplast is located near the DV in a conspicuous 
cytoplasmic focus, segregates into merozoites late in development, and is 
Apicomplexan-specific, which could explain the seemingly diverged localisation of 
Pfµ2. On the surface, an apicoplast or mitochondrial localisation would seem 
inconsistent with trafficking biology since the adaptins do not travel with the vesicle 
to the cargo destination, and these compartments are not known to export cargo 
molecules, though the biology of these organelles are still under investigation. In 
some images of parasites stained with antibodies against ACP, µ2 did overlap with 
some ACP-labelled apicoplast structures. However, this staining was poorly 
reproducible, and µ2 was clearly distinct from staining with an antibody against the 
apicoplast-localised AAA-type ATPase CDC48, which is involved in protein import 
into the apicoplast. (Fig 44, top panels), as well as MitoTracker staining, which 
highlights the mitochondrial lumen.  
 In schizonts, immunostaining against structures other than the apical complex 
organelles is particularly difficult because of the small size of the individual  
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Figure 42 Localisation of µ2 with clathrin and factors of the early secretory pathway 
Thin smears of parasites expressing µ2-3xHA were made in ring, trophozoite, and schizont stages, 
and the localisation of µ2 was examined with respect to the ER (anti-BiP), cis-Golgi (anti-ERD2), and 
clathrin heavy chain (anti-CHC) by indirect immunofluorescence.  
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Figure 43 Examination of localisation of µ2 and several RabGTPases  
The localisation of µ2 with respect to several RabGTPase family members was examined by indirect 
immunofluorescence in trophozoites and schizonts. Rab5A, Rab5B, Rab7, and Rab11A were 
examined. Rab5A may be involved in haemoglobin uptake; Rab5B is implicated in targeting vesicles 
to the food vacuole and plasma membrane, Rab7 to post-Golgi endosomes, and Rab11A to the IMC. 
All anti-Rab antibodies were used at 1:150 dilution and were provided courtesy of Prof Gordon 
Langsley. (Figure on previous page) 
 
merozoite, the number of merozoites in the segregating schizont, and the limits of 
this light microscopy resolution. The ER, cis-Golgi, apicoplast, and mitochondria all 
segregate into merozoites late in schizogony, but the staining of these structures does 
not correlate with µ2 staining (Figs 42,44, 45).  
 Given that the observed localisation pattern for µ2 does not correspond to 
any common macrostructures in the cell, correlation with known trafficking 
molecules was probed. Specifically, Rab GTPases are key effectors of vesicular 
traffic and are found on the cytoplasmic surfaces of vesicles and organelles283. Rab-
specific tethers found on target membrane surfaces interact with these Rab GTPases, 
which mediate vesicular docking in their GTP-bound state283. In Plasmodium, Rabs 
are less well characterised, but they are still known to mediate specific compartment-
to-compartment traffic and can thus provide insight into the trafficking routes in 
which AP-2 may participate in the cell.  
 In P. falciparum, there are 11 Rab family membranes annotated in the 
genome284. Several publications have provided insight into how individual Rabs 
function, however broadly these molecules lack extensive characterisations. Using 
published antibody reagents, localisation of µ2 with respect to Rab5A, Rab5B, Rab7, 
and Rab11A was probed. Rab5C was also probed, but the antibody stained nearly the 
entire cell in my hands. Though distinct Rab-specific spots were observed and an 
image most representative of the punctate localisation is shown in Figure 43, many 
images taken with these Rab antibodies contained high background fluorescence in 
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the cell that artificially inflated the Pearson’s correlation coefficient, therefore this 
PCC value was not calculated for these costained cells. Any correlation between µ2 
and Rab-specific spots is discussed qualitatively here, and further work is necessary 
to improve the resolution of this analysis.  
Of all Rabs examined, punctate spots of maximum Rab5B and Rab11A 
intensity were localised very near those for µ2, particularly in trophozoites and 
schizonts (Fig 43). In other organisms, the Rab5 family are markers of the early 
endosome, the target of AP-2 mediated endocytosis285. One study in P. falciparum 
localised Rab5A by EM to vesicular structures consistent in size with small 
haemoglobin-containing vesicles and showed an overexpressed constitutively-active 
mutant form of Rab5A disrupted haemoglobin uptake and digestive vacuole 
integrity191. The cellular role of Rab5B is less clear with one study showing it is 
involved in traffic to the digestive vacuole and another suggesting it may be involved 
in targeting proteins to the parasite periphery and food vacuole via the secretory 
pathway286,287. Rab7 seems to be involved in cargo sorting at the trans-Golgi and 
mediates vesicular traffic to cytosolic endosomes288. Rab11A has been implicated in 
the biogenesis of the IMC and therefore has a potential role in late secretory 
traffic289. That µ2 may be spatially nearby both Rab5B and Rab11A suggests a 
potential role for the AP-2 complex in targeting towards the cell periphery.  
Interestingly, a recent study showed that AP-2 in human neuronal cells is also 
capable of mediating retrograde traffic from the endosomal system back towards the 
plasma membrane, which may be more consistent with these observations than a 
canonical endocytic role for AP-2290. 
Surprisingly, µ2 staining does not correlate with structures labelled with an 
antibody against P. falciparum clathrin heavy chain (Fig 42,45). AP-2 is one of  
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Figure 44 Localisation of µ2 with respect to subcellular markers and lipids 
Localisation of µ2-3xHA with respect to various subcellular lipid-rich compartments was examined 
using indirect immunofluorescence (CDC48, Nile Red, LipidTOX-488) and live-cell imaging 
(MitoTracker). CDC48 (top panel) and MitoTracker (second panel) stain the apicoplast and 
mitochondria respectively. Though µ2 is in close apposition to the apicoplast, no correlation was 
observed. Nile Red and LipidTOX are lipid stains. Nile Red emits red light when interacting with 
polar lipids; LipidTOX stains neutral lipid deposits. µ2 correlates partially with Nile Red and not with 
LipidTOX, suggesting an association with membranes comprised of polar lipids. All antibodies used 
are described in Table 3. 
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Understanding that no two molecules can spatially colocalise, the correlation of fluorescent signal 
between µ2 and various subcellular markers was quantified using the Pearson’s Correlation 
Coefficient (PCC) as described in Section 3.6 in the ring and schizont stages. Colocalisation with 
DAPI is considered a negative control and colocalisation of anti-GFP and anti-K13 signal in a 
parasite expressing a GFP-K13 fusion was considered a positive control. These two thresholds were 
used to characterise ranges of PCC values that are used to define the terms colocalisation, partial 
colocalisation, and no colocalisation in this thesis. The PCC metric of colocalisation is more robust on 
larger than smaller fluorescent objects (i.e. schizonts compared with ring stages). Therefore, the 
threshold for colocalisation and partial colocalisation was decreased by 0.1 units in ring stages to 
accommodate this and capture the positive colocalisation control. Mean PCC and standard error is 
shown of at least 35 cells. K10 and TRiC do not have standard error shown because less than 35 
images were available for analysis.  
 
 
 
 
Figure 45 Analysis of colocalisation of µ2 with subcellular markers 
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the canonical clathrin adaptor complexes in eukaryotes, and they function together in 
nearly all cell types studied. A brief characterisation of clathrin heavy chain is 
provided in Appendix VI. To the best of our knowledge, this is the first description 
of clathrin in the parasite, and as discussed in greater detail in Appendix VI, clathrin 
heavy chain labels punctate structures at the periphery and in cytosol, consistent with 
what has been reported in higher order eukaryotes. 
  Lastly, I examine whether the near-DV structures labelled by µ2 
corresponded to neutral lipid bodies. Two studies have shown these structures are 
involved in haem crystallisation but the details of this process remain under 
investigation291,292. Using two lipid-specific stains, LipidTOX Green and Nile Red, 
neutral lipids were labelled (Fig 44, bottom panels). LipidTOX stains neutral, non-
polar lipids and is known to highlight conspicuous compartments closely apposed to 
the DV. The emission wavelength of Nile Red fluorescence depends on the polarity 
of the lipid environment. In neutral, polar lipids (membrane phospholipids), Nile 
Red is intensely red (emission maximum: 640 nm), whereas in neutral, non-polar 
lipids (storage lipids), Nile Red emission is blue shifted and emits yellow light 
(emission maximum: 590 nm). µ2 signal correlates well with Nile Red when viewed 
under excitation and emission parameters for red fluorescent proteins (excitation: 
590 nm; emission: 620 nm), indicating a presence in phospholipid-rich bodies or 
surfaces, whereas µ2 does not overlap with the DV-apposed, lipid-enclosed sites of 
haemoglobin degradation labelled with LipidTOX Green. The Alexa-488 emission 
spectrum corresponding to µ2 overlaps partially with the yellow light emission by 
Nile Red in neutral, non-polar lipid environments. However, the lack of overlap of 
µ2 (when detected with an Alexa-594-conjugated secondary antibody) and 
LipidTOX-488, which has no spectral overlap with Alexa-594, suggests that 
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Figure 46 Effects of Brefeldin A exposure on µ2 localisation 
The effect of Brefeldin A on µ2 localisation was examined by treating ring stage parasites expressing 
µ2-3xHA with 5 µg/ml BFA for 16 hours. Parasitised red cells were fixed and stained in suspension 
and imaged. Mean and standard error are shown for the Pearson’s Colocalisation Coefficient (PCC) 
for the overlap between the µ2-HA and PMV signal intensities across ten cells. By a t-test of 
independent means, PCC are significantly different (P = 0.005). 
 
the correlation observed with µ2 and Nile Red is indicative of a localisation of µ2 to 
phospholipid-rich membranes, which is also consistent with adaptor protein complex 
biology224. 
 While performing these localisation studies, I examined whether the fungal 
metabolite Brefeldin A effected localisation of µ2. BFA is canonically used to 
investigate trafficking factors and blocks ER-exit traffic by blocking exchange of 
ARF-bound GDP for GTP293. Over time, any protein that is trafficked down the 
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secretory pathway accumulates in or at the ER288,294.  To examine the effects of BFA 
exposure on µ2 localisation, ring stage parasites were treated with 5 µg/ml BFA or 
equivalent methanol solvent for 16 hours. The localisation of µ2 with respect to the 
ER-resident protein plasmepsin V was examined by indirect immunofluorescence. 
These slides revealed significant evidence of relocalisation of µ2 to a perinuclear 
ring from its normal punctate cytoplasmic localisation. In BFA-treated cells, µ2 
staining is perinuclear and correlates well with PMV (BFA: PCC = 0.89 ± 0.02; 
MeOH vehicle: PCC = 0.60 ± 0.07), consistent with a localisation along the 
secretory pathway (Fig 46). However, BFA is cytotoxic and it is unclear whether this 
“relocalisation” is a result of a true secretory location of µ2 or an artefact of the cells 
dying. Neither µ2 nor any other AP-2 component has an ER signal sequence, though 
this relocalisation could occur if µ2 is peripherally associated with membranes. 
Though BFA relocalisation experiments can be difficult to interpret, these results are 
still supportive of a localisation of µ2 near the ER or in the secretory system. 
 
5.4 Examination of µ2 localisation by immuno-electron microscopy 
 
 To provide greater resolution, µ2 localisation was probed by immunoelectron 
microscopy and immunocolocalisation on thin sections with gold-conjugated 
antibodies in collaboration with Dr Rachel Edwards and Prof Audrey Odom John at 
Washington University, St Louis. 
 Because ring stages are so small and difficult to capture on thin sections, 
localisation was examined in trophozoites and schizonts. In trophozoites, 18-nm gold 
particles corresponding to µ2 were consistently observed in the endoplasmic 
reticulum and vesicular structures in the cytosol (Fig 47, 48). In a few images, µ2 
was detected at the plasma membrane; however, this localisation was seen 
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infrequently (<4% of all images, Table 8) and is inconsistent with the fluorescence 
data presented in the previous section. Additionally, µ2 was not detected on 
membranes forming cytostomes or any budding structures from the plasma 
membrane.  
 In Plasmodium parasites, the endoplasmic reticulum extends throughout the 
cytoplasm in long tubular structures. In a given section, it is unclear if vesicle-like 
structures in the cytoplasm are actually detached and free vesicles or if they are 
simply cross-sections of these ER extensions. To examine this, co-staining was 
performed with a commercial antibody against protein disulfide isomerase (PDI), an 
ER-resident folding chaperone (Fig 47), which was detected using a secondary 
antibody conjugated to 12-nm gold particles. While we cannot rule out the 
possibility that some of these structures are free µ2-labeled vesicles, these co-stained  
 
 
 
 
 
 
 
 
 
 
 
Figure 47 Localisation of µ2-3xHA by immunoelectron microscopy 
A representative image of µ2-3xHA by immunoelectron microscopy. Localisation was examined in 
trophozoites. Sections were stained with anti-HA and anti-PDI (protein disulfide isomerase; luminal 
ER marker) to visualise µ2 in relation to the ER. A secondary antibody conjugated to 12 nm gold 
particles was used to label bound anti-PDI antibody, and an 18 nm gold particle-conjugated secondary 
antibody was used to detect anti-HA antibody. Immunoelectron microscopy in Figs 47-49 was 
performed by the Electron Microscopy Core Facility at Washington University, St. Louis, USA in 
conjunction with Dr Rachel Edwards and Prof Audrey Odom-John.  
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Figure 48 Colocalisation of Rab5B and µ2 by immunoelectron microscopy 
Two representative images of µ2-3xHA colocalisation by immunoelectron microscopy with Rab5B. 
Cryo-preserved thin sections were probed with anti-HA and anti-Rab5B. µ2-3xHA (18 nm gold 
particles) localisation is consistent with that reported above, and Rab5B staining (12 nm gold 
particles), though few spots are detected, labels vesicle-like structures in the cytosol. µ2 label 
colocalises with Rab5B in cytosolic vesicles.   
 193 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 49 Localisation of µ2-2xFKBP-GFP by immunoelectron microscopy 
A representative image of µ2-2xFKBP-GFP localisation by immunoelectron microscopy. To 
corroborate the localisation of µ2-3xHA observed by immunoelectron microscopy, the localisation of 
µ2-2xFKBP-GFP in trophozoites was also examined. Cryo-preserved thin sections were probed with 
anti-GFP and anti-PDI. The localisation of µ2-2xFKBP-GFP is consistent with the localisation 
observed for µ2-3xHA by IEM. µ2-2xFKBP-GFP (18 nm gold particles) colocalises with ER 
structures demarcated by anti-PDI staining (12 nm gold particles) and some vesicle-like structures in 
the cytosol.  
 
 
images suggest that the majority of the structures in the cytoplasm are cross-sections 
of tubular ER extensions. Indeed, these vesicle-like structures are consistent with  
vesicular tubular clusters present in higher order eukaryotes, which define ER-to-
Golgi trafficking departure sites295.  
 Additionally, an antibody against Rab5B was used to probe the correlation 
reported in the previous section (Fig 48). These images resolved that a subset of 
cytoplasmic vesicle-like structures may co-label with µ2 and Rab5B. Without a  
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Table 8 Analysis of localisation of m2 by immunoelectron microscopy 
 
The localisation of gold particles detecting anti-HA and anti-GFP antibodies bound to µ2-3xHA or 
µ2-2xFKBP-GFP molecules in fixed thin sections of trophozoites expressing these fusion proteins 
was quantitated. In each section, the location of each spot was assigned to one of the categories listed 
which correspond to structures that were clearly visible and well described in the literature or co-
labelled with an antibody (i.e. anti-PDI for Tubular ER extension/Golgi). Percentages indicate the 
number of images where the indicated structure was labelled for µ2, if it was visible. (i.e. 5.8% of 
images in which the DV was visible had anti-HA/GFP gold label). (All images available were 
analysed. N = 66 for HA-tagged µ2; N = 72 for µ2-GFP) 
 
triple-labelled section, it is still impossible to say if these structures exist still within 
the ER or if they are free vesicles. However, their more circular structure seems 
different from the elongated, tubular structures labelled by PDI in previous images 
(comparing Figs 47 and 48).  
 While these immunoelectron micrographs support that µ2 is located at an ER 
interface and in cytoplasmic vesicles, they contained relatively few spots and 
provided little clarity on the identity of clear, singular punctate structures observed 
by immunofluorescence. The linear triple HA tag was initially selected to label µ2 
because it is spatially small and would be unlikely to disrupt protein function. 
However, because it is so small, the tag may not be well exposed in thin sections, 
depending on the conformation of the C-terminal linker and tag when the cells are 
fixed and sectioned. Therefore, to try to capture more molecules per image, the 
3xHA tag was swapped for a much larger 2xFKBP-GFP tag. Parasites expressing 
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µ2-2xFKBP-GFP were previously created by the laboratory of Prof Tobias 
Spielmann at the Bernhard-Nocht-Institut für Tropenmedizin in Hamburg, Germany 
using the selection-linked integration technique his laboratory recently pioneered. 
Using a polyclonal anti-GFP antibody, µ2 localisation was probed in thin sections of 
trophozoites prepared from this line. As expected, the same localisation pattern was 
broadly observed (Fig 49, Table 8).  
Overall, these localisation experiments do not provide clear evidence of 
exactly where the AP-2 complex is in the cell. By epifluorescence, punctate 
structures labelled by µ2 partially correlate with the ER and known regulators of 
secretory traffic; by immunoelectron microscopy, µ2 clustering seems to consistent 
with vesicular tubular clusters. This localisation does not seem to be an artefact of 
the fixation method because the same punctate structures are observed when cells are 
fixed for immunostaining in acetone/methanol and formaldehyde either in solution 
or on a slide. Additionally, the µ2 localisation pattern visualised by both indirect 
immunofluorescence and immunoelectron microscopy was consistent between two 
different antibodies detecting the 3xHA and 2xFKBP-GFP tagged molecules. 
Overall, these experiments suggest a non-canonical role for µ2 in Plasmodium 
falciparum that warrants further functional characterisation. 
 
5.5 µ2 is required for asexual growth 
 
 
 In other organisms, the adaptor protein complexes are necessary for cell 
survival296,297. Therefore, given the potential divergence in µ2 function from 
canonical pathways discovered in this study, the essentiality of µ2 for asexual  
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Figure 50 Inducible knockdown of pfap2mu with the glmS ribozyme 
A Schematic of the integrated µ2-3xHA-glmS chromosomal locus and mechanism of glmS-mediated 
knockdown. In the presence of 5 mM glucosamine (glcN), the glmS ribozyme self-cleaves; thus, the 
ribozyme removes the 3’ UTR from a newly-transcribed mRNA molecule, targeting it for degradation 
before translation. B Analysis of pfap2mu mRNA knockdown on levels of µ2-3xHA protein after two 
development cycles when growth fully arrests. Schizont-infected red blood cells were saponin lysed, 
and soluble proteins were extracted with RIPA buffer and analysed by SDS-PAGE electrophoresis 
and western blotting (anti-HA; and anti-GAPDH, loading control). C Glucosamine-induced pfap2mu 
knockdown is lethal. The growth of µ2-glmS-expressing parasites, determined by FACS with SYBR-
Green/MitoTracker Deep Red, is significantly disrupted after two cycles in the presence of 5 mM 
glucosamine whereas control parasites are not. Arrow indicates that all cultures were diluted to 1% 
parasitaemia to prevent overgrowth over an additional development cycle. D Analysis of growth in 
(B) by determination of fold replication after each invasion cycle in control and glucosamine-treated 
parasites. E Addition of 200 µM isopentenyl pyrophosphate (IPP) does not rescue glmS-mediated 
pfap2mu knockdown, indicating µ2 is not involved in traffic to the apicoplast.  
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parasite survival was explored using the inducible glmS ribozyme embedded into the 
3’ UTR directly after the stop codon in the 3D7-µ2-3xHA-glmS line (Fig 50A).  
 To initiate the mRNA knockdown, 5 mM glucosamine (GlcN) or solvent 
control vehicle (deionised water) was added to early ring stage parasites in 6-well 
plates. Parasite medium with glucosamine or water control was refreshed daily. 
Glucosamine treatment induced a substantial knockdown of µ2-3xHA levels over 
two asexual cycles (Fig 50B). Parasite proliferation was then assessed by FACS with 
SYBR-Green and MitoTracker Deep Red as described in Section 3.4.5.3.  
After one cycle, a 50% reduction in parasite replication was observed. 
However, after a second cycle in the presence of glucosamine, no further replication 
was observed. This delayed death phenotype was consistent across two independent 
clones. By knocking down pfap2mu mRNA in schizonts, the parasites in the next 
cycle are non-viable (not shown). Interestingly, no obvious, single-stage 
developmental stalling or death phenotype was observed by Giemsa stain during the 
knockdown. In some cases, some parasites seemed to die as late trophozoites, and in 
others, it seemed like some rings failed to develop properly after invasion.  
Though these ribozyme knockdown experiments showed that µ2 is required 
for intraerythrocytic parasite survival, the glmS system only produced a transient 
protein knockdown rather than a complete and irreversible genetic knockout. 
Further, in aqueous solution, the glmS activator, glucosamine, is light sensitive and 
unstable. Though in this study and others, glucosamine was refreshed in the culture  
medium each day and produced a protein-level knockdown, it is not known if 
mRNA levels recover between doses of glucosamine as the molecule degrades. 
Thus, interpreting the consequences of glmS-knockdown of a constitutive factor like 
µ2 is complicated. 
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Figure 51 Inducible knockout of pfap2mu by Cre recombinase 
Schematic for the inducible chromosomal deletion of pfap2mu with Cre recombinase. The pL6 
construct used to integrate the 3xHA-glmS elements into pfap2mu was modified to install a synthetic, 
loxP-containing intron into the pfap2mu CDS near the 5’ end of the gene, 1.5 kbp of recodonised 
CDS, and a 3xHA tag and downstream loxP site into the 3’ UTR immediately after the stop codon. 
Additionally, a DHFR-expressing cassette was also integrated under the control of the hsp86 
promoter. These elements were efficiently integrated into the genome by Cas9 editing. The addition 
of rapamycin will induce the dimerisation of constitutively-expressed split-Cre recombinase, which 
will excise the loxP-flanked region (“floxed”), deleting the majority of the pfap2mu-3xHA CDS. 
Dimerisable-Cre (“DiCre”)-expressing 3D7 parasites were obtained from Prof Michael Blackman. P1 
and P2 indicate the annealing location of PCR primers used to examine the efficiency of the Cre-
mediated knockout. P1 lies upstream of the 5’ homology region encoded on the pL6 knockout 
plasmid construct, and thus should only amplify the transgenic locus from successfully modified 
parasites.  
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The dimerisable Cre recombinase (DiCre) system is an alternative inducible 
approach and can be used to permanently excise regions of a chromosome. Cre 
recombinase binds to loxP recognition sequences and loops out any sequence that is 
flanked with two loxP elements (“floxed”). By splitting the Cre enzyme into two 
halves, each fused to a rapamycin-inducible dimerisation domain, an irreversibly 
dimerised, active Cre recombinase is formed by the addition of rapamycin298,299. 
This system has been used to generate irreversible, inducible genetic 
knockouts of factors of interest in Plasmodium and other organisms300,301. Unlike the 
ribozyme, which reduces expression in each parasite, genetic excision is an all-or-
nothing process. Though some parasites in the population may not excise the floxed 
region, this proportion of cells is expected to be very small, and all other cells will 
display a complete knockout phenotype.  
Given the advantages of this system, a construct was designed to integrate 
loxP elements into the µ2 CDS and 3’ UTR, respectively. Pfap2mu does not have an 
endogenous intron within which to embed the 5’ loxP, therefore, the pfsera2 intron 
with a loxP site was engineered into the CDS266. Even if pfap2mu encoded an intron 
in the 5’ region of the gene, branch points in Plasmodium introns have not been well 
characterised, and inserting the loxP element blindly into any endogenous intron 
could block proper splicing. In 2011, Zhang et al described the consensus splice site 
sequence requirements around Plasmodium introns, and using these guidelines, the 
sera2-loxP “artificial intron” has been introduced into other genes without apparent 
consequence266,302. Using the same Cas9 guide RNA construct used to integrate 
theI592T mutation and 3xHA-glmS element, a homology template encoding a floxed, 
3xHA-tagged CDS and a cassette to drive genomic expression of the human DHFR 
selectable marker was integrated into the endogenous pfap2mu locus (Fig 51).  
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This inducible knockout construct was co-transfected with pUF1-Cas9 into a 
3D7-based P. falciparum parasite line provided by Prof Michael Blackman that 
constitutively expresses a split, FKBP/FRB-tagged Cre recombinase, which 
dimerises and activates in the presence of rapamycin. Parasites were selected with 
WR99210 and DSM-1, and drug resistant parasites were observed in culture after 
two weeks. This line was only recently generated and because wild type, unmodified 
parasites were not detected in culture by PCR, this line was not cloned so a 
characterisation of the consequences of pfap2mu knockout could be provided for this 
thesis. Cloning of this line by limiting dilution is underway. 
 These cells were seeded at 1% parasitaemia and treated with 10 nM 
rapamycin for 1 hour in early ring stages. After 24 hours, >99% of the floxed  
 
 
 
 
 
 
 
 
 
Figure 52 Cre-mediated pfap2mu knockout blocks parasite development 
A Cre-mediated knockout was induced by adding 10 nM rapamycin to an early-ring stage culture for 
1 hour. After 1 hour, rapamycin was extensively washed off. Genomic DNA was extracted from 
excised and unexcised cultures 24 hours after addition of rapamycin. The transgenic locus was 
amplified using primers P1 and P2 (Fig 52), which selectively amplify the transgenic locus. B 
Analysis of growth by FACS with SYBR-Green/MitoTracker Deep Red. Rapamycin-induced 
excision of pfap2mu disrupts parasite growth within 1 development cycle.   
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pfap2mu region had been excised (Fig 52A). Parasite development was monitored by 
Giemsa staining and FACS every 24 hours. Parasite development proceeds normally 
until schizogony, when there is an obvious defect in merozoite formation and 
segmentation (Fig 53, middle panel). Rather than segmenting normally into distinct 
daughter merozoites within the parasitophorous vacuole, pfap2mu- schizonts contain 
merozoites that seem to stay linked as beads on a string (Fig 53, middle panel). 
Additionally, these defective schizonts occupy approximately 50% less volume 
within the erythrocyte compared to wild type schizonts (Fig 53, left panel).  
Even though merozoite formation does not proceed normally, the 
parasitophorous vacuole seems to rupture, and the defective merozoites stay 
connected within the red blood cell, even with an additional 12 hours of incubation 
on an orbital shaker (Fig 53, right panel). By FACS, pfap2mu- parasites do not  
 
 
 
 
 
 
 
 
 
Figure 53 Examination of the effects of pfap2mu knockout by Giemsa staining 
48 hours after the addition of rapamycin, parasites lacking pfap2mu display an abnormal schizont 
phenotype. Solvent-treated parasites (left) are well segmented and occupy the entire volume of the 
infected red cell; some parasites have undergone egress and invasion. Rapamycin-treated parasites 
(middle) have not properly segmented and few parasites have undergone egress and invasion. These 
cells were imaged 12 hours later and still had not segmented properly or egressed (right). pfap2mu- 
merozoites do not fill the red cell volume and seem linked together by an unknown structure. Some 
cells have undergone egress and invasion, though these may not have successfully excised pfap2mu 
or may not have integrated the knockout transgene (this is an uncloned parasite line).   
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proliferate (Fig 52B). When rapamycin is added in the ring stage, even up to 24 
hours post-invasion, parasites mostly do not complete development and proliferate. 
Though some new rings are observed and parasitaemia does gradually recover, this 
is expected because this parasite line was not cloned. Therefore, this residual 
population is likely consists of either unintegrated or unexcised parasites, which 
recrudesce with time following a single treatment with rapamycin.  
 
5.6 Effect of pfap2mu knockout on cell development  
 
 These data show that µ2 is required for parasite development and revealed a 
visible defect in schizont maturation resulting from pfap2mu knockout. To better 
characterise the nature of this developmental requirement, the DNA content of each 
cell and the integrity of several organelles were examined. Synchronous early ring 
stage 3D7-µ2-floxed-HA parasites were treated with 10 nM rapamycin or equivalent 
DMSO for 1 hour and incubated at 37oC. Media was refreshed 24 hours after 
rapamycin treatment. When parasites reached the late trophozoite stage, 10 µM 
Compound 2 (reversible protein kinase G inhibitor; Table 4) was added to prevent 
wild type cells from initiating egress. Cells were closely monitored by Giemsa 
staining until approximately 75% of wild type cells were well segmented; cells were 
kept in this Compound 2 block for less than 2 hours.  
 To examine whether pfap2mu- cells display a defect in nuclear replication, 
100 µl of rap- or DMSO-treated egress-blocked culture was mixed with an equal 
volume of 1:5000 SYBR Green in PBS and analysed by flow cytometry. Overlaid 
histograms plotting the SYBR-Green signal detected across all gate-stopping events 
indicates there is no significant difference in DNA content between WT and KO 
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schizonts, suggesting DNA replication occurs normally, and the defective schizonts 
have the same DNA content as wild type schizonts (Fig 54).   
 Thin smears were also prepared from these DMSO- or rapamycin-treated 
cultures in order to probe the localisation and integrity of key markers of subcellular 
structures by indirect immunofluorescence. Specifically, the localisation of 
plasmepsin V (ER), ERD2 (cis-Golgi), GAP45 (IMC, soluble), GAP50 (IMC, 
transmembrane), MSP1 (plasma membrane), EXP2 (PV), CDC48 (apicoplast), 
AMA1 (micronemes), and RON4 (rhoptries) was examined (Fig 55). Between 
knockout and wild type cells, the ER and cis-Golgi appeared equivalent in 
morphology and distribution. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 54 Comparison of DNA content in pfap2mu KO and WT parasites 
Compound 2-blocked pfap2mu knockout (red traces) and wild type (blue traces) schizonts were 
stained with SYBR Green (1:10,000; Molecular Probes) and analysed by FACS (LSR-II, BD 
Bioscience). Wild type and knockout samples were analysed twice, and each FACS analysis 
corresponds to 100,000 gate-stopping events. Cell population around 0 SYBR Green absorbance units 
corresponds to uninfected red cells. Overlays were created using FlowJo version X, showing technical 
replicates.  
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Figure 55 Effects of pfap2mu knockout on organelle biogenesis 
The effects of pfap2mu knockout on organelle biogenesis and integrity was analysed in DMSO- (top 
panel) or rapamycin-treated (bottom panel) fixed, compound 2-blocked schizonts by indirect 
immunofluorescence. Antibodies against plasmepsin V (ER), ERD2 (cis-Golgi), EXP2 (PVM), 
GAP45 and GAP50 (IMC), MSP1 (plasma membrane), CDC48 (apicoplast), AMA1 (micronemes), 
and RON4 (rhoptries) were used. For each marker, at least 70 cells were examined. Abnormal 
labelling refers to the organisation, abundance, and apposition of the organelle marker with respect to 
the parasite nuclei relative to the localisation observed in wild type parasites (top panel). Cells were 
imaged on a Nikon TI-3000 inverted microscope, and image analysis was performed in Nikon AR 
Analysis software.  
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 Interestingly, MSP1, GAP45, GAP50, and to a lesser extent, EXP2, are 
mislocalised in schizonts lacking µ2. In comparison to the bright staining demarking 
the parasitophorous vacuole membrane in wild type cells, EXP2 staining is more 
diffuse and less contiguous. Most cells seem to have an intact PVM, but the integrity 
of the membrane seems compromised in many cells (WT: 100% correct localisation; 
KO: 55% correct localisation). MSP1 staining reveals a defect in membrane 
organisation in the developing daughter merozoites. While some nuclei in a given 
schizont seem to be fully encircled with MSP1 staining, most nuclei are still bundled 
within a single parasite plasma membrane, with MSP1 staining encircling the 
schizont rather than the individual merozoites. GAP45 localisation is similarly 
affected. In wild type cells, the GAP45-stained inner membrane complex encircles 
each merozoite. However, in pfap2mu- cells, GAP45 staining is abnormal, staining 
discontinuous structures localised near each DAPI-stained nucleus. These spots 
resemble GAP45 staining in early IMC development, as described by Ridzuan et 
al303. As with MSP1 staining, some merozoites are encircled by GAP45 staining, but 
within a single schizont, the majority of merozoites display the abnormal staining. 
GAP50, a transmembrane component of the IMC, is similarly mislocalised to diffuse 
structures that are clearly different from the perinuclear staining characteristic of late 
segmented schizonts. Surprisingly, the apicoplast marker CDC48, microneme 
marker AMA1, and rhoptry marker RON4, are completely absent from schizonts 
lacking µ2, whereas these all stain the expected punctate structures in DMSO-treated 
cells.  
 It is possible that µ2-knockout parasites arrest before the IMC forms, 
membranes segment, and rhoptries and micronemes form. However, because wild 
type and µ2-knockout schizonts have similar total DNA content and the nuclei seem 
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to have segmented by Giemsa staining, it seems unlikely that these knockout cells 
arrest long before these developmental checkpoints. Additionally, the apicoplast is 
present throughout the cell cycle, so that CDC48 is also not detected indicates that 
µ2 deletion causes a significant defect in the secretory system. AMA1, RON4, and 
CDC48 were also probed by western blot in wild type and knockout cells confirming 
they are mislocalised and undetectable rather than degraded (Fig 56). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 56 Effect of µ2 knockout on protein levels of secretory markers 
The effect of µ2 knockout on markers of secretory organelles (AMA, 1:10,000, micronemes; RON4, 
1:10,000, rhoptries; CDC48, 1:5000, apicoplast) was examined by western blot. µ2 knockout was also 
confirmed by anti-HA blotting (1:5000). Equal amounts of rap- or DMSO-treated late-stage schizonts 
were lysed in 5 volumes of 20 mM Tris, 150 mM NaCl, 0.5% Triton X-100, pH 7.5 with protease 
inhibitors. Soluble extracts were separated on a 4-12% TruPAGE gel (Sigma).  
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 These data show that µ2 affects the integrity of several membrane-bound 
organelles and support a role for the AP-2 complex in the early secretory pathway.  
 
 
5.7 Immunoprecipitation of µ2 and examination of interacting partners  
 
 Because these data show that pfap2mu encodes a non-canonical AP-2µ 
subunit located near the endoplasmic reticulum that can mediate significant levels of 
ring-stage artemisinin resistance and is required for asexual maturation, I sought to 
identify what factors might interact with AP2µ. As previously described, P. 
falciparum does not encode a recognisable AP-2 subunit. A similar streamlining 
occurs in Dictyostelium in which the 1 swaps into the AP-2 complex236. I 
speculated the same occurred in Plasmodium and aimed clarify this via 
immunoprecipitation and mass spectrometry. Additionally, a IP-MS characterisation 
would provide clarification on the lack of fluorescent correlation with clathrin.  
Traditionally, immunoprecipitations, or pulldowns, are performed by 
isolating parasites from red cells by saponin lysis and then lysing the parasites in 
buffer containing 0.5%-1% (v/v) detergent. The soluble lysate material is then 
passed over antibody-conjugated beads to remove the tagged factor of interest and 
interacting partners. However initial solubilisation experiments showed that µ2 was 
insoluble under common extraction conditions (not shown). µ2 could be efficiently 
solubilised in RIPA, however this harsh condition is typically unsuitable for 
identifying protein interacting partners, and introducing crosslinking reagents to 
capture interactions can result in a high number of non-specific hits.  
 Recently, Prof Mark Field at the University of Dundee has pioneered the 
adaptation of cryomilling to lysing Trypanosoma bruceii parasites for IP-MS  
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Figure 57 Examination of several µ2 extraction and pulldown conditions 
After trophozoite-stage saponin-lysed parasites were cryo-milled, the solubility of µ2-3xHA and 
pulled-down interacting factors were examined under five different extraction conditions. Two basic 
buffer conditions were utilised, one consisting of 20 mM HEPES, 100 mM NaCl, pH 7.4 and the 
other 20 mM HEPES, 250 mM NaCitrate, 1 mM MgCl2, 10 mM CaCl2, pH 7.4. The first buffer was 
supplemented with either 0.1% (w/v) Brij-58, 0.5% (w/v) CHAPS, 0.1% (w/v) Tween-20, or 0.1% 
(w/v) Triton X-100, and the second buffer was supplemented with 0.1% (w/v) CHAPS. All buffers 
were supplemented with EDTA-free protease inhibitors, including PMSF and TLCK. Solubility of 
µ2-3xHA was examined in each condition by Western Blot (left), and pulled-down partners were 
examined by silver stain (right). S and P refer to soluble and insoluble fractions. 
 
 
pipelines. Cryomilling is a new technique by which parasites released from red cells 
by saponin lysis are rapidly frozen in liquid nitrogen. These pellets are then ground  
into a fine powder in a bead mill also at liquid nitrogen temperatures. This powder 
can be lysed with 90-95% less detergent than standard lysis conditions. This 
procedure preserves labile protein-protein interactions that could be lost in 
traditional pulldown conditions.  
 Developing trophozoites between 24 and 36 hours post-invasion were 
harvested and saponin lysed. Approximately 3 ml of saponin-lysed, pelleted 
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parasites were resuspended with an equal volume of PBS, frozen in liquid nitrogen, 
and milled as described in Section 3.3.4. Several extraction buffer conditions were 
examined for their ability to solubilise µ2-3xHA. Four of these buffers were based 
on a standard 20 mM HEPES, 100 mM NaCl, pH 7.4 buffer and included either 
0.1% (v/v) Brij-58, 0.5% (v/v) CHAPS, 0.1% (v/v) Tween-20, or 0.1% (v/v) Triton 
X-100 and EDTA-free protease inhibitors (Roche). Additionally, a fifth extraction 
condition was included, which had previously been designed and optimised for 
clathrin heavy chain pulldowns from Trypanosoma spp. This extraction buffer 
consisted of 20 mM HEPES, 250 mM sodium citrate, 1 mM MgCl2, 10 mM CaCl2, 
0.1% (v/v) CHAPS, pH 7.4 and EDTA-free protease inhibitors. Most of these 
conditions solubilised µ2-3xHA well, and the four H100 (HEPES + 100 mM NaCl) 
buffers seemed to pull down similar factors by silver stain with the exception of 
several high-molecular weight proteins around 250 kDa (Fig 57). The H100 + 
CHAPS pulldown seemed to contain considerably less of an approximately 240 kDa 
protein, whereas it did retain an approximately 230 kDa protein. While the Brij-58 
and Tween-20 extraction conditions contained both of these fragments, they seemed 
to isolate more of the larger protein. The Triton-based condition seemed to contain 
approximately equal amounts of both proteins. Interestingly, the T. brucei-optimised 
extraction condition seemed to pull down the fewest interacting factors, though this 
may be due to underloading. Since the four H100 buffers extracted similar proteins, 
H100 + Triton was selected for proteomic-scale IP’s because it isolated roughly 
equal amounts of the high molecular weight fragments that seemed differentially 
isolated in the other conditions (Fig 57, right panel, lane D). The H20*/0.1% 
CHAPS buffer was also selected because it is optimised for T. brucei clathrin heavy 
chain and appeared to pull out different size proteins.  
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Figure 58 Immunoprecipitation and mass spectrometry reveals potential µ2-interacting factors 
Proteins identified from immunoprecipitation and mass spectrometry experiments in both triton- and 
CHAPS-based extraction conditions were annotated with a putative localisation by the information 
and annotations available in the Malaria Parasite Molecular Pathways (MPMP) resource embedded in 
PlasmoDB. 37 factors were shared between the triton and CHAPS datasets, with 85 and 46 unique 
factors remaining in those datasets, respectively. Overall, proteins putatively involved in cytosolic, 
ER, peripheral/export, and traffic-related functions account for more than 80% of the µ2 interactome. 
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The proteomics-scale anti-HA pulldowns were performed as described in 
Section 3.3.4, and bound protein was eluted and detected by LC-MS/MS at the 
University of Dundee. Control pulldowns were performed by incubating µ2-3xHA 
lysate with Rabbit anti-Ig beads (same Fc as anti-HA beads with a different antigen 
binding domain) and wild-type trophozoite lysate with the same anti-HA beads. 
These experiments were performed under the guidance of Martin Zoltner in 
Prof Mark Field’s laboratory. Pulldowns and mass spectrometry were performed in 
duplicate. Peptides were mapped to the 3D7 reference proteome using MASCOT, 
and contaminants were filtered using MaxQuant and Perseus.   
Identified proteins were filtered such that only factors with greater than or 
equal to 2-fold enrichment over the control and identified from at least two peptides 
in both replicates were considered. Putative localisations or pathways for each factor 
were annotated based on entries in the Malaria Parasite Molecular Pathways 
(MPMP) database embedded in PlasmoDB.  
Broadly, the identified interacting factors from each extraction condition 
support the localisation of µ2 determined above and a role for µ2 and the AP-2 
complex in secretory traffic (Fig 58). Both conditions extracted factors that map to 
components or functions of many organelles in the cell including cytosolic 
metabolism, translation, and regulation proteins, ER folding and stress response 
factors, peripheral and export-related proteins, and intracellular transport factors, but 
cytosolic, ER, and export factors are most enriched. Additionally, a few 
mitochondrial, apicoplast, DV, and IMC factors were also identified (Table 7). 
Interestingly, a large number of ribosomal and ribosome-related proteins were 
identified in both conditions that seemed to be enriched above the background 
identified in control pulldowns. Because there are so many ribosomal subunits and 
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ribosome-associated proteins, these were largely excluded from the analysis 
presented in this section simply because they obscure the potential importance of 
other interacting partners. Additionally, it is very important to note that only two 
biological replicates have been performed so far, and these ribosomal factors are 
common “sticky” protein contaminants identified in LC-MS/MS experiments. 
Additional replicates and controls are currently underway, but the data from these 
experiments were not yet available for analysis in time for this thesis. Therefore, for 
these reasons, though ribosomal factors may be important interactors requiring 
further investigation, for the purposes of this thesis, they will be, for now, not 
considered further.    
With these factors excluded, the CHAPS-based extraction condition revealed 
122 enriched interacting factors, and the triton-based extraction identified 83 factors. 
37 proteins were shared between both datasets (Table 9). Approximately 80% of the 
overlapped proteome corresponds to cytosolic, ER, peripheral/exported, and 
trafficking factors. The unique datasets are similarly enriched for these four groups, 
though proteasome-related factors were also identified as approximately 8-10% of 
the interacting factors. Broadly, these data support a localisation of µ2 near the ER 
and suggest interactions with machinery involved in intracellular traffic and protein 
turnover.   
 Specifically, these data confirm the hypothesis that the core AP-2 complex is 
comprised of 2, 1, µ2, and 2. This is consistent with invertebrate biology where 
a single gene often encodes 1 and 2. These factors were enriched between both the 
triton and CHAPS extraction conditions, and µ2 was the most abundant protein in 
either dataset. No other adaptor protein complex subunits were significantly 
enriched. Interestingly, the only other trafficking factors found in both datasets were  
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Table 9 Highly enriched µ2 interacting factors identified by LC-MS/MS in both CHAPS- and 
Triton-based extraction conditions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
List of proteins identified in µ2-3xHA pulldowns performed in CHAPS- and Triton-based extraction 
conditions. Cellular extracts, pulldowns, and interactomes were prepared as described in Sections 
3.3.4 and 3.3.5. Pulldowns using the same cellular extracts (containing µ2-3xHA) were performed 
using magnetic anti-rabbit IgG beads of the same species (donkey) as the anti-HA beads used to 
isolate µ2-3xHA. Enrichment is calculated as the ratio of the abundance of a given protein in the anti-
HA pulldown to the abundance in the control pulldown, which was performed in parallel. Proteins 
were assigned to a putative location by their annotation in the Malaria Parasite Molecular Pathways 
database (MPMP) in PlasmoDB. Enriched proteins (> 2 peptides, >2-fold enrichment) identified in 
both extraction conditions are listed. Bold black script indicates identified adaptor protein subunits; 
red bold script indicates factors that were selected for in vitro validation. Enrichment is averaged from 
two replicate pulldowns.  
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ADP Ribosylation Factor GTPase Activating Protein (ArfGAP), MON1, 
Rab11B, and an EH-domain containing protein. ArfGAP and MON1 are both 
regulators of the second messengers GTP and GDP. ArfGAP is a GTPase-activating 
protein, which leads to the hydrolysis of GTP to GDP; MON1 is part of a guanine 
nucleotide exchange factor complex (GEF), which exchanges hydrolysed GDP for 
GTP216,304. In higher order eukaryotes, these two factors function as regulators of 
intracellular traffic304,305. Rab11B has been shown to be required for IMC biogenesis 
in Toxoplasma gondii and regulates secretory traffic downstream of the ER306. The 
EH domain-containing protein identified here shares homology with EHD4, which is 
an effector of AP-2 in humans223. Several exported factors including the major 
virulence factor EMP1 and components of the signal recognition particle (SRP) are 
enriched between both extraction conditions, hinting at the possibility that µ2 could 
be involved in the transportation of proteins destined for the cell periphery from a 
sub-region of the ER.  
 Surprisingly, a kelch-domain containing protein, Kelch protein 10 
(hereinafter referred to as K10), were significantly enriched across both datasets. 
K10 is similar to K13 in that both proteins have a kelch-type -propeller domain. 
However, the K10 propeller seems to contain 5 blades and be located at the N-
terminus whereas the K13 contains a 6-bladed C-terminal propeller. Additionally, 
K10 does not appear to contain a BTB/ POZ domain. Though pfkelch10 mutations 
have not been linked directly to artemisinin resistance as with K13, K10 variants 
have been epistatically associated with artemisinin resistance in a GWAS study307. 
K10 shares some homology with KLHDC4 in humans, which has been linked to 
poor cancer outcomes, though is also functionally uncharacterised308. K13 has been 
proposed to be a regulator of parasite phosphatidylinositol-3-kinase (PfPI3K),  
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Figure 59 Analysis of high-molecular weight µ2 interacting proteins by mass spectrometry 
To more specifically probe whether clathrin heavy chain is present in the µ2-3xHA interactome, 
several high molecular weight fragments around the approximate expected size of clathrin heavy 
chain were excised from a silver stained gel of µ2-3xHA pulldowns performed in each buffer 
condition used for proteomics. These gel slices were submitted to the proteomics facility at the 
University of Dundee for peptide identification. No clathrin was detected in any of the slices 
submitted. The highest abundance proteins detected in these slices were AP2, AP1, and K10, as 
annotated, further supporting their interaction with µ2. These experiments were performed in 
collaboration with Dr Martin Zoltner and Prof Mark Field at the University of Dundee. 
 
 
 
however, PfPI3K was not found in either dataset. Instead, phosphatidylinositol-3-
and-4-kinase and phosphatidylinositol-4-phosphate-5-kinase are identified here, 
but their significance is unclear.  
Conspicuously, the µ2 interactome is lacking clathrin heavy chain and 
clathrin light chain. Both genes are annotated in the Plasmodium falciparum 
genome, and eukaryotic dogma says that the AP-2 complex associates with clathrin. 
While it is important to note that peptides mapping to clathrin heavy chain 
are detected in both replicates of both extraction conditions, there was no evidence 
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of enrichment in the µ2 samples compared to the controls. Though this supports 
conclusions from my localisation data, this observation was still unexpected. To 
further clarify whether µ2 interacts with clathrin, several high molecular weight 
fragments around the expected size of clathrin heavy chain (255.1 kDa) were excised 
from a silver-stained gel of pulldowns performed in both extraction buffer conditions 
and sent for peptide identification by mass spectrometry. Peptides identified from 
slices of the same regions of a gel of a control pulldown performed in each buffer 
condition using the IgG agarose beads were used to subtract contaminants from the 
anti-HA gel slices. No clathrin was detected in any of the fragments. However, these 
slices did re-identify AP2, AP1, and K10 as highly enriched interactors in both 
conditions (Fig 59).  
The full lists of the factors uniquely enriched in each extraction buffer can be 
found in Appendix I. As stated above, these interactors cluster similar to the 
common interactors between the datasets, with 80% of identified factors putatively 
involved in ER-, periphery- and export-, cytosol-, and trafficking-related processes. 
Largely, these factors suggest the same story as the overlapped interactomes and 
reveal more proteins related to ER and Golgi quality control, sorting, and export. 
Given the functional similarity between the two datasets, as additional replicates are 
available for analysis, it is possible that some of these unique factors may be 
common to both extraction conditions. In lieu of additional experiments, that the two 
extraction and pulldown conditions used in this study are so different (in ionic 
strength, detergent, and divalence), should give some additional confidence in the 35 
proteins identified between the two conditions. However, several factors were 
further explored in cultured parasites to provide empirical support for this list of 
proteins that may interact with µ2.  
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5.8 Validation of µ2 interacting factors identified by IP-MS 
 
 Mass spectrometry is known for generating long lists of potential interacting 
factors. While one may be generally safe in assuming some of the expected and most 
enriched hits probably interact with the tagged handle protein of interest, steps 
should be taken to empirically validate the interactions of some of these expected 
factors as well as some of the more interesting or unexpected factors. 
 From the list of 35 µ2 interactors identified in the previous section, several 
factors were selected for tagging and in vivo validation. The criteria for selection 
were that, if possible, the factors would have been tagged before to show that they 
can be tagged without disrupting their function. Additionally, these factors should be 
amenable to overexpression and have relevance to understanding the mechanism or 
localisation of µ2.  
 Given the intense interest in mechanisms of artemisinin resistance, K10 was 
immediately selected. K10 was one of the most enriched and highest confidence hits 
but has not been previously characterised. TCP-1 ring complex subunit epsilon 
(TRiC) was selected because this is a known ER-associating factor. Lastly, MON1 
and ADP-ribosylation factor, GTPase-activating Protein (ArfGAP) are competing 
GTP exchange factors that were recently shown to have a punctate localisation by 
immunofluorescence that resembles that of K13 and µ2192. ArfGAP and MON1 in 
higher order eukaryotes are known regulators of vesicular traffic in the cell304,305.  
 The CDS for each protein was cloned into the pDC2-cam-BSD Plasmodium 
expression vector in frame with a short, flexible linker and GFP (Fig 60A). In the 
case of 1, the CDS was amplified from cDNA to remove introns and, based on 
studies in other organisms indicating C-terminal GFP is not tolerated, was cloned 
downstream of an N-terminal GFP and linker. K13 was also N-terminally tagged 
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because the -propeller kelch domain comprises the C-terminus, and tagging this 
domain would likely interfere with its folding and function. Additionally, Birnbaum 
et al recently described the localisation of an N-terminally tagged K13192. 
These constructs were transfected by Nucleofection into 3D7-µ2-3xHA-glmS 
schizonts and selected with 2.0 µg/ml blasticidin-S until parasites were observed by 
Giemsa stain. In all of these episomal transfections, blasticidin-resistant transgenic 
parasites were obtained within 5-8 days. Interaction of these factors with µ2 was 
validated by immunofluorescence and co-immunoprecipitation (Fig 60). Pearson’s 
Correlational Coefficients for each marker are presented in Fig 45.   
 As previously reported by Birnbaum et al, ArfGAP-GFP and MON1-GFP 
displayed a punctate cytoplasmic localisation192. In rings, these structures are located 
near the nucleus and are localised near the digestive vacuole in the developing 
trophozoite, ultimately segmenting into a single structure per merozoite. As 
examined in ring stages and schizonts, µ2-3xHA signal correlates well with both 
ArfGAP-GFP and MON1-GFP signal. There are some ArfGAP and MON1 spots 
that do not overlap with µ2, namely in rings, however all µ2-3xHA-labeled 
structures overlap with MON1 and ArfGAP signal, within the limits of resolution of 
this technique. The µ2 interacting factors identified in Section 5.7 may not 
exclusively interact with µ2, therefore it is not expected that they would exclusively 
localise near µ2. The same was true of TRiC, a cytosolic chaperone complex. The 
signal observed for most of the labelled TRiCGFP structures correlates with µ2-
3xHA structures, and all µ2-3xHA structures overlap with TRiCGFP structures. 
Correlation between µ2-3xHA and K10-GFP localisation was similar. To the best of 
my knowledge, the localisation of K10 has never been reported, and therefore this 
finding provides the first evidence that K10 may also be located in the cytosol and  
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Figure 60 Validation of selected µ2 interacting factors 
To validate the µ2 interactome determined in Section 5.7, several factors were episomally 
overexpressed as fusion proteins with GFP. Specifically, ADP ribosylation factor GTPase-activating 
protein (ArfGAP), vacuolar fusion protein MON1, T complex protein 1 subunit epsilon (TRiC), 
Kelch 10 (K10), and Kelch 13 (K13) were selected. A The CDS for each factor was cloned in frame 
with either N-terminal or C-terminal GFP, as shown. These constructs were transfected into 3D7-µ2-
3xHA-glmS parasites and selected with 2 µg/ml BSD. Colocalisation of each factor with µ2-HA was 
examined in formaldehyde-fixed schizonts and ring stages by indirect immunofluorescence using 
anti-HA (rat, 1:150, 3F10; anti-rat-488, goat, 1:150, Invitrogen) and anti-GFP (rabbit, 1:500, A. 
Holder Lab; anti-rabbit-594, goat, 1:150, Invitrogen) antibodies. B ArfGAP-GFP, MON1-GFP, and 
K10-GFP were also pulled down using magnetic anti-GFP beads (M. Field laboratory) in H100+0.1% 
Triton X-100 buffer (Section 5.7) from cryo-milled parasites (Section 3.3.4). Eluted fractions were 
run on a 4-12% TEA-Tricine TruPAGE gel (Sigma) and analysed by western blot for the presence of 
GFP-tagged and HA-tagged species.   
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near the ER. The localisation of episomally-expressed GFP-K13 was also punctate 
and cytoplasmic, as found by Birnbaum et al, and showed strong correlation with µ2 
throughout life stages.  
To better understand whether these factors interact with µ2 beyond simple 
colocalisation, co-immunoprecipitations were performed using anti-GFP magnetic 
beads. For these experiments, only ArfGAP-GFP, MON1-GFP, and K10-GFP were 
analysed. Parasites expressing µ2-3xHA with episomes expressing the GFP fusions 
of interest were harvested by saponin lysis and flash frozen in liquid nitrogen as 50% 
(w/v) in PBS. These parasite pellets were ground into a powder at liquid nitrogen 
temperatures and lysed in buffer consisting of 20 mM HEPES, 100 mM NaCl, 0.1% 
(v/v) Triton X-100, pH 7.4 supplemented with protease inhibitors (Roche). The 
lysate was cleared by centrifugation and incubated with magnetic anti-GFP beads 
(Mark Field laboratory) for 1 hour. The beads were washed several times with lysis 
buffer, and bound material was eluted using gel loading buffer. The eluted material 
was separated by SDS-PAGE electrophoresis and probed for the presence of the 
GFP-tagged interacting partner and µ2-HA by western blot (Fig 60B). These co-
immunoprecipitation experiments revealed that ArfGAP, MON1, and K10 all 
interact with µ2, providing empirical support for the mass spectrometry-determined 
µ2 interactome. Experiments are underway to validate the interaction of TRiC with 
µ2. Additionally, experiments to validate the colocalisation and interaction of AP-1 
with µ2 are also planned.  
Given the similarity in the ART-R phenotype mediated by µ2 mutation 
(Section 4.4), I also probed the localisation of µ2 with respect to K13. Using the 
same episomal approach as above, I introduced an N-terminally GFP-tagged K13 
into the µ2-3xHA tagged parasite line and examined the localisation of µ2 and K13 
 221 
by IFA. The localisation of K13 reported by Birnbaum et al is very similar to what I 
have observed for µ2 (cytoplasmic, near the DV), and in my hands, the localisation 
of these species correlate well, within the limits of resolution of widefield light 
microscopy (Fig 60A, 45). We are currently investigating this localisation further 
and how it may relate to the function of µ2 and both proteins’ involvements in 
artemisinin resistance. 
 
5.9 Discussion 
 
 These results suggest a possible repurposing of traditional trafficking 
machinery in Plasmodium. Rather than participating in receptor-mediated 
endocytosis from the plasma membrane to the early endosome compartment, AP-2 
seems to play a role in the early secretory pathway near the ER. By 
immunofluorescence, µ2 labels a punctate sub-compartment near the ER throughout 
most of the asexual cycle. This structure either replicates or somehow segregates into 
the daughter merozoites so that each merozoite and new parasite inherits a single 
focus. When examined with immunoelectron microscopy, µ2 mainly decorates distal 
surfaces of the ER that resemble the vesicular tubular clusters of mammalian cells. 
Due to the limits of resolution of light microscopy, the punctate structures observed 
by IFA and tubular structures identified by IEM are probably the same. By super-
resolution structured illumination microscopy, each previously observed single focus 
may contain several smaller foci. Either way, these data show that AP-2 is not 
primarily located at the plasma membrane, in contrast to other eukaryotes. To the 
best of our knowledge this is the first description of such a divergence in the adaptor 
protein complexes. AP-1 has been shown to traffic from the Golgi to the apical 
secretory organelles including the rhoptries in Toxoplasma and potentially also in 
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Plasmodium. While other eukaryotes obviously do not have these organelles, and in 
that respect Apicomplexan AP-1 may broadly have a novel function, AP-1 still 
mediates a trans-Golgi to vesicular body transport route.  
Recently, AP-2 has been described as mediating retrograde traffic from 
endosomes to the plasma membrane in human neuronal cells290. At the time, this 
finding again was dramatic because AP-2 canonically mediates anterograde traffic 
from the plasma membrane to the early endosome. It was recognised that recycling 
of transmembrane receptors from the endosome to the plasma membrane occurs, but 
this process was thought to proceed via a different route.  
The observations in this chapter may be consistent with retrograde secretory 
traffic as µ2 co-purifies with several ER- and export-related elements. Interestingly, 
µ2 partially colocalises with Rab5B and Rab11A by IFA. By immunoelectron 
microscopy, µ2-3xHA and Rab5B co-label vesicular structures in the cytosol. Both 
of these Rab GTPases have been shown to mediate traffic towards the cell periphery, 
with Rab5B directing to the plasma membrane and Rab11A to the IMC. Consistent 
with this, knocking out µ2 seems to cause defects in peripheral membrane 
organisation in segmenting schizonts including of the parasite plasma membrane and 
the IMC.  
The lack of µ2 at the plasma membrane may be possible because the malaria 
parasite has adapted to obligate intracellular life inside the parasitophorous vacuole. 
The parasite is known to perform a massive endocytic event in the ring stage to 
ingest a large volume of haemoglobin from the host cell, and small endocytic events 
occur throughout the life cycle via cytostomes191. Because AP-2 classicly engages 
with specific cargo by facilitating receptor-mediated endocytosis in higher order 
eukaryotes, for AP-2 to be involved in these endocytic processes seems inconsistent. 
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Further, it is not clear how receptor-mediated endocytosis could occur in the context 
of a double membrane system. Importantly, the immunoelectron microscopy 
performed in this study did identify cytostomes, and µ2 was not detected anywhere 
along these structures.  
 IP-MS characterisation of µ2/AP-2-interacting factors provided further 
support for this localisation and potential function of AP-2 in the cell. Specifically, 
these data support the hypothesis that AP-2 actually exists as a hybrid AP-1/2 
complex, necessary because one of the canonical large subunits of the AP-2 complex 
is missing from the P. falciparum genome. Bioinformatic analysis of the conserved 
proteins of unknown function with similar abundance to the 2 subunit did not 
reveal a 2 subunit (not shown). 
Without a detailed characterisation of the cis-Golgi and some of the 
trafficking factors that interact with the AP-2 complex, it is difficult to state from 
these data exactly to which compartment AP-2 directs cargo. From these data, the 
most plausible possibilities include to the plasma membrane as a direct export 
mechanism or to the IMC, but all secretory pathway destinations should still be 
carefully considered. Given the enrichment of nearly the entire signal recognition 
particle and ribosome (ribosomal subunits were omitted from the discussion in 
Section 5.7, but nevertheless may still be important), it is tempting to speculate a 
model of µ2-mediated cargo aggregation by which the AP-2 complex assembles near 
the SRP, which cotranslationally imports nascent polypeptides into the ER. Though 
speculative, bioinformatic analysis of the identified enriched peripheral and exported 
proteins did not reveal conserved N-terminal or C-terminal sequences that might be 
consistent with the YXX or dileucine motifs characteristic of µ2 cargo recognition 
elements. Identifying cargo molecules will be difficult but will provide important 
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insight into these observations and shed further light on how the secretory pathway 
functions in Plasmodium falciparum.  
Interestingly, when expressed in human cells (Appendix IV), PfAP2µ seems 
to be localised to the cell periphery, consistent with its canonical localisation and 
function. Given how much is known about how the human AP-2 complex functions, 
this orthologous expression system may provide a valuable path to probing PfAP2µ 
biology and the functional impacts of clinically relevant mutations. Overall these 
data suggest that though key processes in Plasmodium may be diverged from 
eukaryotic dogma, the underlying molecules may be functionally similar. Though 
Plasmodium biology may seem very strange and different, the parasite may have co-
opted conserved systems to suit its obligate intracellular needs.   
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Chapter 6 
Modulation of in vitro Plasmodium falciparum artemisinin sensitivity 
by physiochemical perturbation 
 
 
 
 
  
 
6.1 Rationale for pursuing physiochemical perturbation experiments  
 
 To date, published studies and informal conversations indicate that we as a 
field are trying to understand artemisinin resistance by comparing artemisinin 
resistant, K13mut parasites to artemisinin sensitive, K13wt parasites using multi-omic 
tools193. However, over the course of this thesis, I began to wonder whether this 
approach is appropriate. Artemisinin is unlike any antimalarial that has been used in 
the field because it does not seem to disrupt a single enzyme or target a specific 
pathway. Additionally, stably acquiring resistance takes the parasite an impressively 
long time, and any resistance achieved is partial. K13R539T is the most potent of the 
known K13 mutations, conferring 20-30% survival in the RSA (Section 4.4). Yet 
even these parasites are 70-80% sensitive to artemisinin in the ring-stage in vitro. In 
contrast, chloroquine resistant parasites are totally insensitive to therapeutic doses of 
chloroquine, and in vitro EC50 estimates of sensitivity to chloroquine in these 
parasites can be multiples of the EC50’s of sensitive parasite strains. Therefore, 
“artemisinin-resistant” parasites still mostly sensitive to artemisinin. The one multi-
omic investigation of K13mut parasites that has so far been published supports this 
idea because the authors identified only subtle differences at the proteomic, 
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transcriptomic, and metabolomes levels, compared to wild type cells193. Instead of 
trying to back into an understanding of artemisinin resistant via K13 mutations or 
poly-omic investigations, I wondered whether we might find ways of reversibly 
rendering sensitive parasites less sensitive to artemisinin and thereby explore the 
cellular modulations required for artemisinin resistance. 
 
 
6.1.1 A primed stress response may underlie artemisinin resistance  
 
The data presented thus far in this thesis show that a genetic change in the µ2 
trafficking factor can generate significant levels of artemisinin resistance in vitro. 
Subsequent molecular characterisation of this factor revealed an unexpected 
interaction with the artemisinin resistance factor K13 and suggested a role for both 
proteins in secretory traffic.  
 Recent work has shown that ring-stage translational dormancy is the basis of 
K13-mediated artemisinin resistance202. As described in Section 1.5.3.1, this 
dormancy is marked by a signalling cascade initiated by BiP in the ER that triggers 
phosphorylation of cytosolic eIF2. BiP, also known as GRP78, is a soluble ER-
resident HSP chaperone that is capable of responding to ER stress202,311. Under 
normal cellular conditions, BiP/GRP78 interacts with newly synthesised and 
translocated proteins in the ER lumen and is one of several chaperones that mediates 
proper folding. When proteins abnormally accumulate in the ER, BiP alternatively 
activates ER membrane kinases, which activate the unfolded protein response and 
reduce translational activity until the ER stress subsides. Therefore, given that 
artemisinin triggers the UPR, and the drug accumulates in the ER of other eukaryotic  
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Figure 61 Chemical manipulation of ER protein dynamics and artemisinin sensitivity 
The impacts of Brefeldin A (BFA), known to disrupt trafficking and protein dynamics at the ER, was 
examined for its ability to disrupt artemisinin sensitivity. Brefeldin A is a fungal metabolite that 
blocks ER-to-Golgi traffic, leading to a buildup of secretory material in the ER. In other eukaryotic 
systems, BFA has been used to induce and study the unfolded protein response and disrupt ER protein 
dynamics, which canonical induces phosphorylation of cytosolic eIF2 by a PERK-dependent 
mechanism. eIF2-P interacts with ribosomes to globally reduce translational initiation. 
 
 
cells, it is possible that “artemisinin resistance” is really just a primed ER-based 
stress response202,312. Since K13 mutations mediate ring-stage artemisinin resistance 
via an ER-based, BiP-dependent translational dormancy, and as described in Chapter 
5, the wild type molecule is clearly located near the ER and interacts with trafficking 
partners, it follows that K13 mutations may induce an ER-based stress response 
rooted in a dysregulation of secretory traffic. In yeast, deletion of ER-to-Golgi 
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trafficking factors confers hypersensitivity to artemisinin, suggesting the cell cannot 
simultaneously cope with artemisinin-induced damage and a near-lethal 
accumulation of material in the ER313. However, a modulation of this ER traffic 
resulting in low-level accumulation of material in the ER may result in a primed 
stress response capable of inducing a short period of dormancy, mitigating oxidative 
stress caused by artemisinin.   
 In this line of thinking, I wondered whether I could reversibly trigger an ER 
stress response in drug-sensitive parasites that would phenocopy these artemisinin-
resistant parasites. To this end, I investigated the effects of short exposures to 
brefeldin A, transient changes in environmental temperature, chemical ablation of 
the apicoplast, and reversible depletion of µ2 on parasite susceptibility to artemisinin 
and latency as detected by survival in the RSA and cytosolic eIF2 phosphorylation 
in the drug-sensitive 3D7 line. The 3D7 line was isolated and culture adapted in the 
1970s and has never been exposed to artemisinins in the field and should therefore 
have no adaptive response to artemisinins. The studies and analysis presented in this 
chapter both predated and were informed by the publication of the recent Zhang et al 
study showing that eIF2 phosphorylation and translational dormancy underpins 
ring-stage artemisinin resistance202.  
 
 
6.2 Effect of Brefeldin A on artemisinin sensitivity  
 
 The data presented in Chapter 5 suggest that traffic is involved in artemisinin 
resistance. To therefore establish whether interfering with this process can protect 
cells from artemisinin, the effects of Brefeldin A treatment on RSA survival was 
examined.  
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As described in the previous chapter, Brefeldin A (BFA) is a fungal 
metabolite that rapidly and reversibly blocks ER-to-Golgi traffic in eukaryotic cells. 
This blockade ultimately causes the fusion of the Golgi and the ER as Golgi-destined 
vesicles cannot exit the ER.  
The build-up of secretory proteins in the ER leads to the upregulation of 
protein turnover machinery and a reduction in global protein synthesis until ER 
stress can be mitigated or the cell dies. Recent efforts to study the programmed 
cellular response to ER stress in various mammalian pathologies leveraged the 
mechanism of BFA to interfere with protein homeostasis in the ER. In these studies, 
Brefeldin A treatment induces phosphorylation of eIF2Ser51314,315. Thapsigargin 
is typically used to induce and study the UPR in eukaryotic cells. However, a recent 
study has shown that thapsigargin does not stimulate the same calcium-release 
pathway in Plasmodium as in higher order cells, and molecular docking suggests 
PfSERCA, the orthologue of the human target (hSERCA), is incapable of interacting 
with the molecule316. Therefore, only Brefeldin A was used. 
To probe the effects of Brefeldin A on artemisinin sensitivity, 2-hour-post-
invasion ring stage parasites were treated with 5 µg/ml BFA or equivalent methanol 
control for 1 hour (Fig 62A). At hour 3 post-invasion, an equal volume of 1.4 µM 
DHA or DMSO equivalent was added to the cells (final concentration 0.7 µM DHA, 
2.5 µg/ml BFA), and the cells were incubated for a further 4 hours. Thereafter, both 
drugs were extensively washed off, and cells were returned to culture. Parasite 
survival was determined by FACS with SYBR Green and MitoTracker Deep Red. 
As anticipated, pre-treatment of early ring-stage parasites with Brefeldin A provided 
substantial protection from artemisinin. Approximately 50% of parasites treated with 
BFA survived the RSA artemisinin pulse, compared with less than 3% of untreated 
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Figure 62 Effects of Brefeldin A on artemisinin sensitivity 
A Schematic of the pulsed physiochemical (PC) treatment/RSA experiments. PC treatment was pre-
performed from hours 2-3 post-invasion, and the RSA was administered from hours 3-7 post-
invasion. B Pulsed exposure to 5 µg/ml Brefeldin A (BFA) has little effect on parasite proliferation in 
the absence of DHA. C Pulse exposure to 5 µg/ml Brefeldin A provides significant protection from 
artemisinin-mediated cytotoxicity. Mean of at least 3 experiments each performed in technical 
duplicate. Each technical replicate was counted by FACS twice and contains 100,000 gate-stopping 
events. D Western blot of eIF2P in PC-treated or control cells. Anti-eIF2P (rabbit, 1:1000; Cell 
Signalling) was generously provided by Prof Sibylle Mittnacht at UCL. Equal amounts of protein (15 
µg) as determined by Bradford Assay were loaded in each lane. 
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cells. Further, eIF2is phosphorylated in BFA-treated cells, supporting the notion 
that BFA exposure provokes a cell stress response.   
 
 
6.3 Effect of pulse temperature on artemisinin sensitivity  
 
 I then wondered if a similar ER stress/ART-R response could be more 
broadly triggered by varying the culture temperature during the RSA. In practice, we 
can slow down parasite growth as a synchronisation technique by leaving culture 
flasks at room temperature for several hours or in the refrigerator for short periods of 
time. Especially when performed in the ring stage, this environmental perturbation 
has minimal effect on parasite development other than just slowing the cell cycle. 
One can even leave ring-stage cultures at 4°C overnight and still resume growing the 
cultures nearly normally the next day. As I made this observation by mistake while 
performing the above experiments, I wondered whether a similar induced ring-stage 
dormancy is involved and could also provoke a cytoprotective response. Indeed, in 
stroke patients, rapidly cooling the patient provides protection from oxidative 
damage, and in neuronal cell culture models, mild hypothermia has been shown to 
activate the unfolded protein response and induce cytoprotective dormancy317–321. 
Cooling has also been used to study trafficking dynamics as mild hypothermia slows 
down intracellular vesicular traffic322. If in Plasmodium, hypothermia treatment only 
causes parasite development to slow down, this would theoretically extend the ring 
stage, which is hyper-sensitive to artemisinin, and no wild type parasites would 
survive the RSA. However, if hypothermia slows down trafficking and induces a 
protective ER stress response, these cells should be less susceptible to artemisinin.  
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Figure 63 Effects of pulse temperature on artemisinin sensitivity 
Temperature pulse experiments were carried out exactly as for Brefeldin A exposures. From hours 2-3 
post-invasion, cultures were cooled to the stated temperature; DHA or solvent was added at hour 3, 
and the RSA pulse was performed at the stated temperature. A Transient cooling has little effect on 
parasitaemia after reinvasion in the absence of DHA (red circles), whereas this cooling dramatically 
effects parasite susceptibility to artemisinin (blue squares). B Ring stage survival estimates with 
respect to pulse temperature. These experiments were carried out in the same format described in 
Figure 62A. Mean of at least 3 experiments each performed in technical duplicate. Each technical 
replicate was counted by FACS twice and contains 100,000 gate-stopping events.  
 
 
 
 
 
As a proof of principle experiment, I left a synchronous ring-stage culture (2 
HPI) on the bench in a 17°C (RT) water bath for 1 hour and then incubated these 
parasites with either 700 nM DHA or solvent similarly for a further 4 hours. The 
parasites were washed extensively with pre-warmed media and returned to culture. 
More than 50% of cells survived the DHA treatment without significant consequence 
to development or reinvasion due to the reduced temperature as compared by 
Giemsa smear or FACS.  
To probe the relationship between temperature and artemisinin resistance, I 
performed a temperature titration by pre-incubating parasites for 1 hour and 
performing the RSA at a series of temperatures from 17C-37°C. Cells were also 
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incubated at 4°C in the refrigerator. These experiments showed a sigmoidal 
relationship between temperature and RSA survival, where mild hypothermic pre-
treatment (24-28°C) provides significant artemisinin resistance (> 5% survival). 
Cells incubated at 4°C for 2 hours were examined for their eIF2phosphostatus and, 
as expected, contained phosphorylated eIF2Fig 62D).  
Although total phosphorylated eIF2was lower than in the BFA-treated cells 
despite these cells displaying a greater RSA survival, some of the survival may be 
due to broad slowing of enzymatic and chemical processes. Hypothermia is likely to 
also attenuate the rate of protein synthesis and the rate of activation of artemisinin. 
Artemisinin stability in aqueous solution is temperature dependent323; therefore, it is 
reasonable to expect that the thermodynamic spontaneity of activation is similarly 
temperature dependent in vivo. However, the presence of eIF2P indicates that at 
least some of the decreased susceptibility to artemisinin comes from an induced ER 
stress response, possibly caused by attenuated activity of chaperones and protein 
folding leading to an accumulation of misfolded and mis-trafficked proteins in the 
ER.  
 
 
6.4 Effect of chemical ablation of the apicoplast on artemisinin 
sensitivity  
 
 The results described above and Zhang’s results establish a compelling 
relationship between the cell stress response and artemisinin sensitivity in the early 
ring-stage parasite. Specifically, the profound antagonistic effects of brefeldin A 
exposure on artemisinin cytotoxicity shows manipulation of secretory traffic can 
induce this response and provide protection from artemisinin. However, longer 
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exposures to brefeldin A are lethal and therefore this induced state cannot be 
maintained. I wondered if there was a way of non-lethally maintaining disrupted 
secretory traffic. To the best of my knowledge, nearly all secretory trafficking routes 
are essential. However, apicoplast traffic can be successfully knocked out by genetic 
or chemical means and complemented. 
 The apicoplast, evolutionarily descended from the chloroplast, is a relic 
organelle that participates in 4 core biosynthetic processes: haem, iron-sulphur 
cluster, fatty acid, and isoprenoid biosynthesis. In the blood stage, isoprenoid 
biosynthesis is the only apicoplast pathway that is required for parasite survival82. 
Though many of the genes involved in these four processes are encoded by the 
nuclear genome, the apicoplast contains its own organellar genome and performs 
some de novo protein synthesis using prokaryotic-like ribosomes. Because of the 
unique prokaryotic nature of the organelle, the apicoplast is a target for antimalarial 
chemotherapy. In particular, as described in Section 1.4.5, certain antibiotics 
including doxycycline and azithromycin exert their antimalarial properties by 
inhibiting apicoplast-resident prokaryotic ribosomes. Antibiotic-treated parasites 
cannot replicate the apicoplast during schizogony and therefore cannot supply 
essential isoprenoids to the daughter parasite. In 2011, Yeh et al showed that 
supplementing parasite growth medium with isopentyl pyrophosphate (IPP), the 
biosynthetic product of the apicoplast isoprenoid pathway, allows antibiotic-treated 
parasites to survive and propagate over multiple development cycles82. Interestingly, 
Yeh et al showed that proteins destined for the apicoplast are mislocalised in IPP-
treated, apicoplast-null parasites82. Although these parasites propagate normally, I 
wondered whether this disrupted secretory traffic would be enough to induce a sub-
lethal ER stress response that would provide ring-stage protection from artemisinin.   
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  To this end, I first planned to chemically ablate the apicoplast in the 
validated artemisinin-sensitive/artemisinin-resistant isogenic parasite pair 
Cam3.IIREV and Cam3.II. While I expected that apicoplast removal would provide 
protection from artemisinin, the inclusion of Cam3.II would reveal any unexpected 
hypersensitivity caused by this manipulation. As described in Chapter 4, Cam3.II 
was isolated from a patient in Cambodia and harbours K13R539T. Cam3.IIREV was 
genetically edited to overwrite the K13 mutation and install the wild type locus. As 
described by Yeh et al, these cells were synchronised and exposed for 48 hours to 2 
µM doxycycline82. After 48 hours, 200 µM IPP was added to the culture medium. 
After 96 hours, doxycycline was removed. To confirm successful apicoplast ablation 
and complementation, a subculture of these cells was cultured for a cycle in the 
absence of IPP. These experiments were performed in tandem with 3D7. 
Unexpectedly, the Cam3.II parasite continued to proliferate normally in the absence 
of IPP, whereas 3D7 DOX-treated cells died without IPP. After titrating the 
sensitivity of the Cam3.II parasites to doxycycline using a standard 96-hour dose 
response, it was clear that these parasites are highly resistant to doxycycline and 
azithromycin (Cam3.II EC50 ≈ 3.2 µM; Cam3.IIREV EC50 ≈ 2.8 µM; 3D7 EC50 ≈ 0.5 
µM; Fig 64). To the best of our knowledge, this is the first demonstration of 
bloodstage antibiotic resistance in Southeast Asian parasites. We are currently 
examining whether these parasites harbour mutations in apicoplast-encoded 
ribosomes that would explain this result. However, validated genetic markers for 
doxycycline resistance are lacking. 
Because the Cam3.II parasites are resistant to doxycycline and azithromycin, 
further experiments were only conducted with the 3D7 strain. A dose response 
experiment with 3D7 and doxycycline in the presence of IPP confirmed that 200 µM  
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Figure 64 Sensitivity of ART-R and ART-S parasites and to 96h exposure to doxycycline 
Cambodian parasites harbouring K13R539T (Cam3.II) and K13WT (Cam3.IIREV) alleles and 3D7 were 
examined for their sensitivity to doxycycline. The primary mechanism of doxycycline cytotoxicity 
kills parasites after two cycles, therefore parasite proliferation was examined after 96 hours of 
exposure to the drug rather than the standard 48 hours. Total DNA content was examined by cell lysis 
and SYBR Green staining as previously described. Cam3.II parasites are dramatically less sensitive to 
doxycycline than 3D7.  
 
IPP compensates for the loss of the organelle.   
 To examine the effects of apicoplast ablation on artemisinin sensitivity, 3D7 
parasites were tightly synchronised and then cultured for 96 hours in the presence of 
2 µM doxycycline and 200 µM IPP to remove the apicoplast. At 96 hours post-
invasion, apicoplast-null parasites were pulsed with 700 nM DHA for 4 hours and 
cultured for a further 65 hours (Fig 65A). IPP was refreshed daily. Parasite 
proliferation was examined by FACS. Though IPP-supplemented parasites cultured 
in parallel continued to proliferate normally, apicoplast-null schizonts did not 
reinvade or proliferate well after Percoll treatment. With this in mind, it seems that a 
substantial proportion of these cells survive the RSA pulse with DHA, although 
solvent-treated RSA control parasites only displayed a 2-fold expansion after 72 
hours rather than the normal 5-6-fold expansion observed during normal  
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Figure 65 Effects of chemical ablation of the apicoplast on ring-stage artemisinin sensitivity 
A 3D7 background parasites were treated with 2 µM doxycycline and 200 µM isopentenyl 
pyrophosphate (IPP) for 96 hours. After 96 hours, early ring stage parasites were synchronised and 
exposed to 700 nM DHA or solvent for 4 hours in the RSA protocol described above. B Ring stage 
survival was determined 65 hours later by FACS with SYBR-Green/MitoTracker Deep Red. Mean 
and SEM are reported of at least 3 experiments each performed in technical duplicate. Each technical 
replicate was counted by FACS twice and contains 100,000 gate-stopping events (left). C Fold 
replication was also enumerated between DMSO-treated cells with and without an apicoplast and 
refers to the ratio parasitaemia before and after the RSA (right). 
 
culture. Given that IPP is exceedingly expensive, sufficient culture volumes could 
not be grown in order to probe eIF2-P status in DOX/IPP-treated parasites. 
Electron micrographs of parasites lacking an apicoplast show that the parasite 
cytoplasm is clogged with apicoplast-targeted vesicles. Presumably there is a 
dynamic equilibrium which eventually causes material destined for the apicoplast to 
back up along the secretory pathway, which may induce a cell stress response, and 
generate DHA resistance.  
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 Because the apicoplast produces haem by an endogenous biosynthetic 
pathway, and haem is believed to be the activator of artemisinin in the cell (Section 
1.5.3.1), I wondered whether these results could be explained as a consequence of 
knocking out this endogenous haem biosynthetic pathway, since the amount of 
haemoglobin per cell volume in ring stages is exceedingly low (Section 1.5.3.1). 
However, parasites lacking two enzymes in the endogenous haem biosynthetic 
pathway, 5-aminolevulinic acid synthase and ferrochelatase, were equally sensitive 
to DHA as compared to wild type progenitors in the RSA (Fig 66). 
Even though these experiments are difficult to interpret alone, the results 
presented in this section are consistent with the results presented above showing that 
disrupting secretory traffic can provide protection from artemisinin in early ring-
stage parasites. Interestingly, during the production of this thesis, a study examining 
the effects of transient plastid-derived biosynthetic precursors on recovery from  
 
 
 
 
 
 
 
 
 
 
Figure 66 Effect of haem biosynthetic knockout on ring-stage sensitivity to artemisinin 
Parasites lacking 5-aminolevulinic acid synthase (ALAS) and ferrochelatase (FC) were obtained from 
Prof Akhil Vaidya and Dr Hangjun Ke at Drexel University (Philadelphia, USA). These cells were 
synchronised and examined for their susceptibility to a ring-stage pulse of DHA in the RSA in 
parallel with wild type D10 parental parasites. RSA was quantified by FACS as previously described. 
Mean and SEM are presented of at least three experiments, each performed in technical duplicate. 
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artemisinin-induced dormancy reported that DOX/IPP-treated parasites recrudesce 
significantly faster than wild type parasites possessing an apicoplast, consistent with 
these results203.   
 
 
6.5 Effect of µ2 knockdown on artemisinin sensitivity  
 
 The results described above and Zhang’s results establish a compelling 
relationship between the ER stress response and artemisinin sensitivity in early ring-
stage parasites202. As described in the Section 6.1, the results described in Chapter 5 
show that K13 is somehow involved in AP-2-dependent traffic. It is therefore 
tempting to logically link the phenomena of mutant trafficking factors causing 
resistance and physiochemically disrupted ER dynamics causing resistance into a 
model of how artemisinin resistance occurs. However, I wanted to find genetic 
support for this link.  
Without knowing what the AP-2 complex is trafficking, it is difficult to 
directly monitor the rates of this traffic in artemisinin-resistant and -sensitive  
parasites. Additionally, because µ2 knockout parasites are not viable, it is impossible 
to perform the RSA on ring stage parasites devoid of µ2. Therefore, to investigate 
whether defective AP-2 traffic causes artemisinin resistance, I aimed to created a 
parasite in which the abundance of µ2 could be transiently manipulated. To this end, 
I planned to introduce a regulable copy of pfap2mu into my inducible DiCre 
pfap2mu knockout parasite line. Specifically, I planned to knock out the 
chromosomal pfap2mu locus and grow the parasites on an episome expressing a 
titratable µ2-GFP-DDD under the control of the cam promoter.  
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Figure 67 Schematic of µ2 complementation and transient regulation 
A Schematic of complementation of DiCre-mediated µ2 knockout with episomally-expressed µ2-
GFP. B Schematic of modification of pDC2-cam-pfap2mu-GFP-BSD construct to introduce the 
DHFR degradation domain (DDD) onto the C-terminus of episomally-expressed µ2, enabling 
transient protein-level knockdown of µ2 once the endogenous pfap2mu CDS has been excised by Cre 
recombinase. Trimethoprim (TMP) stabilises the DDD tag and can be washed out of culture medium 
to induce rapid degradation of the µ2-GFP-DDD fusion protein.   
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Principally, the DHFR destabilisation domain (DDD) is a trimethoprim 
(TMP)-sensitive protein unfolder. In the absence of TMP, the DDD element is 
destabilised and is marked for degradation. Thus, any protein fused to the DDD 
element can be stabilised or degraded by adding or removing TMP from the cell 
culture. In previous studies, the DDD element has been shown to cause degradation 
of a target factor within minutes324. 
The previously described (Section 5.5) 3D7-µ2-floxed-HA parasite line is 
aptly suited for these experiments because TMP is a DHFR substrate analogue and is 
mildly toxic to parasites. Therefore, to use the DDD system, the parasites must 
express an additional copy of DHFR, which my µ2 knockout parasite line does. 
Additionally, by fusing µ2 to GFP, I can independently monitor the levels of both 
the endogenously-expressed, HA-tagged µ2 and the episomal, regulable µ2-GFP. 
Lastly, because the cam promoter is constitutively active, whereas the endogenous 
pfap2mu promoter has a stage-specific transcriptional profile, functional µ2-GFP-
DDD could be transiently knocked down and restored by removing or adding TMP 
to the culture. If the endogenous promoter were used, the cells may not retranslate 
sufficient amounts of µ2 until much later in the cell cycle, by which time the cells 
may have died. Thus, the cam promoter would allow me to examine the 
consequences of transiently depleting µ2 at various times in the cell cycle.  
  This scheme depends entirely on the assumption that episomally-expressed 
µ2-GFP can complement an endogenous pfap2mu knockout. To investigate this, a 
episomal construct expressing µ2-GFP under the control of the cam promoter was 
created based on the pDC2-expression system. This construct was transfected into 
3D7-µ2-floxed-3xHA schizonts by Nucleofection and selected continuously. 
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Figure 68 Episomally-expressed pfap2mu-GFP can complement an endogenous pfap2mu 
knockout 
A Growth of 3D7-µ2-floxed-HA/µ2-GFP parasites treated with rapamycin or equivalent DMSO was 
monitored with SYBR Green/MitoTracker Deep Red FACS over multiple life cycles. Rapamycin was 
added in trophozoites; at 24 hours post-excision, parasites cultures were in the ring stage. Genomic 
DNA was extracted 48 hours post-excision to examine the efficiency of excision (B), and cultures 
were lysed at 144 hours post-excision for a Western Blot to examine the presence of endogenous µ2-
HA and episomal µ2-GFP (C). 
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Figure 69 Cells proliferate normally when complemented with episomal µ2-GFP 
At 24 hour intervals after rapamycin-induced excision of the endogenous pfap2mu locus, thin smears 
were prepared for Giemsa staining and indirect immunofluorescence to examine the cell morphology, 
presence of endogenous µ2-HA, and localisation of episomally-expressed µ2-GFP in rapamycin- and 
solvent-treated parasites. Cell development appears unaffected by episomal complementation of an 
endogenous pfap2mu knockout, and endogenous µ2-HA signal decays in a single intraerythrocytic 
development cycle (IDC). (Figure on previous page).  
 
 Once these cells were stably growing, the culture was split, and 10 nM 
rapamycin or equivalent DMSO solvent was added to trophozoites for 1 hour. After 
1 hour, the cells were extensively washed and returned to culture. Parasite growth 
was monitored daily with SYBR-Green/MitoTracker-Deep Red FACS for several 
asexual cycles. Before the knockout was induced, thin smears stained for both the 
endogenous and episomal µ2 showed the two molecules colocalised well, 
confirming the episomally expressed µ2 is in the expected location in the cell. 
Throughout this growth experiment, thin smears were prepared at several points to 
examine cell morphology by Giemsa staining and the half-life of endogenous µ2-
3xHA. Both cultures were maintained on 2 µg/ml blasticidin-S.  
 Over multiple cycles, pfapmu- cells complemented with episomal µ2-GFP 
expressed by the cam promoter grew as well as the WT cells, indicating these 
knockout parasites could be successfully grown on an episome for multiple cycles 
(Fig 68,69). Morphologically, cells with and without endogenous µ2 appeared 
equivalent with no gross deformations (Fig 69). Genomic DNA was extracted 48 
hours after treatment with rapamycin, and PCR amplification of the floxed µ2-HA 
locus confirmed nearly complete excision. µ2-3xHA signal disappeared within the 
same cycle as the excision and was not re-detected later. Western blot analysis 144 
hours after rapamycin treatment confirmed the absence of µ2-HA and presence of 
µ2-GFP.  
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 Because these proof of concept experiments validate this experimental 
approach and indicate cam-expressed episomal µ2 complements an endogenous 
knockout, a construct expressing the planned µ2-GFP-DDD was transfected into 
3D7-µ2-floxed-HA schizonts by Nucleofection. Transgenic parasites were 
continuously selected with 2 µg/ml blasticidin-S and recovered within 1 week.  
 These cells were then cultured on 10 µM TMP for 2 cycles to stabilise 
episomally-expressed µ2. The endogenous pfap2mu was then knocked out with 
rapamycin as previously described. To explore the role of functional µ2 in ring-stage 
sensitivity to artemisinin, reinvading parasites were washed into medium containing 
0, 1, 5, or 10 µM TMP. Parasites were incubated in this medium for 3 hours, 
synchronised, and then exposed to 700 nM DHA or DMSO equivalent also in the 
presence of this TMP titration from hours 3-7 post-invasion. After the RSA4h was 
performed, and at hour 7, the cells were extensively washed, and all cells treated ith 
TMP were washed into medium containing 10 µM TMP. Medium containing TMP 
was refreshed daily and cell proliferation was examined by FACS.  
As expected, parasites not treated with rapamycin that retained the endogenous 
pfap2mu gene were completely sensitive to DHA. However, µ2-GFP-DDD-
knockdown ring stage cells lacking chromosomal pfap2mju were much less sensitive 
to artemisinin. In the presence of 5 µM or 1 µM TMP, 50.2% and 68.4% of cells 
were resistant to the ring-stage pulse of artemisinin. Cells could not be propagated 
when transiently cultured without TMP indicating that the parasite cell is sensitive to 
the level of µ2, even in the ring stage. Interestingly, cells treated with 10 µM TMP 
still displayed a 14.8% ring-stage survival to artemisinin. This could indicate µ2-
GFP-DDD is still unstable, even in the presence of TMP, or that the DDD element 
partially disrupts the normal function of µ2, generating a stress response. 
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Figure 70 Effects of transient µ2 knockdown on ring-stage artemisinin sensitivity 
(Top panel) 3D7 background parasites were treated with 10 µM trimethoprim (TMP) or DMSO, 
refreshed daily, for two lifecycles (grey). These cells were then treated with 10 nM rapamycin or 
DMSO for 1 hour in the ring stage (blue). From the end of this second cycle (T = -1 HPI), these cells 
were then washed into 0, 1, 5, or 10 µM trimethoprim for 4 hours while they were synchronised to 
regulate the amount of µ2-GFP-DDD in the cell. These synchronised parasites were then exposed to 
700 nM DHA or solvent for 4 hours in the RSA protocol described above. Cells treated with any 
concentration of TMP during the RSA were then incubated with 10 µM TMP for a further 65 hours. 
(Bottom panel) Ring stage survival was determined by FACS with SYBR-Green/MitoTracker Deep 
Red. Mean survival from one experiment performed in technical duplicate. Each technical replicate 
was counted by FACS twice and contains 100,000 gate-stopping events. *NS indicates no survival. 
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While more experiments are certainly required to clarify and probe this 
result, such as IFA and western blots to confirm the transient knockdown of µ2- 
GFP-DDD and examine the magnitude of the knockdown in relation to the 
artemisinin resistance phenotype, these data are consistent with my previous data  
suggesting that transient manipulation of secretory traffic protects the parasite cell 
from artemisinin. Interestingly, these data also suggest that simply triggering the 
proteasome in the cytosol is not sufficient for ring-stage artemisinin resistance. In 
this experiment, cells expressing µ2-GFP-DDD in the absence of TMP should be 
constitutively degrading this destabilised protein. However, these cells (Fig 70, first 
column) are fully sensitive to artemisinin. Thus, because we know µ2 is in the 
cytosol rather than in the ER lumen, it follows that the disruption of µ2-GFP-DDD 
may induce a ER-like stress response, that protects cells from artemisinin like the 
experiments described by Zhang et al202.   
 
 
6.6 A model of artemisinin resistance in P. falciparum  
 
Taken together, these data suggest that artemisinin resistance centres around 
the ER. BFA is commonly used in mammalian culture systems to stimulate the ER 
stress response, also known as the unfolded protein response.  Though Plasmodium 
species do not have many of the classic components of the UPR, they do have 
eIF2, a stress-sensitive translation repression factor. The data shown here show that 
BFA antagonises the action of artemisinin in early ring-stage parasites and leads to 
eIF2phosphorylation. Because this phosphorylation process is one of the few 
recognisable elements of the UPR in Plasmodium, we can conclude that BFA 
treatment induces a UPR stress response. These data are consistent with the findings 
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of Zhang et al indicating activation of this pathway underpins artemisinin 
resistance202.   
The manipulations discussed in this chapter provide important logical 
connections to understanding how variants of K13 and µ2 may reduce parasite 
susceptibility to artemisinin. The data presented in Chapter 5 strongly support that 
µ2 is localised along the early secretory pathway, that K13 and µ2 interact, and that 
knocking out µ2 causes a lethal defect in parasite maturation by disrupting the 
integrity and biogenesis of multiple secretory organelles. Previous data shows that 
K13 is also required for asexual survival192. Therefore, µ2 and K13 both play 
important roles in parasite development.    
It is known that mutations in K13 cause ring-stage artemisinin resistance, and 
the data presented in Chapter 4 shows that a mutation in µ2 causes a similar 
phenotype. Molecular modelling suggests that resistance-causing mutations in K13, 
which occur in the -propeller, may disrupt disulfide bond formation and propeller 
integrity (unpublished data), and the resistance-causing µ2(I592T) mutation possibly 
disrupts the folding of the µ2 core domain (Appendix II). Supporting this, reversibly 
disrupting µ2 in early ring stages induces artemisinin resistance in otherwise 
sensitive cells (Section 6.5). Therefore, these data all suggest that ring-stage 
artemisinin resistance arises when ER/secretory protein dynamics are disrupted in 
the young, developing parasite. eIF2P is a hallmark of disrupted ER dynamics and 
cell stress, and both K13C580Y and ring-stage BFA treatment induce this regulatory 
phosphorylation. 
Tentatively, I would like to suggest a model for ring-stage artemisinin action 
and resistance (Fig 71). Activated artemisinin seems to cause disseminated oxidative 
damage in the cell. In response to this generalised, systemic stress, the cell must 
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respond by upregulating and activating protein turnover machinery. Therefore, to 
survive artemisinin-induced stress, parasites need to either 1) avoid or reduce 
activation of artemisinin or 2) enhance or pre-activate their stress response 
mechanisms. Since the parasite absolutely requires haemoglobin, it is unlikely that 
this process can be majorly manipulated to achieve resistance. It is known that 
resistant parasites upregulate genes associated with the stress response and protein 
turnover. However, the molecular basis for this is unclear. In other words, why are 
these factors upregulated in artemisinin-resistant cells under normal, drug-free 
conditions? 
My suggestion is that these parasites, whether they harbour K13 or µ2 
mutations, are treated with BFA, lack apicoplasts, or have reduced levels of µ2, all 
display defects in secretory traffic. Intracellular traffic exists as a delicate 
equilibrium between the origin and destination, and as molecules accumulate in one 
compartment or another, the literal traffic on the intracellular highways backs up. In 
response to this stress, the cell responds by upregulating turnover machinery. When 
these cells encounter artemisinin, they are better suited to respond to artemisinin-
induced damage and propagate to the next cycle.  
If these cells have enhanced stress responses, why does artemisinin resistance 
only occur in the ring stage? Multiple studies suggest that haemoglobin metabolism 
activates artemisinin, and the amount of haemoglobin per cell volume in ring stage 
parasites is exceptionally low (Section 1.5.3.1). Additionally, data presented in 
Section 6.4 show that endogenous haem biosynthesis is not responsible for ring-
stage activation of artemisinin. My suggestion is that though the concentration of 
DHA may be the same in exposed ring and trophozoite or schizont stages, the 
proportion of activated DHA may be quite low in ring stages when there is  
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Figure 71 A model for ring-stage artemisinin resistance 
A model for ring-stage artemisinin resistance based on the data presented in Chapters 5 and 6. Under 
normal conditions, AP-2 and K13 interact and localise along the early secretory pathway. µ2 and K13 
are both essential molecules, supporting the importance of this trafficking route. Disruptions to the 
underlying pathway either by genetic mutation or physiochemical modulation induce a stress response 
that provides protection from artemisinin. The diagram presented is not intended to imply direct 
molecular interaction because the annotated molecules may interact via unknown scaffolds, but are 
designed to label potentially important molecules. Additionally, it is unknown exactly from where the 
AP-2 complex traffics, however it is likely to be somewhere in the early secretory pathway near the 
ER. The small AP-2 structure (right) is meant to depict disrupted traffic.  
 
comparably little haem and haemazoin. Therefore, the hurdle may be quite low for 
ring stages to achieve resistance, and the parasite cell may tolerate manipulations to 
these essential pathways in early ring stages when metabolism is starting, whereas 
the comparable manipulations in the much-more-active trophozoites would be lethal.   
Perhaps the most concerning deduction from this model is that, while K13 
mutations dominate in Southeast Asia, potentially any mutation that disrupts ring-
stage secretory traffic in a non-lethal way may reduce parasite susceptibility to 
artemisinin.  
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Chapter 7 
Exploration of the cellular role of the Plasmodium falciparum Ubp1 
ubiquitin hydrolase and its potential as a drug target 
 
 
7.1 Deubiquitination in Plasmodium falciparum 
  
 Deubiquitination, as discussed in Chapter 1, is a dynamic post-translational 
modification process that contributes to nearly every signalling pathway in the 
eukaryotic cell. For every ubiquitin ligation reaction, there is a downstream 
deubiquitination step catalysed by a ubiquitin hydrolase, also known as a 
deubiquitinase, that recycles ubiquitin monomers back into a free ubiquitin pool240. 
In Plasmodium falciparum, 30 different deubiquitinases (DUBs) have been 
annotated in the genome195. Of these 30, only one has been characterised. This 
enzyme, PfUCHL3, was interrogated structurally and biochemically by Artavanis-
Tsakovas et al250. Interestingly, this group showed this enzyme did not bear 
structural similarity to the mammalian orthologue, and also unlike its orthologues, is 
capable of removing Nedd8, a ubiquitin-like protein, from neddylated substrates. Her 
work also provides experimental evidence that some of the other putative DUBs 
interact with ubiquitin and potentially also Nedd8249.  
 Because the work described in Chapter 4 shows that Ubp1, one of the 30 
putative P. falciparum DUBs, can modulate parasite susceptibility to frontline 
chemotherapy, including artemisinin, I also sought to explore the role of Ubp1 using 
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cellular and molecular approaches. DUBs represent promising drug targets in cancer 
cells, and they may be similarly exploitable in the malaria parasite.  
 
 
7.2 Generation of transgenic P. falciparum expressing Ubp1-GFP 
  
 To determine where Ubp1 is located in the cell and begin to understand its 
function, I designed a CRISPR-Cas9-based scheme to tag Ubp1 at the genomic 
locus. Transcriptomic evidence suggests that the entire ~3200 bp mRNA is 
transcribed and spliced, but it is possible that the protein is post-translationally 
processed to release a smaller, catalytically active domain. In order to detect the 
putative active DUB, I aimed to GFP or HA tag the C-terminal catalytic domain.  
 The structure of the chromosomal copy of pfubp1 is comprised of three exons 
and two introns. The putative catalytic domain spans exons 2 and 3, and exon 3 is 
only 341 bp. Based on my experience selecting sgRNAs for Cas9-modification of 
pfap2mu, I selected a guide sequence at the 5’ end of exon 3 with a DRA (predicted 
guide activity) score of greater than 50%. A 500 bp region immediately upstream of 
intron 2 was selected as the 5’ homology arm, exon 3 was recodonised and fused to a 
short poly(Gly-Ser) linker and GFP, and 500 bp of the 3’ UTR was selected as the 3’ 
homology arm. This donor template was also modified to swap the endogenous 
intron 2 with the synthetic sera2-LoxP intron sequence and insert a second LoxP site 
immediately after the stop codon to mediate DiCre conditional excision of the 
putative catalytic domain (Fig 72A). An HA tag was also included in frame between 
the lox elements, which could be used to examine the efficiency of Cre-mediated 
excision on a protein level. The donor construct with and without the DiCre elements  
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Figure 72 Schematic of the tagging of PfUbp1 
A A pL6-based Cas9 donor repair template was designed to integrate loxP sites to flank the putative 
Ubp1 catalytic domain (flox), swap the endogenous intron 2 with the synthetic loxP-containing sera2 
intron, and install tandem HA and GFP tags via a selected PAM site downstream of intron 2. After 
rapamycin-inducible Cre-mediated excision, the coding sequence for the HA-tagged putative catalytic 
domain would be excised, while leaving the GFP CDS in frame. This tagging scheme failed. 
B A second tagging scheme using the selection-linked integration (SLI) approach. The 3’ 1.5 kbp of 
the genomic pfubp1 sequence, including intron 2, was cloned in frame with a GFP-T2a-NeoR coding 
sequence. G418-treating parasites harbouring this pSLI episome selects for parasites that successfully 
integrated the desired transgene by single-crossover recombination.  
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along with pUF1-Cas9 were transfected into 3D7 and a 3D7-based DiCre-expressing 
parasite line by Nucleofection, as described in Section 3.4.3.3.  
Transfected parasites were selected with WR99210 and DSM-1 as described. 
After three weeks, parasites recovered in both transfections but were unmodified. A 
second transfection with the tagging-only donor template and pUF1-Cas9 was also 
unsuccessful. Like the original µ2(S160N) attempts, these failures indicate a 
problem with the transgenesis strategy. This could be due to poor targeting of the 
sgRNA-Cas9 complex to the genome or a broader problem with the tagging scheme, 
for example if Ubp1 does not tolerate C-terminal tags.   
 Rather than selecting another guide sequence, I switched to the selection-
linked integration (SLI) method of transgenesis192. This technique involves fusing 
the protein of interest to an aminoglycoside phosphotransferase (NeoR), which 
provides resistance to neomycin (G418), with a self-cleaving T2a peptide (Fig 72B). 
In this setup, a single homology arm of approximately 1-1.5 kbp is cloned upstream 
of an affinity or fluorescent tag and the T2a-NeoR element. Transfected parasites are 
first selected for those containing the SLI donor plasmid, and then they are selected 
with G418 for parasites which have successfully integrated the plasmid by single-
crossover recombination. These cells express the tagged protein of interest and the 
neomycin resistance factor.   
 Using this method, the 3’ 1.5 kbp of the genomic pfubp1 sequence was 
cloned into Prof Tobias Spielmann’s pSLI-GFP-NeoR vector192. This construct was 
transfected into purified 3D7 schizonts by Nucleofection. Transfected parasites were 
selected with 2.5 nM WR99210 for 17 days until recovered parasites were growing 
stably. At this point, these parasites were seeded at 3% parasitaemia in 2%  
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Figure 73 PCR confirmation of PfUbp1 tagging construct integration  
After G418 selection, genomic DNA was extracted from G418-resistant parasites, and successful 
integration of the pSLI-Ubp1cat-GFP-neoR tagging construct into the 3D7 genome was confirmed by 
PCR. A forward primer annealing upstream of the single-crossover integration homology arm and 
reverse primer annealing in the neoR gene CDS were used to specifically amplify the expected, 
modified pfubp1-GFP-neoR chromosomal locus (2415 bp fragment). Wild type 3D7 genomic DNA 
was amplified in a parallel to confirm the specificity of the primers for the transgenic locus.  
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haematocrit in two wells of a 6-well plate and treated with 0.4 µM G418 for 48 
hours. The drug was washed off, and successfully integrated parasites expressing 
Ubp1-GFP-NeoR were obtained one week later. Integration was confirmed by PCR 
and IFA (Fig 73 and 74). 
 
 
7.3 Localisation of Ubp1 
  
 I had hoped to be able to observe Ubp1 localisation by live microscopy. 
However, the GFP signal observed was too faint to reproducibly characterise across 
any stage of the asexual lifecycle. Thin smears were prepared in ring, trophozoite, 
and schizont stage, and Ubp1-GFP localisation was probed by indirect 
immunofluorescence with an anti-GFP antibody produced by Ellen Knuepfer and 
Prof Anthony Holder. Interestingly, the localisation of Ubp1 resembled beads on a 
necklace around the nucleus, particularly in ring-stage parasites where Ubp1 stains 
punctate structures in a tight perinuclear ring (Fig 74). As the parasite matures 
through the trophozoite stage, Ubp1 staining becomes more diffuse and less intense. 
The few spots observed in mid-trophozoites are in close apposition to the nucleus. In 
schizonts, Ubp1 staining seems punctate, with each merozoite inheriting a single 
Ubp1-labeled structure. These localisation experiments are consistent with 
transcriptomic data showing Ubp1 is expressed in ring stages, lowly expressed in 
trophozoites, and more highly expressed in schizonts.  
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Figure 74 Localisation of Ubp1-GFP throughout the asexual lifecycle 
The localisation of Ubp1-GFP was examined throughout the asexual lifecycle by IFA in 
formaldehyde-fixed thin smears using anti-GFP (rabbit, 1:500; Holder laboratory) and anti-rabbit-594 
(1:150, Invitrogen). Ubp1-GFP staining appears perinuclear in ring-stages, ring-like but hardly above 
background in early trophozoites, developing into a large punctate spot that segments into daughter 
merozoites in schizonts.  
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7.4 Interaction of Ubp1 with ubiquitin 
  
Ubp1 is functionally annotated as a putative deubiquitinase. As stated above, 
a previous study showed that some DUBs may also catalyse the hydrolysis of 
ubiquitin-like modifiers, including Nedd8249. Though the C-terminus of the protein 
shares sequence homology with known DUBs and while molecular threading 
algorithms suggest a similar folding is possible, it is unknown whether P. falciparum 
Ubp1 can interact with ubiquitin. Additionally, it is unknown whether the entire 
annotated gene encodes a single DUB. Therefore, to first probe the size of mature 
Ubp1, whole cell lysates were prepared from mixed stage cultures and analysed by 
western blot. However, using both 4-12% TEA-Tricine gels (Sigma) and 3-8% Tris-
Acetate gels (Invitrogen) and extracts prepared in RIPA buffer, no Ubp1-GFP could 
be consistently detected by anti-GFP western blot, even though clear signal could be 
detected by IFA and correct integration was confirmed by PCR. 3D7-Ubp1-GFP 
lysates were also passed over anti-GFP beads to enrich any GFP-tagged species. 
However, eluted fractions from these test pulldowns also did not reveal any GFP-
positive species by western blot.  
Because transfer efficiency of high molecular weight proteins from 
polyacrylamide to nitrocellulose is known to be relatively poor (Ubp1 is expected to 
be ~416 kDa), the presence of a GFP-tagged species was probed by dot blot. To do 
this, 2 µl of RIPA-extracted mixed-stage soluble lysate was dotted onto 
nitrocellulose, dried, and probed against GFP. Compared to approximately equal 
amounts (5 µg total lysate) of either unmodified 3D7 or 3D7-MON1-GFP lysates 
(GFP control, created in Section 5.7), there was a very faint GFP-positive signal in  
 
 
 261 
 
 
 
 
 
 
 
 
Figure 75 Dot blot of soluble extracts from Ubp1-GFP-expressing parasites 
Because Ubp1-GFP could not be resolved and detected by SDS-PAGE electrophoresis and western 
blotting, a dot blot was performed. 2 µl of cell extract was dotted onto a nitrocellulose membrane and 
probed with anti-GFP (mouse, Sigma; 1:5000) and anti-mouse-HRP (BioRad, 1:5000). Dot 1: 
positive control, 3D7-MON1-GFP RIPA lysate; dot 2: 3D7-Upb1-GFP RIPA lysate; dot 3: elution of 
anti-GFP pulldown on RIPA-extracted Ubp1-GFP lysate; dot 4: wild type 3D7 control.  
 
 
the 3D7-Ubp1-GFP cell extract. The pulldown experiment was repeated in RIPA 
buffer, and the eluted fraction (without bromophenol blue) is clearly enriched for the 
GFP-tagged molecule (Fig 75). Because there is no size resolution with a dot blot, it 
is impossible to say that the GFP species detected here is definitively Ubp1-GFP. 
However, because by PCR the SLI construct was successfully integrated, and by IFA 
there is a conspicuous localisation pattern, it is likely that the signals detected here 
correspond to Ubp1-GFP.  
To examine whether Ubp1 is capable of interacting with ubiquitin, a labelling 
experiment involving Ub-HA-VME, a synthetic ubiquitin analogue, was performed. 
Ub-HA-VME is a reagent commonly used to study DUBs. It consists of a ubiquitin 
monomer with an N-terminal HA epitope tag and C-terminal vinyl sulfone (VS) 
group. As described in Section 1.9, ubiquitin is typically conjugated to a target 
substrate via an isopeptide linkage between an -NH3 of a lysine side chain and 
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Gly76 of ubiquitin. The isopeptide bond is hydrolysed by DUBs. In Ub-HA-VME, 
the vinyl methylether group replaces Gly76 and forms an irreversible thioether with 
the sulfhydryl group of reactive cysteines in target proteins that is immune to DUB-
mediated hydrolysis.  
Whole cell lysates were again prepared with RIPA buffer supplemented with 
1 mM PMSF. These lysates were incubated with 1 µM Ub-HA-VME, a synthetic 
ubiquitin analogue, for 90 minutes at room temperature before being diluted with an 
equal volume of RIPA supplemented with 2x protease inhibitors. This reaction 
solution was then incubated with anti-GFP beads overnight at 4oC. After overnight 
incubation, the anti-GFP beads were washed, and bound material was eluted and 
analysed by dot blot. As expected, blotting against the activity-based probe with 
anti-HA antibodies produced a clear HA-positive signal in the eluted protein 
fraction. These simple labelling experiments suggest that native Ubp1 is capable of 
interacting with ubiquitin in vitro (Fig 77).  
 
 
7.5 Exploration of experimental hUSP7 inhibitors in P. falciparum   
  
Ubp1 is functionally annotated as a putative deubiquitinase. As stated above, 
a previous study showed that some DUBs may also catalyse the hydrolysis of 
ubiquitin-like modifiers, including Nedd8. Though the C-terminus of the protein 
shares some sequence homology with known DUBs and molecular threading 
algorithms show a USP7-like conformation is possible, it is unknown whether Ubp1 
is either a functional DUB or can be similarly targeted with known DUB inhibitors.  
To begin to probe some of these questions surrounding druggability of 
deubiquitinases in Plasmodium falciparum, three recently described hUSP7  
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Figure 76 Molecular structures and antimalarial activity of three hUSP7 inhibitors 
Three known inhibitors of hUSP7 were probed for their antimalarial activity against the 3D7 strain 
using standard 48-hour exposures to serial dilutions of compound. EC50 estimates are a mean of at 
least 2 biological replicates, each performed in technical duplicate. EC50 estimates were calculated 
using Prism 7.0 as described elsewhere in this thesis. 
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inhibitors were examined for their anti-plasmodial effects: HBX 19818, FT671, and 
FT827 (Fig 76). HBX 19818 is a hetero-tricyclic ring that was identified through a 
high-throughput library screen at Hybrigenics Pharma, which covalently inactivates 
the active cysteine of hUSP7 both in vitro and in vivo with an IC50 of approximately 
20-30 µM325. Though HBX 19818 was thought to be highly specific for hUSP7, this 
compound has since been shown to also exert off-target effects against other DUBs.  
FT671 and FT827 were discovered by Turnbull et al in a 2017 collaboration 
between the University of Oxford and Forma Therapeutics326. FT671 and FT827 
build on extensive research into hUSP7 inhibitors as anti-cancer drugs since the 
discovery of HBX 19818.  
FT671 and FT827 are related compounds based on a pyrazolo-piperidine 
scaffold but have important chemical differences and functionality. FT671 reversibly 
inhibits hUSP7 through a fluoropyrazole group that interacts with sidechains in the 
catalytic pocket of USP7, preventing a conformational shift required for hUSP7 to 
accept ubiquitin. FT827 uses a vinyl-sulfonamide group to irreversibly target the 
active cysteine of hUSP7 by a similar mechanism as the vinyl sulfone group of the 
Ub-ABP described in Section 7.4. Importantly, FT671 binds hUSP7 with a KD of < 
100 nM whereas FT827 targets hUSP7 with a KD of approximately 8 µM. Despite 
this difference in affinity for the molecule, both FT compounds display highly-
specific activity against hUSP7 in vitro and in vivo, even up to 50 µM.  
The sensitivity of the 3D7 Plasmodium falciparum strain to these compounds 
was determined using standard 48-hour drug exposures and SYBR-Green 
quantitation as described in Section 3.4.5.1. To HBX 19818 and FT827, 3D7 
displayed EC50’s of 5.2 µM and 15.4 µM, respectively. FT671 is ineffective against 
3D7 at concentrations under 25 µM. Interestingly, for HBX, this EC50 is well below 
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the reported KD and IC50 reported for hUSP7 and HEK293 cells by Reverdy, whereas 
for FT827, the EC50 determined here is similar to the KD reported for hUSP7 by 
Turnbull325,326. On the other hand, P. falciparum is more than 500 times less 
sensitive than human cells to FT671.  
 
7.6 In vitro validation of experimental hUSP7 inhibitors in P. falciparum  
  
These sensitivity data suggest important differences in structure and function 
between the Plasmodium falciparum and human DUBs, particularly as highlighted 
by the FT-series compounds. Importantly, the results of the previous section do not 
clarify whether these USP8 inhibitors are active against Ubp1. As stated above, 
FT671 is a reversible binding pocket blocker for the human USP7; it does not 
interact with or inactivate the catalytic cysteine. Instead, FT671 prevents a 
conformational shift in the catalytic domain required for USP7 to accept and 
hydrolyse ubiquitin chains. The fact that FT671 does not appreciably kill 
Plasmodium falciparum at concentrations below 30 µM yet disables the human 
enzyme at low nanomolar concentrations is consistent with important differences 
existing in the three-dimensional DUB fold between the two enzymes, even though 
molecular modelling suggests a similar tertiary structure is possible for PfUbp1 
(Appendix II). FT827 attacks and covalently modifies the active cysteine of USP7 
and does not dock in the same way with the USP7 fold as FT671326.  
To probe the ability of these two compounds to disrupt Ubp1’s interaction 
with ubiquitin, simple delabeling experiments were performed (Fig 77). HBX was 
not taken forward to these experiments because this compound is known to have 
pleiotropic effects in other systems and no libraries were generated around this 
compound, while the FT series have several libraries available for lead optimisation.  
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Figure 77 In vitro chemical Ubp1-ubiquitin delabelling assay 
Schematic of Ubp1 delabelling assays. 3D7-Ubp1-GFP lysates were prepared in RIPA buffer and 
incubated with 30 µM FT671, 30 µM FT827, or solvent. These lysates were then treated with HA-
Ub-VME and pulled down on anti-GFP beads. Bound material was eluted and examined for the 
presence of HA-Ub-VME by dot blot (right). Densitometric analysis of HA signal in FT671 and 
FT827 elution fractions with respect to the DMSO control reveals 53.6 ± 6.3% and 83.1 ± 5.2% 
reduction in labelling due to 30 µM FT671 and FT827 respectively. 
 
Briefly, RIPA-lysed cells were incubated for 45 minutes with either 30 µM 
FT827 or FT671 or equivalent solvent at room temperature. After this incubation, 
excess Ub-HA-VME was added to both drug-treated and untreated samples for a 
further 60 minutes at room temperature. Then, an equal volume of RIPA buffer with 
2x protease inhibitors was added to quench labelling and prevent further degradation 
of proteins in solution. Anti-GFP beads were then added to both reactions and 
incubated overnight at 4oC. These beads were washed extensively and eluted, and  
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bound material was analysed by anti-HA dot blot. Interestingly, both drugs block 
HA-Ub-VME labelling of Ubp1. As expected, FT827 dramatically reduces the 
amount of HA-Ub-VME bound to Ubp1, though FT671 may still be capable of 
partially inhibiting Ubp1 (FT671: 53.6 ± 6.3%, FT827: 83.1 ± 5.2% reduction in 
labelling). FT671 is a reversible inhibitor of USP7 and therefore will also compete 
with ubiquitin for Ubp1 binding, which may also contribute to its lower potency 
against P. falciparum since there are likely differences in the conformation of the 
active site of Ubp1. 
 
 
7.7 Discussion 
 
The data described in this chapter provide preliminary insights into the cell 
and molecular biology of the Ubp1 putative deubiquitinase. Interestingly, prior to 
this work, Ubp1 was believed to be a putative homologue of the human USP7 
deubiquitinase.  USP7 is located in the nucleus in human cells, where it regulates the 
turnover of the Mdm2 tumour suppresor327. In contrast to this expected nuclear 
localisation, PfUbp1 is localised to a near-nuclear location in the cell, which may be 
the ER. Although I could not resolve Ubp1-GFP on a western blot, potentially due to 
its annotated size (> 400 kDa), I did detect and successfully enrich what is likely 
Ubp1-GFP using an anti-GFP pulldown. Using a ubiquitin activity based probe, I 
also show that this GFP-tagged species interacts with ubiquitin, providing further 
support that native Ubp1 is a functional deubiquitinase. Further colocalisation and 
EM experiments will provide a clearer localisation of Ubp1, and in vitro 
deubiquitinase experiments using recombinant and native Ubp1 will be necessary to 
formally demonstrate DUB activity.  
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 Because of their essential functions in cellular regulation, DUBs, and USP7 
in particular, are attractive drug targets for broad human pathologies. Several known 
USP7 inhibitors were explored for their anti-plasmodial activity in this chapter, and 
two covalent inhibitors, HBX 19818 and FT827, display low micromolar potency 
against the 3D7 Plasmodium falciparum strain. HBX 19818 is promiscuous in 
human cells, but FT827 has been shown to specifically target USP7 even at 
concentrations as high as 50 µM. In vitro delabeling experiments using a ubiquitin 
activity-based probe (HA-Ub-VME) suggest that FT827 is capable of blocking 
ubiquitin interaction with Ubp1, which presents Ubp1 as a new target that could be 
considered for antimalarial drug development. It is important to note that the 
experiments described in Section 7.6 do not prove the antiplasmodial effects of 
FT827, demonstrated in Section 7.5, are on-target. They show that Ubp1 can be 
targeted by FT827, but additional DUBs may still be inhibited by FT827.  
Screening drug-DUB interactions via these delabeling experiments is very 
low throughput and labour intensive, but previous efforts have shown that ubiquitin 
activity-based probes can be used for high-throughput mass spectrometry-based drug 
discovery and simultaneously reveal DUB specificity of the compounds screened. 
FT827 will never be a viable antimalarial because it was designed for human cancers 
and invariably will therefore have a poor selective index. However, many FT827-
like molecules have been synthesised and screened for anti-cancer and cytotoxic 
effects. The compounds which have been binned as ineffective against human cancer 
cell lines yet are non-toxic to non-cancerous cells could be screened for their 
antimalarial properties using the techniques outlined in this chapter and mass-
spectrometry based approaches.  
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Chapter 8 
Discussion 
  
 
This thesis set out to address four major questions under the theme of understanding 
antimalarial drug resistance. Though detailed discussions of the work presented in 
each chapter are included in each chapter, several points of summary are provided 
here with respect to the general aims outlined in Chapter 2.  
 
Specifically, this thesis asked: 
1. To what extent is there continued evidence of directional selection of 
pfap2mu and pfubp1 variants in patient samples from Western Kenya?  
 
The results presented in Chapter 4 suggest that there may be ongoing 
selection of the pfap2mu(S160N) variant allele. Similar selection was observed in 
the samples analysed from this study and those from our previous study 
conducted in the same town in Western Kenya. Specifically, the prevalence of 
the S160N allele approximately tripled between pre-treatment and post-treatment 
samples when considering samples from the same patient. However, the 
prevalence of this mutation several weeks after treatment was nearly back to 
baseline 16%. It is important to note that the patient sample collection protocol in 
this study was deeply flawed, and over half of the study samples remain in 
Africa. Therefore, the prevalence of this variant allele may change as the analysis 
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of these samples is completed in the future. However, the preliminary data 
suggest the pfap2mu(S160N) variant is selected during ACT treatment. It is 
unclear why this mutation has not increased in prevalence in this study site over 
the four years between the two studies if it is actually associated with treatment 
failure since ACT therapies have been the frontline treatment option over this 
time. Additionally, ACT efficacy remains high in this area. 
 Analysis of selection of pfubp1 variants is more complicated due to the 
dramatic sequence diversity at the resistance-associated “Borrmann hotspot” near 
Ubp1(E1528). Sequencing of this region revealed 16 different haplotypes in 
parasite samples from this same clinical trial. Interestingly, when the E1528D 
mutation identified by Borrmann et al was considered independent of this 
surrounding diversity there was some evidence of selection, with the prevalence 
of the mutation approximately doubling between pre- and post-treatment 
samples251. However, when the entire haplotype of this region was considered as 
a unit, the selection landscape reveals a different haplotype with more than half 
of recrudescent parasites having a single variant haplotype encoding D1525E and 
a three-amino-acid insertion. Previous studies have not considered this whole 
region as a single haplotype and instead have focused on single residues. 
Reanalysis of previous data should be conducted to examine whether a similar 
trend has been previously identified and not reported. 
 
 
2. To what extent do mutations in pfap2mu and pfubp1 contribute to reduced 
susceptibility to frontline antimalarial chemotherapies in laboratory strains 
and culture-adapted clinical parasite isolates. 
 
To validate the involvement of pfap2mu and pfubp1 variants in sensitivity 
to frontline chemotherapies, variants in these genes were installed in the 3D7 
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genome by CRISPR-Cas9 editing. Specifically, the S160N mutation identified 
from patients in Kenya and the I592T mutation identified from an artemisinin-
resistant Plasmodium chabaudi clone were installed into pfap2mu, and the 
V3306I and V3275F mutations identified in the same Plasmodium chabaudi 
study were installed into pfubp1. These parasites displayed minor changes in 
their sensitivity to chloroquine, quinine, dihydroartemisinin, lumefantrine, 
mefloquine, and piperaquine by standard 48-hour drug exposure assays. 
However, by the ring-stage survival assay, parasites expressing the mutant 
µ2(I592T) and Ubp1(V3275F) displayed reduced ring-stage susceptibility to 
artemisinin. The resistance phenotype displayed by these parasites is moderate, 
yet significant, as it is above the 5% RSA survival cut-off assigned by WHO, 
validating the involvement of these proteins in determining parasite sensitivity to 
artemisinin. These are the first data showing that SNPs in genes other than 
pfkelch13 may cause ring-stage artemisinin resistance.  
This thesis also produced the first transfection and Cas9-mediated 
transgenesis of a recently culture-adapted African clinical parasite isolate. This 
thesis establishes a protocol for transfecting these poor-growing, relatively 
fragile parasite lines. Though the pfap2mu(S160N) mutation has been 
successfully installed into an African isolate, we have not yet been able to 
successfully clone these parasites, which has delayed the characterisation of this 
important line. Though this variant had no effect on parasite susceptibility to 
frontline chemotherapies in the 3D7 background, characterising the effects of 
this mutation in an African isolate is still important. 
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3. Given there are well defined orthologues of PfAP2µ and PfUbp1 in 
mammalian cells by sequence similarity, how similar are the localisations 
and functions of P. falciparum proteins to their counterparts?  
 
To examine the localisation and function of µ2 and Ubp1 in the parasite 
cell, both proteins were tagged by genome editing. By immunofluorescence and 
immunoelectron microscopy, µ2 seems to be located in the early secretory 
pathway near the ER. This is surprisingly diverged from the canonical eukaryotic 
function of the AP-2 complex in receptor-mediated endocytosis. Knocking out 
µ2 causes broad defects in the biogenesis of several membrane-bound organelles 
including the micronemes, rhoptries, and apicoplast, which further supports a 
role for µ2 in early secretory traffic. A µ2 interactome generated by 
immunoprecipitation and mass spectrometry shows that the core AP-2 complex 
consists of three canonical AP-2 subunits and AP-1. This AP complex 
hybridisation is common in invertebrates and has been previously noted in 
Dictyostelium. A µ2 interactome generated through immunoprecipitation and 
mass spectrometry identified several trafficking factors and supports a role in 
early secretory traffic near the ER. The identification of Rab11B suggests that 
AP-2 traffic may aimed towards the plasma membrane or IMC. 
Additionally, the µ2 interactome contains several artemisinin resistance-
associated factors including K13 and another kelch domain-containing factor 
called K10. Co-immunoprecipitation experiments revealed that these factors 
interact with µ2. This non-canonical localisation and association with K13 also 
seems to exist in Plasmodium knowlesi, supporting a repurposing of traditional 
endocytic machinery in Plasmodium spp., which may be a consequence of 
adaptation to an obligate intracellular life.  
 274 
 During the course of this exploration into the biology of µ2, I also began an 
initial characterisation of clathrin heavy chain. Clathrin heavy chain is localised 
to vesicles throughout the cytoplasm and the cell periphery. Additionally, as 
expected, many components of key late secretory organelles pulldown with 
clathrin, suggesting that clathrin-coated vesicles deliver essential cargo 
throughout the cell.  
 Ubp1 is also located in the cytosol and may be associated with the ER, given 
its perinuclear localisation in early ring stages. The data presented in Chapter 7 
reveal Ubp1 is capable of interacting with ubiquitin and may be a drug target 
using experimental hUSP7 inhibitors. However, USP7 is localised in the nucleus 
of human cells, indicating a functionally different role for Ubp1 than what has 
been determined for USP7, though this is not unexpected as the sequence 
similarity between the two factors is limited.  
 
 
 
4. To date, none of the resistance-causing pfkelch13 mutations have been 
detected in parasites from African patients. Do the results of these studies 
provide any insight into how artemisinin resistance occurs at the cellular 
level or could occur in Africa? 
 
Overall, the results of Chapters 5 and 6 provide compelling evidence for 
a model of artemisinin resistance centred around the ER and protein homeostasis. 
The AP-2 complex associates with K13 in the cell, and mutations in both confer 
varying degrees of protection from artemisinin to ring stage parasites. Given that 
AP-2 is localised to the early secretory pathway, it follows that dysfunction may 
disrupt or slow down secretory traffic. Experiments described at length in 
Chapter 6 provide support for this theory and show that physically and 
chemically disrupting protein dynamics confers high levels of artemisinin 
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resistance to ring stage parasites. Building off of this, transient degradation of µ2 
in the ring stage also confers a cytoprotective effect. Overall, these data imply 
that K13-mediated artemisinin resistance may result from a dysfunctional 
intracellular trafficking system that induces a low-level stress response in the 
absence of artemisinin. By pre-activating or priming this stress response, cells 
are better equipped to mitigate the disseminated oxidative damage caused by 
artemisinin. My theory both explains and is supported by transcriptomic, 
proteomic, and in vitro biochemical data implicating an enhanced, ring-stage 
stress response in artemisinin resistance.  
Recently, Bhattacharjee et al proposed a trafficking-related mechanism 
for artemisinin resistance, though they focus mostly on protein export and 
PfEMP1 as causative effectors of K13200. Though protein export machinery is 
implicated in the mechanism of the AP-2 complex in P. falciparum, neither PI3K 
nor PI3P interacting proteins (also implicated by Bhattacharjee et al and 
Mbengue et al) were detected196,200. Some of the work presented by 
Bhattacharjee in support of their model, particularly regarding the involvement 
of PI3P as a causative molecule, ignores clear criticisms pointed out by Boddey 
et al, which represents the work of six separate laboratories201. Therefore, the 
model presented by Bhattacharjee et al, though generally related to my model by 
implicating intracellular traffic, demands further support and explanation, 
complicating the interpretation of their results.  
Ultimately, this thesis provides little insight into how and whether 
artemisinin resistance will occur in African parasites. That a single mutation in 
pfap2mu, a gene that has been shown to be under some directional selection in 
East Africa, can confer significant levels of artemisinin resistance is rightly 
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concerning. However, this mutation has never been detected in circulating 
parasites anywhere in the world. One of the more concerning conclusions from 
this thesis is that mutations in potentially many proteins involved in protein 
homeostasis may confer resistance to artemisinin, if the presented model is 
correct. However, there are good arguments for why the high transmission 
setting across many parts of Africa may complicate the evolution of artemisinin 
resistant strains, but these are the subject of another thesis. 
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Chapter 9 
Future Directions 
 
 
The work outlined in this thesis provide proof-of-principle and justification for 
pursuing many further lines of work. Four of these additional projects are described 
here: 
 
1. Explore the impact of genetic background on the effects of mutations in 
pfap2mu on parasite susceptibility to frontline chemotherapies. 
 
In this thesis, the pfap2mu(S160N) variant does not alter parasite 
susceptibility to the frontline chemotherapies examined. However, in 
Henriques et al, Dd2 parasites (CQ-resistant background) expressing 
an additional copy of the mutant gene displayed decreased 
susceptibility to quinine and DHA206. This could be caused by the 
overexpression of µ2, a dominant negative effect of the additional, 
mutant copy, or a consequence of different metabolism caused by a 
mutant PfCRT. Dd2(S160N) parasites should be created by Cas9-
mediated editing and examined for their drug sensitivity, and 
additional copies of pfap2mu could be integrated into wild type 
backgrounds to explore the consequences of overexpression. 
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2. Further characterise the cellular effects of µ2 knockout. 
 
This thesis shows that inducible pfap2mu knockout disrupts several 
membrane-bound compartments, including the micronemes, 
rhoptries, and apicoplast, as well as the IMC and plasma membrane. 
This knockout should be further characterised by electron microscopy 
to understand the cross-sectional morphology of these cells, which 
may provide greater insight into the role of µ2. Additionally, the 
regulable µ2-DDD described in Chapter 6 may be a valuable genetic 
tool for looking at the effects of manipulating µ2 levels in the cell. 
The construct described here can be integrated into an attB site as is, 
and a cloned, single-copy integrant would be required for these 
experiments. Additionally, this parasite line might allow the 
identification of AP-2 cargo molecules with TMT-labelling and 
whole-cell proteomics. Proteins that are differentially abundant 
shortly after a protein-level µ2 knockdown might represent important 
cargo molecules. Understanding these cargo molecules may provide 
further insight into the artemisinin resistance phenotype induced by 
µ2 knockdown and µ2 mutation.  
  
3. Explore the viability of parasite DUBs as antimalarial drug targets. 
 
Chapter 7 turns an important page in understanding the biology of 
deubiquitinating enzymes in the parasite. These enzymes are 
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becoming important anti-cancer drug targets and could represent 
viable antimalarial targets. Specifically, the HA-Ub-VME reagent 
described here and widely utilised to study mammalian ubiquitin 
biology is a powerful molecular tool and can be used for high 
throughput mass spectrometry-based drug screening. Forma 
Therapeutics has designed several libraries of compounds around the 
pyrazolo-piperadine scaffold that produced FT671 and FT827. These 
libraries have already been screened against human cells, resulting in 
a sub-library of negatively screened compounds which might target 
the malarial DUBs. Simple cytotoxicity assays can be performed in 
very high throughput to identify compounds for further 
characterisation using ABPs and mass spectrometry. Forma have 
already stated their interest in pursuing this work.  
 
4. Characterise role of clathrin in the malaria parasite 
This thesis provides a very preliminary characterisation of clathrin 
heavy chain in Plasmodium falciparum. Clathrin heavy chain clearly 
is involved in transporting cargo to many important compartments in 
the cell, and a full characterisation of the molecule will provide 
valuable insights into parasite cell biology. The techniques described 
and used in Chapter 5 should be deployed in these studies. 
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Appendix I: Molecular modelling of PfAP2µ and PfUbp1 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Molecular model of the Plasmodium falciparum µ2 subunit (red) generated using 
molecular threading (I-TASSER) through the Rattus norvegicus AP2m1 subunit 
(green) co-crystallised as the heterotetrameric AP-2 complex (RCSB: 2VGL). Five 
non-homologous Plasmodium-specific loops project out of the core Plasmodium 
falciparum µ2 fold, which aligns well with the mammalian homologue (RMSD = 
1.2A over backbone atoms). 
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Spatial examination of the two pfap2mu mutations discussed in this thesis. S160 is 
located on the first loop connecting the core beta-sheet and sigma-homology domain, 
projecting into solvent-exposed space and is not spatially nearby the other complex 
subunits (top). I592 is a semi-conserved buried residue between the layered beta-
sheets of the core µ2 fold (bottom). I592 is not solvent-exposed and instead resides 
within a hydrophobic pocket where it is predicted to mediate major van der Waals 
contacts holding the layers together. 
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Molecular model of the Plasmodium falciparum Ubp1 putative catalytic domain 
(grey) generated using molecular threading (I-TASSER) through the human USP7 
catalytic domain (purple) co-crystallised with ubiquitin (yellow, RCSB: 1NBF). 
Three conserved residues that constitute a catalytic triad are positioned as expected 
in the modelled structure with respect to the C-terminal tail of ubiquitin (catalytic 
Cys, green; supporting residues, blue). 
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Spatial examination of the two pfubp1 mutations identified from the P. chabaudi 
study208. V3275 is located in a hydrophobic pocket which positions the C-terminal 
tail of ubiquitin for hydrolysis. V3306 resides in the ubiquitin-binding “hand”- like 
domain. V3306 is predicted to make contacts with ubiquitin. Mutation of both 
residues is expected to cause steric clash with neighbouring residues and disrupt 
catalytic activity (red bubbles, right inset boxes).   
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Appendix II: Transfection of recently culture-adapted clinical 
isolates 
 
 
 A secondary goal of this thesis is to evaluate the impacts of the mutations 
characterised above in recently culture-adapted clinical isolates. Examining the 
phenotypes of mutations in robust laboratory strains like 3D7 is technically 
established. Transfection protocols are well described in the literature. However, 
these parasite lines have never been exposed to artemisinin combination therapies 
and do not represent the genetic backgrounds that currently circulate in the field. We 
know that drug resistance, especially artemisinin resistance, involves many loci, and 
interrogating a mutation in one gene in the absence of potentially many other 
unknown background mutations (i.e. in a laboratory strain) may obscure some 
phenotypic consequences of that mutation of interest. For SNPs like the µ2(I592T) 
or Ubp1 mutations discussed above, examining these mutations in clinical isolates is 
less important because they have not been observed in human infections. However, 
the µ2(S160N) mutation was only observed in natural infections, and therefore it 
should be examined in a representative clinical isolate before being written off as 
having no phenotypic consequence.  
 Because the µ2(S160N) mutation was identified in Kenya around the late 
2000s and again in this thesis work in the early 2010s, I decided to also characterise 
this mutation in the HL1402 P. falciparum strain in our laboratory. HL1402 was 
culture adapted by Dr Donnelly van Schalkwyk from a blood sample from a 
symptomatic patient who contracted malaria after visiting a similar region of Kenya 
in 2014.  
 At the time of these experiments, no publications had described the 
transfection of a recently adapted African clinical isolate. The Cam3.I and Cam3.II 
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series parasites described by researchers in Prof David Fidock’s laboratory are 
clinical isolates but are also robust parasites that grow well under normal culture 
conditions. Our stable of African isolates typically do not propagate unless cultured 
in medium supplemented with human serum, and even under these conditions may 
still expand slowly. Given that CRISPR-Cas9 editing in P. falciparum involves two 
biological bottlenecks, transfection of plasmid DNA and successful chromosomal 
targeting, cleavage, and repair, I sought to determine whether HL1402 could be 
transfected under our current protocols and techniques.  
 HL1402 was transfected with the pEFGFP reporter construct described by 
Talman et al, which expresses GFP under the control of the pfeF1 promoter, using 
the schizont-stage Nucleofection, ring-stage electroporation, and spontaneous uptake 
of DNA methods described in Section 3.4.3328. The laboratory strain Dd2 was also 
transfected alongside HL1402 in these methods. While GFP-expressing parasites 
were obtained from all methods in the Dd2 strain, GFP-expressing HL1402 were 
only observed in the spontaneous DNA uptake transfections despite additional  
 
 
 
 
 
 
 
Figure 78 Episomal expression of a GFP reporter into a recently adapted clinical isolate 
HL1402 is a recently culture-adapted P. falciparum clinical isolate collected from a patient who was 
infected while traveling in Kenya. To establish whether clinical isolates can be transfected, several 
transfection methods were used to introduce the pEFGFP reporter construct, which expresses GFP 
under the control of the eF1promoter. The spontaneous DNA uptake method was the only 
transfection method that yielded modified parasites after WR99210 selection. The Dd2 parasite line, 
which grows robustly and is readily transfectable, was included alongside as a transfection control. 
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attempts with the other methods. Transfectants were selected for 14 days with 2.5 
nM WR99210, and GFP-expressing transfectants were observed in culture after 4 
weeks. Despite parasites recovering from drug selection, many parasites in the 
culture were not green, suggesting a subset of the parasites had been successfully  
transfected (Fig 38). HL1402, like all of our culture-adapted clinical isolates, is 
polyclonal. So far, we have not been able to successfully clone these parasites by 
limiting dilution. Therefore, it may be that certain clones are more robust than 
others, and these clones were the ones transfected. However, this experiment serves 
as proof of principle that at least a subpopulation of HL1402 can be successfully 
transfected, and the spontaneous DNA uptake method is the only suitable 
transfection method, probably because it is gentler on the parasites themselves than 
the electroporation methods. Therefore, the spontaneous DNA uptake method was 
used for transfecting genome editing constructs into HL1402. 
 
 
Generation of a transgenic P. falciparum strain harbouring a µ2 
mutation from a recent African clinical isolate  
 
 Based on the reporter transfection experiments discussed above in Section 
4.7, the spontaneous DNA uptake method was used for transfecting 100 µg of pL6-
AP2µ(S160N)-sgDNA and 100 µg of pUF1-Cas9 into HL1402 to install the 
µ2(S160N) mutation. DNA-loaded red cells were exposed to Percoll-enriched 
HL1402 schizonts for 96 hours before selection with WR99210 was begun. Parasites 
were visible by Giemsa stain after 3 weeks. Several frozen stabilates were prepared 
once the culture exceeded 1% parasitaemia. PCR-RLFP mapping confirmed the  
 324 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 79 PCR-RFLP mapping of transgenic HL1402 bearing pfap2mu(S160N) 
PCR-RFLP mapping was performed to determine the genotype of transfected HL1402 parasites and 
estimate the proportion of unmodified parasites in the uncloned culture using two different sets of 
primers, both annealing outside the 5’ and 3’ homology regions of the Cas9 repair template. PCR 
products (1343 bp and 1156 bp) were digested with 0.5 units SnaBI and XbaI for 4 hours at 37oC. 
Green and red arrows annotate low abundance RFLP fragments indicating the presence of low-level 
wild type genomes in the uncloned culture. * indicates possible incomplete WT digestion product.  
 
presence of the mutant locus but also revealed the presence of unedited parasites in 
the culture (Fig 41). So far, our laboratory has not been able to successfully clone the 
parasites in our stable of culture-adapted African clinical parasite isolates because 
they do not yet grow robustly.  
 To attempt to derive a cloning protocol for these strains, I first used HL1212, 
one of our laboratory’s best-growing strains. HL1212 was isolated in 2012 from a 
patient who was infected while traveling in Nigeria, and although it requires medium 
supplemented with 5% (v/v) human serum to grow well in vitro, its rate of expansion 
is similar to that of our laboratory strains. Previous attempts to clone HL1212 by 
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limiting dilution using the standard protocol by others in our laboratory had failed. I 
wondered whether culture medium supplemented with conditioned medium would 
simulate a parasite-dense culture environment and promote the growth of single 
clones. At high parasitaemia, conditioned medium provokes gametocytogenesis; 
however anecdotally, medium supplemented with small amounts of conditioned 
medium stimulates parasite growth in other laboratories. Under this rationale, I 
attempted to clone HL1212 using the standard limiting dilution cloning protocol 
with either 10% or 25% (v/v) conditioned medium in fresh complete medium. All 
medium for culturing clinical isolates contains either 10% (v/v) equine serum or 5% 
(v/v) human serum; in our hands, there is no significant difference in parasite growth 
between either serum (data not shown). For these cloning experiments, 10% (v/v) 
equine serum was used.  
 After 20 days, 10 wells of the 96-well cloning plate treated with 10% (v/v) 
conditioned medium were positive for parasite growth by the LDH colourimetric 
assay. These clones were expanded into a 1 ml culture at 2% haematocrit in a 24-
well plate. No parasites were observed by Giemsa staining after a further 2 weeks in 
culture, and there were no positive wells in the plate treated with 25% (v/v) 
conditioned medium. When the original positive wells from the 96 well plate were 
smeared and examined by Giemsa staining, some gametocytes were observed as well 
as some asexual parasites. Since the establishment of a robust protocol for cloning 
clinical isolates was not one of the primary aims of this thesis, this work was not 
pursued further.  It is possible that conditioned medium supports cloning at in the 
first few weeks but then begins to provoke terminal gametocytogenesis as the 
parasites reach a higher density in each well. An optimal protocol might blend the 
use of conditioned and unconditioned medium.  
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 Because Hl402-pfap2mu(S160N) parasites have not been cloned, the 
sensitivity of these parasites to frontline chemotherapies was not determined. Any 
observed phenotype would be an average of genotypes in the culture, and since it is 
also unclear which parental subclone(s) was/were transfected, appropriate controls 
for any drug sensitivity comparison cannot be selected. Further work should aim to 
resolve these issues and characterise the drug sensitivity profile of this parasite line. 
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Appendix III: µ2 interactome 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Identified µ2 interacting factors unique to CHAPS-based extraction condition (20 mM 
HEPES, 250 mM sodium citrate, 0.1% (w/v) CHAPS, 1 mM MgCl2, 10 mM CaCl2, pH 7.4). 
Factors are grouped by putative location as listed on MPMP.   
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Identified µ2 interacting factors unique to Triton-based extraction condition (20 mM 
HEPES, 100 mM NaCl, 0.1% (w/v) Triton X-100, pH 7.4). Factors are grouped by putative 
location as listed on MPMP. (Continued on next page)  
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Identified µ2 interacting factors unique to Triton-based extraction condition (20 mM 
HEPES, 100 mM NaCl, 0.1% (w/v) Triton X-100, pH 7.4). Factors are grouped by putative 
location as listed on MPMP. (Continued from previous page) 
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Appendix IV: Expression of µ2 and K13 in HeLa cells 
 
 
 The divergence of µ2 localisation and function in the Plasmodium genus with 
that observed in other cells was so unexpected that I wondered whether PfAP2µ 
retained the ability to localise properly in mammalian cells. It is reasonable to 
propose that the AP-2 complex is recruited to membranes of vesicular origin by 
other factors. Therefore, it could be that these factors are actually the ones that have 
evolutionarily diverged and µ2 is simply following these recruitment factors and 
may not be intrinsically diverged. To investigate this question, I cloned the Pfµ2-
3xHA CDS into the pTriEx mammalian expression system, transfected the resulting 
pTriEx-Pfµ2-3xHA construct into 1x106 HeLa cells with Lipofectamine 3000, and 
examined the localisation of µ2-3xHA by immunofluorescence.  
 Interestingly, Pfµ2 was localised mainly at the cell periphery (Fig 80). 
Currently, we do not have further reagents to probe the localisation of Pfµ2 in 
human cells, but these data tentatively suggest Pfµ2 may be capable of functionality 
similar to the human orthologue, and the non-canonical behaviour reported here in 
Plasmodium may be due to divergence at a different level of the vesicle formation 
process. Structural modelling suggests Pfµ2 may occupy a similar folded 
conformation to the mammalian factor and would support this hypothesis (Appendix 
II). Though hµ2 and Pfµ2 only share 35% sequence homology over their entire 
sequences, there is clear conservation in long tracts which map to architectural 
structures in the µ subunit core, which provides further support for possible 
conservation of the molecule between species, even though the species-specific 
function may be diverged. Alignments are provided in Appendix IV.  
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Figure 80 Transient transfection and localisation of Pfµ2-HA into HeLa cells 
The pfap2mu-3xHA coding sequence was amplified from modified 3D7-µ2-3xHA-glmS parasites and 
cloned into the pTriEx4 expression vector under the control of the cmv promoter and enhancer 
(Merck; top panel). This construct was transiently transfected into 1x106 HeLa cells with 
Lipofectamine 3000, and localisation of Pfµ2-3xHA was examined 24 hours after transfection by 
indirect immunofluorescence. Anti-HA immunostaining (rat, Sigma 3F10, 1:150) with anti-rat-488 
(Invitrogen, 1:150) detected Pfµ2-3xHA at the periphery of HeLa cells, consistent with the 
localisation of hµ2 observed in other human cells (lower panel; image from Abcam).  
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I similarly expressed PfK13 in HeLa cells to explore its localisation. Unlike 
Pfµ2, PfK13 exhibited no similarity with previously reported localisations of its 
putative homologue, hKEAP1. hKEAP1 has been previously reported to localise 
predominantly to the cytosol, whereas PfK13 is clearly in distinct foci in the nucleus 
of transfected HeLa cells (Fig 81). It is difficult to read too far into these data as K13 
and KEAP1 only share 21% sequence homology. Outside of the annotated, but 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 81 Transient transfection and localisation of PfK13 into HeLa cells 
The pfkelch13 coding sequence was amplified from 3D7 parasites and cloned into the pTriEx4 
expression vector under the control of the cmv promoter and enhancer (Merck; top panel). This 
construct was transiently transfected into 1x106 HeLa cells with Lipofectamine 3000, and localisation 
of PfK13 was examined 24 hours after transfection by indirect immunofluorescence. Anti-K13 
immunostaining (mouse, D. Fidock laboratory, 1:150) with anti-mouse-488 (Invitrogen, 1:150) 
detected PfK13 in the nucleus of HeLa cells.  
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barely homologous, BTB/POZ and kelch repeat domains in PfK13, there is little 
expectation that PfK13 and hKEAP1 would function similarly.  
Overall, these studies were aimed to be preliminary and exploratory, and 
future work could aim to further validate this evolutionary divergence by pulling 
down Pfµ2-3xHA from transgenic HeLa lysates and probing interactions with other 
known hAP-2 components or attempting to rescue a conditional hµ2 knockout with 
Pfµ2. Alternatively, hµ2 could be introduced into Plasmodium for similar 
experiments.  
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Appendix V: Alignments of selected Plasmodium proteins of interest 
and their human orthologues 
 
 
 
 
 
 
Alignment of PfAP2µ and hAP2m1 protein sequences  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Alignment of PfAP2 and hAP2s1 protein sequences  
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Alignment of PfAP2 and hAP2a1 protein sequences  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Alignment of PfAP1 and hAP1b protein sequences  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Alignment of PfCLC and hCLCA protein sequences  
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Alignment of PfCHC and hCLH1 protein sequences  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Alignment of PfK13 and hKEAP1 protein sequences  
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Alignment of PfUbp1(3166-3486) and hUSP7(210-531) protein sequences 
(catalytic core) 
 
 
 
 
*  catalytic triad is highlighted in red.  
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Appendix VI: A brief characterisation of Clathrin Heavy Chain in 
Plasmodium falciparum  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Foreword:  
 
 
During the course of the production of this thesis and the investigation of the AP-2 
complex, my experiments began with roots in clathrin-mediated trafficking dogma. 
However, as we came to realise, AP-2 in Plasmodium may not interact with clathrin. 
While AP-2 is near the ER, clathrin appeared peripheral. Therefore, given the lack 
of knowledge about clathrin in Plasmodium and the importance of endocytosis to 
parasite biology, I decided to undertake a brief characterisation of clathrin heavy 
chain. The parasite lines and antibodies described here are attributed to those who 
created or supplied them. 
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Clathrin in Plasmodium falciparum 
  
 As described in Section 1.8, clathrin cages participate in several trafficking 
routes in higher order eukaryotes. They are often found at the plasma membrane 
where they participate in clathrin-mediated endocytosis, typically of receptor-bound 
cargo329. Clathrin also participates in traffic between various endosomal 
compartments downstream from the Golgi. Canonically, clathrin interacts with one 
of the large subunits of the clathrin adaptor protein complexes (AP complexes), 
which recognise and aggregate cargo molecules during vesicle formation215,231. After 
several molecular processes including cage polymerisation and actin scaffold 
formation, the budding vesicle is cleaved from the origin membrane, and clathrin 
and the associated molecules disassemble from the nascent vesicle. 
Structurally, clathrin cages are made up of two core components: clathrin 
heavy chain and clathrin light chain228. The heavy chain is a unique, high molecular 
weight molecule that forms a three-legged triskelion structure, with each leg 
consisting of two jointed limbs fused by a central hub domain. By comparison, the 
light chain is small, typically less than 20 kDa, and associates with the heavy chain 
in the polyhedral cage structure at triskelion junctions228. Both components are 
nearly universally found in higher order eukaryotic organisms. In Plasmodium, 
PF3D7_1219100 is annotated as clathrin heavy chain, and PF3D7_1435500 is 
annotated as clathrin light chain.  
To our knowledge, there is no existing characterisation, in part or in full, of 
clathrin in Plasmodium falciparum. One would expect that it participates in similar 
roles in the cell, but based on the surprising and divergent function of the AP-2 
complex demonstrated in Chapter 5, it is conceivable that clathrin function is 
similarly diverged. In the process of investigating the AP-2 complex, we received a 
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parasite line expressing an endogenously GFP-tagged clathrin heavy chain and a 
monoclonal antibody against clathrin from the laboratories of Tobias Spielmann and 
Frances Brodsky, respectively, with which I pursued a preliminary molecular 
characterisation.  
 
 
Localisation of Clathrin Heavy Chain in Plasmodium falciparum 
 
 
 The localisation and distribution of clathrin in the GFP-tagged parasite line 
was examined via live microscopy. Consistent with clathrin being one of the most 
abundant proteins in the cell, the endogenously-integrated clathrin-GFP fusion was 
readily visible in all parasite stages (Fig 82). Throughout the lifecycle, clathrin is 
predominantly localised to the parasite periphery in discrete foci. In ring stages, a 
single clathrin focus exists at the plasma membrane. As the parasite matures, 
additional foci appear at the plasma membrane and in the parasite cytoplasm in close 
proximity to the digestive vacuole. In segmented schizonts, merozoites seem to 
receive a single clathrin-labelled structure. In contrast to the AP-2 complex, clathrin 
in ring stages is much further away from the nucleus and never observed in a 
perinuclear space consistent with the ER. The localisation of clathrin in trophozoites 
was not consistent between trophozoites, suggesting a changing localisation.  
In mammalian systems, clathrin-coated vesicles form and bud quickly. In 
yeast, these processes have been better characterised and visualised and seem to take 
place over the course of 30 seconds to a few minutes. To better understand the 
dynamics of clathrin in trophozoites, live microscopy was performed on poly-L 
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Figure 82 Localisation of clathrin heavy chain in fixed cells 
The localisation of clathrin heavy chain was examined in live cells in ring stages and in schizonts. 
Trophozoites are not displayed because clathrin localisation is highly variable due to the putatively 
dynamic nature of clathrin-coated vesicles. In ring stages, clathrin-2xFKBP-GFP is clearly at a single 
punctate location at the cell periphery. In schizonts, clathrin exists as multiple punctae. Each 
merozoite seems to inherit a single clathrin-labeled structure.  
 
 
lysine-immobilised, infected red cells. The microscope stage was sealed, heated, and 
gassed to 5% CO2 to mimic standard culture conditions, and 3D7-CHC-2xFKBP- 
GFP trophozoites were observed prior to nuclear replication. In each cell, there were 
many GFP foci throughout the cell periphery and in the cytosol, in contrast to ring 
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Figure 83 Visualisation of clathrin-GFP dynamics in live trophozoites 
Clathrin in immobilised 3D7-CHC-2xFKBP-GFP trophozoites was imaged by live microscopy. Serial 
Z-stacks (0.1µm steps) were acquired through green and white light channels every 6 minutes and 
overlaid in Nikon Advanced Research Elements software (top panel). 3D stacks were projected into a 
2D image using ImageJ. The average intensity of several GFP spots in the cell were quantitated and 
plotted over time (lower panel). 
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stages which clearly possessed a single peripheral focus (Fig 83, top panel). When 
observed continuously, fluorescent signal for any signal focus seemed to fade over 
roughly 30 seconds, however during this time, no new foci appeared suggesting this 
is more due to photobleaching than vesicle budding and clathrin disassembly. 
Instead, Z-stack images of immobilised trophozoites were collected every 6 minutes 
for several hours to capture broad changes in clathrin-GFP distribution in the cell 
over time. 2-dimensional projections of these Z-stacks were generated, and the 
average intensities of single foci were calculated using 11px diameter circular ROIs 
in ImageJ. These intensities were plotted over time, and it seems that once a vesicle 
forms, it may complete the budding process within 15 minutes (Fig 83, lower panel). 
Further characterisation is required to better time this process, but this initial 
characterisation highlights the dynamic nature of the clathrin-coated architecture in 
the cell, and suggests a role for clathrin at the cell periphery and in the cytosol, 
consistent with the role of clathrin in vesicular traffic at these locations in other 
eukaryotes.  
 
 
Examination of Clathrin Heavy Chain in Plasmodium falciparum by 
immunoelectron microscopy 
 
 
To better characterise the localisation of clathrin, thin sections of 3D7-CHC-
2xFKBP-GFP trophozoites were imaged by immunoelectron microscopy (Fig 84-
87). These images supported the localisation of clathrin at the cell periphery and in 
vesicles as observed in the previous section.  
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Figure 84 Immunoelectron micrographs of clathrin in the cytosol in Plasmodium falciparum 
trophozoites 
Localisation of CHC-2xFKBP-GFP by immunoelectron microscopy in trophozoites. Clathrin (18 nm 
particles) is located in vesicular structures near the ER (anti-PDI, 12 nm particles) and at the plasma 
membrane (Fig 85). Visualised at 20,000x magnification. N: nucleus; DV: digestive vacuole.   
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Figure 85 Localisation of clathrin at the plasma membrane of infected erythrocytes by IEM 
Localisation of CHC-2xFKBP-GFP (anti-GFP; 18 nm particles) at the parasite plasma membrane 
(inset boxes) and ER structures (anti-PDI; 12 nm particles) by immunoelectron microscopy in 
trophozoites. Visualised at 20,000x magnification. N: nucleus; DV: digestive vacuole. Inset boxes 
show Type I (top panel) and Type II (bottom panel) vesicles.   
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Figure 86 Type I and Type II clathrin-coated vesicles 
Immunoelectron micrographs of “Type I” and “Type II” clathrin-coated vesicles (18 nm particles). 
Top panel: characteristic Type I vesicle. Bottom Panel: characteristic Type II vesicle. Major and 
minor axes were measured in ImageJ as depicted. 12 nm particles represent anti-PDI (ER lumen). 
Visualised at 20,000x magnification. Inset indicates major and minor axis measurements. 
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Interestingly, sections colabeled with antibodies against protein disulfide 
isomerase (PDI, 12 nm particles), a luminal ER folding chaperone, reveal some 
colocalisation between PDI and clathrin (18 nm particles). This is surprising because 
canonically, clathrin is located in the endosomal and Golgi network and at the 
plasma membrane, not the ER. Traffic out of the ER is typically mediated by 
elements of the COPII complex.  
 Additionally, several sections revealed what appears to be vesicular 
structures labelled with clathrin. Some of these vesicular structures are located near 
the ER and some seem contiguous with at least the parasite plasma membrane. 
Greater resolution and membrane preservation is needed to clarify this observation 
and determine whether the parasitophorous vacuole membrane is also invaginated 
into these budding structures. Near-ER vesicular structures could be the Golgi. 
Because Plasmodium spp. do not have stacked Golgi cisternae, identifying the Golgi 
without a Golgi-specific antibody is difficult. 
 Additionally, when observing these labelled micrographs, there seemed to be 
two different sized clathrin-labelled vesicles (Fig 87). Neither of these structures 
were labelled with anti-PDI, indicating they are likely not extensions of the ER. To 
provide additional clarity on this, straight-line diameter measurements were taken in 
ImageJ. Possibly because of the sectioning process, some clathrin-labelled vesicular 
structures appeared more elliptical than others, so a single diameter measurement 
fails to capture the dimensions of structure.  Therefore, to better compare the size of 
these vesicles, the major and minor axes of the labelled vesicles were measured and 
plotted and clustered using K-means clustering (K = 2). As expected, the majority of 
vesicles (“Type I”) cluster around average dimensions of 100 nm x 80 nm, with an  
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Figure 87 K-means clustering of elliptical dimensions of clathrin-coated vesicles 
Scatterplot of major and minor axis measurements of clathrin coated vesicles identified by 
immunoelectron micrographs. Measurements were analysed by K-means clustering with K = 2. 
Centroids identified for two clusters are plotted. Type I vesicles (blue points) cluster around Centroid 
I (grey), and Type II vesicles (orange points) cluster around Centroid 2 (yellow). Vesicles were 
clustered by distance to each centroid.  
 
 
elliptical cross-sectional area of approximately 6,000 nm2.  The remaining larger 
“Type II” vesicles cluster around average dimensions of 270 nm x 115 nm, with an 
approximate cross-sectional area of 25,000 nm2. The cellular distribution of these 
potential sub-types of vesicles does not seem to point to a particular functional role  
(i.e. more often at the PM or near the ER, etc.). However, it is interesting to note the 
existence of this difference, and future imaging will clarify whether this clustering is 
artefactual or if there are real differences in the localisation and potential roles of 
these structures.   
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Characterisation of clathrin-interactors by immunoprecipitation and 
mass spectrometry  
 
 
 Because the data presented in this chapter suggest clathrin may participate in 
endocytic events at the plasma membrane and transcytosis events throughout the 
cytosol and given the importance of understanding these processes, the same IP-MS 
pipeline used to characterise AP2µ-HA by cryomilling was applied to reveal 
interacting partners of CHC-2xFKBP-GFP.  
 Trophozoite stage lysates were prepared using the same CHAPS-based 
extraction buffer used in Section 5.7 (20 mM HEPES, 250 mM sodium citrate, 0.1% 
(w/v) CHAPS, 1 mM MgCl2, 10 mM CaCl2, pH 7.4, protease inhibitors). These 
lysates were incubated with custom magnetic (DynaBeads) anti-GFP nanobody 
beads, generated by the Field lab, for 1 hour at 4oC. The beads were washed several 
times with extraction buffer, and bound material was eluted and processed for mass 
spectrometry as described in Section 3.3.4. Control pulldowns were performed using 
lysates from untagged 3D7 lysates. 
 As with the µ2 interactome, these experiments are still ongoing. At the time 
of the printing of this thesis, only one dataset was available for analysis. Therefore, it 
is important not to over-analyse the identified proteins, but instead consider the 
broad patterns of potential interacting factors. Identified ribosomal subunits and 
nuclear factors were omitted from this analysis for the reasons described in Section 
5.7.    
 When examining the putative localisation or function of the identified 
clathrin heavy chain interactors from this single experiment, the vast majority of the 
identified proteins reside along the secretory pathway, centred around the Golgi. Of 
the 227 factors identified, more than 25% are putatively involved in intracellular  
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Figure 88 Overview of a preliminary clathrin heavy chain interactome 
227 potential interacting factors were identified from a single replicate of a clathrin heavy chain-
2xFKBP-GFP pulldown. Within this dataset, trafficking factors were highly enriched, accounting for 
nearly 30% of the identified proteins. These trafficking factors map to many secretory organelles 
including the rhoptries, endosomal system, digestive vacuole, and cell periphery. Additionally, 
elements of endosomal recycling and ER-to-Golgi traffic were also identified, supporting the 
localisation presented above. Left panels show the overlap of this clathrin interactome with the two 
interactomes generated for µ2 in Section 5.7, revealing 36% overlap between the datasets resulting 
from extractions performed in the same CHAPS-based extraction buffer. Proteins were identified by 
MASCOT and filtered against known contaminants using MaxQuant and Perseus. Putative function 
and localisation was assigned using the Malaria Parasite Molecular Pathways (MPMP) database.  
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Table 10 Grouping of CHC-interacting trafficking factors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHC interacting factors were filtered for those with putative functions relating to intracellular traffic. 
These factors were then sub-classified based on data available on MPMP for the location of their 
associated trafficking pathway. These factors were also cross-referenced against the µ2 interactome 
datasets generated using the same CHAPS-based condition as described here and an alternative, 
triton-based extraction condition. (Table continues on next page) 
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traffic, including adaptins, GTPases, secretory complex subunits, and other 
trafficking machinery. Importantly, the putative clathrin light chain was also 
identified.   
 Separating specific clathrin-heavy chain interactors will be difficult because 
clathrin is one of the most abundant proteins in the cell may be inherently sticky 
because clathrin heavy chain is abundant in the control pulls, and only present at 5-
fold enrichment in the anti-GFP pulldown. By comparison, µ2-3xHA was identified 
at 1011-fold enrichment between anti-HA and control pulldowns. These clathrin-GFP 
pulldowns and their wild type controls were not cross-contaminated during 
preparation, and the eluted material was separated on separate gels before 
submission for mass spectrometry. Therefore, it may not be possible to identify low 
abundance, specific interactors because these will also be present in the control 
pulldowns.  
 
 
Discussion  
 
To the best of our knowledge, these data are the first characterisation of 
clathrin heavy chain in Plasmodium falciparum. These data show for the first time 
that clathrin is located at several locations in the parasite cell, including the plasma 
membrane and the cytosol, consistent with known roles for clathrin in endocytosis 
and post-Golgi traffic.  
 By indirect immunofluorescence, as the parasite develops, the clathrin 
system also develops from a single peripheral structure in the ring stage to dynamic 
and short-lived structures throughout the cell in trophozoites, ultimately culminating 
with a single clathrin focus in each merozoite. Immunoelectron microscopy supports 
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this localisation pattern and shows clathrin as localised near the ER in vesicles and 
what may be tubular ER extensions. These micrographs also show clathrin at the cell 
periphery.   
Interestingly, these micrographs suggest a possible role for clathrin at or near 
the ER. Clathrin has never been reported in the early secretory pathway, but the 
colocalisation observed in several images with protein disulfide isomerase, a known 
luminal ER factor, suggests there may be some clathrin-mediated traffic out of or 
near this organelle. These observations require further study. One alternative 
interpretation is that the anti-PDI antibody used in the electron microscopy imaging, 
meant to exclusively stain the ER lumen, may also be labelling aspects of the Golgi. 
Therefore, further experiments should explore other markers of the ER and Golgi in 
IEM to clarify the localisation of clathrin. 
The immunoprecipitation and mass spectrometry work performed in this 
chapter support the notion that clathrin is involved in may transport steps throughout 
the parasite cell, as it is in other eukaryotes. The interactome we generated, which 
requires further refinement with additional datasets and controls, shows a strong 
enrichment in the interactome for trafficking factors that may serve several secretory 
organelles in the cell. Upon further functional classification, the identified putative 
trafficking factors suggest clathrin may be involved in transport to many organelles 
including the rhoptries, cell periphery, post-Golgi endosomal system, and digestive 
vacuole. While this list initially seems like essentially every compartment in the cell, 
at least the mitochondria, apicoplast, and micronemes are all conspicuously missing 
from the list. As some preliminary validation, clathrin has already been shown to be 
involved in traffic to the rhoptries in Plasmodium falciparum and Toxoplasma 
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gondii, and the localisation presented above in Section 8.2 is supported by the 
identification of peripheral, cytosolic, and ER trafficking factors.  
 The data in this chapter may shed light on clathrin dependence of the AP-2 
complex as characterised in Chapter 5. While the entire AP-1 and AP-3 complexes 
and elements of the AP-4 complex are present in this list of potential CHC 
interactors, no AP-2 complex elements, other than AP-1, were identified. One 
would not necessarily expect to find all of the AP-2 subunits, but the presence of µ 
subunits of the other complexes and not AP-2 is intriguing. On one hand, by 
immunoelectron microscopy, clathrin heavy chain seems to have a similar 
localisation to µ2, and there is significant overlap in the µ2 interactome and this 
preliminary CHC interactome. In the CHAPS-based extraction condition, 36% of the 
µ2 interacting factors (34 out of 93) were shared with the CHC interactome. Yet 
paradoxically, no AP-2 components have been identified as interacting with clathrin 
so far, despite the presence of other adaptor complex subunits, including µ subunits, 
in my preliminary CHC interactome, and no experimental data presented in either 
Chapter 5 or Appendix VIfirmly suggest an interaction between AP-2 and clathrin. 
Further experiments are required to explore these observations and clarify whether 
AP-2 and clathrin interact. A full list of the interacting partners identified in this 
experiment are listed in Appendices III and VI.  
 It will be very interesting to probe the function of the AP-3 and AP-4 
complexes and ultimately generate an adaptor complex “roadmap” that accurately 
reflects the dynamics of clathrin-mediated transport within the parasite cell.  
Additionally, the identification of two possible sub-types of clathrin-coated 
vesicles (Type I and Type II) based on their dimensions and elliptical area warrants 
further investigation as these structures may have functional significance in parasite 
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development. Given the size of these vesicles, SEM could be done to better examine 
vesicle morphology and the organisation of the clathrin cage. Overall, this chapter 
provides more questions than answers and should serve as a jumping off point for 
further research.  
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